
<!-- saved from url=(0081)https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm -->
<html xmlns:pfe="http://www.pfizer.com/20241231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html; charset=windows-1252"><meta http-equiv="Content-Type" content="text/html">


<title>pfe-20241231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonnumeric contextref="c-1" name="dei:EntityCentralIndexKey" id="f-35">0000078003</ix:nonnumeric><ix:nonnumeric contextref="c-1" name="dei:DocumentFiscalYearFocus" id="f-36">2024</ix:nonnumeric><ix:nonnumeric contextref="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-37">FY</ix:nonnumeric><ix:nonnumeric contextref="c-1" name="dei:AmendmentFlag" id="f-38">false</ix:nonnumeric><ix:nonnumeric contextref="c-124" name="us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" id="f-704">P4Y</ix:nonnumeric><ix:nonnumeric contextref="c-1" name="pfe:ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" id="f-1072">Consolidated Statements of Operations</ix:nonnumeric><ix:nonnumeric contextref="c-1" name="pfe:IntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" id="f-1073">Consolidated Statements of Operations</ix:nonnumeric><ix:nonnumeric contextref="c-9" name="pfe:IntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" id="f-1074">Consolidated Statements of Operations</ix:nonnumeric><ix:nonnumeric contextref="c-14" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="f-1463">http://fasb.org/us-gaap/2024#OtherAssetsCurrent http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent</ix:nonnumeric><ix:nonnumeric contextref="c-15" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="f-1464">http://fasb.org/us-gaap/2024#OtherAssetsCurrent http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent</ix:nonnumeric><ix:nonnumeric contextref="c-14" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="f-1507">http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent</ix:nonnumeric><ix:nonnumeric contextref="c-15" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="f-1508">http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent</ix:nonnumeric><ix:nonnumeric contextref="c-9" name="us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-1740">http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpense</ix:nonnumeric><ix:nonnumeric contextref="c-1" name="us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-1741">http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpense</ix:nonnumeric><ix:nonnumeric contextref="c-14" name="us-gaap:HedgedLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="f-1790">http://fasb.org/us-gaap/2024#LongTermDebtNoncurrent</ix:nonnumeric><ix:nonnumeric contextref="c-15" name="us-gaap:HedgedLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="f-1791">http://fasb.org/us-gaap/2024#LongTermDebtNoncurrent</ix:nonnumeric><ix:nonnumeric contextref="c-15" name="us-gaap:SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration" id="f-1819">http://fasb.org/us-gaap/2024#AccountsPayableCurrent</ix:nonnumeric><ix:nonnumeric contextref="c-14" name="us-gaap:SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration" id="f-1820">http://fasb.org/us-gaap/2024#AccountsPayableCurrent</ix:nonnumeric><ix:nonfraction unitref="number" contextref="c-708" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="f-2500">0</ix:nonfraction><ix:nonfraction unitref="number" contextref="c-709" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="f-2501">10</ix:nonfraction><ix:nonfraction unitref="number" contextref="c-710" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="f-2502">10</ix:nonfraction><ix:nonfraction unitref="number" contextref="c-711" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="f-2503">40</ix:nonfraction><ix:nonfraction unitref="number" contextref="c-712" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="f-2504">45</ix:nonfraction><ix:nonfraction unitref="number" contextref="c-713" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="f-2505">80</ix:nonfraction><ix:nonfraction unitref="number" contextref="c-714" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="f-2506">5</ix:nonfraction><ix:nonfraction unitref="number" contextref="c-715" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="f-2507">35</ix:nonfraction><ix:nonfraction unitref="number" contextref="c-716" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" format="ixt:fixed-zero" scale="0" id="f-2508">0%</ix:nonfraction><ix:nonfraction unitref="number" contextref="c-717" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="f-2509">10</ix:nonfraction><ix:nonfraction unitref="number" contextref="c-718" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="f-2510">10</ix:nonfraction><ix:nonfraction unitref="number" contextref="c-719" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="f-2511">20</ix:nonfraction><ix:nonfraction unitref="number" contextref="c-720" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="f-2512">45</ix:nonfraction><ix:nonfraction unitref="number" contextref="c-721" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="f-2513">70</ix:nonfraction><ix:nonfraction unitref="number" contextref="c-722" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="f-2514">15</ix:nonfraction><ix:nonfraction unitref="number" contextref="c-723" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="f-2515">35</ix:nonfraction><ix:nonfraction unitref="number" contextref="c-724" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="f-2516">0</ix:nonfraction><ix:nonfraction unitref="number" contextref="c-725" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="f-2517">5</ix:nonfraction><ix:nonfraction unitref="number" contextref="c-726" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="f-2518">95</ix:nonfraction><ix:nonfraction unitref="number" contextref="c-727" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="f-2519">100</ix:nonfraction><ix:nonnumeric contextref="c-742" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="f-2547">P5Y</ix:nonnumeric><ix:nonnumeric contextref="c-743" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="f-2548">P7Y</ix:nonnumeric><ix:nonnumeric contextref="c-745" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="f-2550">P3Y</ix:nonnumeric><ix:nonnumeric contextref="c-746" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="f-2551">P3Y</ix:nonnumeric><ix:nonnumeric contextref="c-747" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="f-2552">P5Y</ix:nonnumeric><ix:nonnumeric contextref="c-748" name="pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomePeriod" id="f-2557">P1Y</ix:nonnumeric><ix:nonnumeric contextref="c-748" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="f-2558">P3Y</ix:nonnumeric><ix:nonnumeric contextref="c-733" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="f-2561">P1Y</ix:nonnumeric><ix:nonnumeric contextref="c-783" name="pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardSettlementPeriod" id="f-2764">P5Y</ix:nonnumeric><ix:nonnumeric contextref="c-784" name="pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardSettlementPeriod" id="f-2765">P7Y</ix:nonnumeric><ix:nonnumeric contextref="c-744" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="f-2766">P3Y</ix:nonnumeric><ix:nonnumeric contextref="c-785" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="f-2767">P5Y</ix:nonnumeric><ix:nonnumeric contextref="c-786" name="pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardSettlementPeriod" id="f-2768">P7Y</ix:nonnumeric><ix:nonnumeric contextref="c-787" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="f-2769">P3Y</ix:nonnumeric><ix:nonfraction unitref="number" contextref="c-788" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-2770">33</ix:nonfraction><ix:nonfraction unitref="number" contextref="c-789" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-2771">33</ix:nonfraction><ix:nonfraction unitref="number" contextref="c-790" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-2772">33</ix:nonfraction><ix:nonnumeric contextref="c-759" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="f-2773">P3Y</ix:nonnumeric><ix:nonnumeric contextref="c-748" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="f-2774">P3Y</ix:nonnumeric><ix:nonnumeric contextref="c-791" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="f-2775">P5Y</ix:nonnumeric><ix:nonnumeric contextref="c-754" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="f-2776">P3Y</ix:nonnumeric><ix:nonnumeric contextref="c-14" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-2816">http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent</ix:nonnumeric><ix:nonnumeric contextref="c-15" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-2817">http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent</ix:nonnumeric><ix:nonnumeric contextref="c-14" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-2820">http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent</ix:nonnumeric><ix:nonnumeric contextref="c-15" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-2821">http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent</ix:nonnumeric><ix:nonnumeric contextref="c-14" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="f-2824">http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent</ix:nonnumeric><ix:nonnumeric contextref="c-15" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="f-2825">http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent</ix:nonnumeric><ix:nonnumeric contextref="c-1" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCostCreditImmediateRecognitionOfActuarialGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleList" id="f-2966">http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpense</ix:nonnumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaref xlink:type="simple" xlink:href="pfe-20241231.xsd"></link:schemaref></ix:references><ix:resources><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitnumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitnumerator><xbrli:unitdenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitdenominator></xbrli:divide></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>pfe:segment</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="medicine"><xbrli:measure>pfe:medicine</xbrli:measure></xbrli:unit><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:unit id="gbp"><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unit><xbrli:unit id="employeestockownershipplan"><xbrli:measure>pfe:employeeStockOwnershipPlan</xbrli:measure></xbrli:unit><xbrli:unit id="tradingday"><xbrli:measure>pfe:tradingDay</xbrli:measure></xbrli:unit><xbrli:unit id="measure"><xbrli:measure>pfe:measure</xbrli:measure></xbrli:unit><xbrli:unit id="period"><xbrli:measure>pfe:period</xbrli:measure></xbrli:unit><xbrli:unit id="company"><xbrli:measure>pfe:company</xbrli:measure></xbrli:unit><xbrli:unit id="patent"><xbrli:measure>pfe:patent</xbrli:measure></xbrli:unit><xbrli:unit id="patent2"><xbrli:measure>pfe:Patent</xbrli:measure></xbrli:unit><xbrli:unit id="complaint"><xbrli:measure>pfe:complaint</xbrli:measure></xbrli:unit><xbrli:unit id="operatingsegment"><xbrli:measure>pfe:operatingSegment</xbrli:measure></xbrli:unit><xbrli:unit id="facility"><xbrli:measure>pfe:facility</xbrli:measure></xbrli:unit><xbrli:unit id="country"><xbrli:measure>pfe:country</xbrli:measure></xbrli:unit><xbrli:unit id="treatmentcourse"><xbrli:measure>pfe:treatmentCourse</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">pfe:NotesDue20271.000Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-02-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:TopElevenProductsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:TopTenProductsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:TopNineProductsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:SeagenMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:SeagenMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-12-14</xbrli:startdate><xbrli:enddate>2023-12-14</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:SeagenMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-10-02</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:SeagenMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:SeagenMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:SeagenMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:DevelopedTechnologyRightsAndOtherIntangibleAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:SeagenMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:DevelopedTechnologyRightsAndOtherIntangibleAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:SeagenMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:DevelopedTechnologyRightsAndOtherIntangibleAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:SeagenMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:SeagenMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:SeagenMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:SeagenMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:SeagenMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-12-14</xbrli:startdate><xbrli:enddate>2023-12-14</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:SeagenMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-12-14</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:SeagenMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:NonrecurringAdjustmentAxis">pfe:RestructuringIntegrationAndAcquisitionRelatedCostsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-12-14</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:SeagenMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:NonrecurringAdjustmentAxis">us-gaap:FairValueAdjustmentToInventoryMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-12-14</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:SeagenMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:NonrecurringAdjustmentAxis">pfe:AmortizationExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-12-14</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:SeagenMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:NonrecurringAdjustmentAxis">pfe:DepreciationExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-12-14</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:SeagenMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:SeagenMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:SeagenMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:NonrecurringAdjustmentAxis">pfe:AmortizationExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:SeagenMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:NonrecurringAdjustmentAxis">pfe:AmortizationExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:SeagenMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:NonrecurringAdjustmentAxis">us-gaap:FairValueAdjustmentToInventoryMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:SeagenMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:NonrecurringAdjustmentAxis">us-gaap:FairValueAdjustmentToInventoryMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:SeagenMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:NonrecurringAdjustmentAxis">us-gaap:InterestExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:SeagenMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:NonrecurringAdjustmentAxis">us-gaap:InterestExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:SeagenMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:NonrecurringAdjustmentAxis">us-gaap:InterestIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:SeagenMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:NonrecurringAdjustmentAxis">us-gaap:InterestIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:GBTMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:GBTMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-10-05</xbrli:startdate><xbrli:enddate>2022-10-05</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:GBTMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">pfe:RestructuringChargesAndAcquisitionRelatedCostsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-10-05</xbrli:startdate><xbrli:enddate>2022-10-05</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:GBTMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:GBTMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:GBTMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-10-05</xbrli:startdate><xbrli:enddate>2022-10-05</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:BiohavenMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:BiohavenMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-10-01</xbrli:startdate><xbrli:enddate>2022-10-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:BiohavenMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-10-03</xbrli:startdate><xbrli:enddate>2022-10-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:BiohavenMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:BiohavenMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:BiohavenMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-10-03</xbrli:startdate><xbrli:enddate>2022-10-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:BiohavenMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArenaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArenaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-03-11</xbrli:startdate><xbrli:enddate>2022-03-11</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArenaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArenaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AssetAcquisitionAxis">pfe:ReViralAssetAcquisitionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-06-09</xbrli:startdate><xbrli:enddate>2022-06-09</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2023-09-19</xbrli:startdate><xbrli:enddate>2023-09-19</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="pfe:AgreementAxis">pfe:ManufacturingAndSupplyAgreementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">pfe:ViatrisMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="pfe:AgreementAxis">pfe:ManufacturingAndSupplyAgreementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">pfe:ViatrisMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">pfe:ViatrisMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">pfe:ViatrisMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:HaleonMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:HaleonMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-03-01</xbrli:startdate><xbrli:enddate>2024-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:HaleonMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">pfe:SaleOfEquityMethodInvestmentInPublicStockOfferingMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-03-01</xbrli:startdate><xbrli:enddate>2024-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:HaleonMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">pfe:SaleOfEquityMethodInvestmentInPrivatePlacementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-03-01</xbrli:startdate><xbrli:enddate>2024-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:HaleonMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-10-01</xbrli:startdate><xbrli:enddate>2024-10-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:HaleonMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">pfe:SaleOfEquityMethodInvestmentInPublicStockOfferingMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-10-01</xbrli:startdate><xbrli:enddate>2024-10-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:HaleonMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">pfe:SaleOfEquityMethodInvestmentInPrivatePlacementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-10-01</xbrli:startdate><xbrli:enddate>2024-10-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:HaleonMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:HaleonMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:HaleonMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:HaleonMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:HaleonMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:HaleonMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-04-01</xbrli:startdate><xbrli:enddate>2024-06-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:HaleonMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-07-01</xbrli:startdate><xbrli:enddate>2024-09-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:HaleonMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:HaleonMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:HaleonMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-10-02</xbrli:startdate><xbrli:enddate>2024-09-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:HaleonMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-10-01</xbrli:startdate><xbrli:enddate>2023-09-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-10-01</xbrli:startdate><xbrli:enddate>2022-09-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="dei:LegalEntityAxis">pfe:GSKMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="dei:LegalEntityAxis">pfe:GSKMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">pfe:ConsumerHealthcareJVSeniorNotesUSDDenominatedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="dei:LegalEntityAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">pfe:ConsumerHealthcareJVSeniorNotesEURDenominatedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="dei:LegalEntityAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">pfe:ConsumerHealthcareJVSeniorNotesGBPDenominatedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="dei:LegalEntityAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">pfe:A1365ConsumerHealthcareJVLoanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-07-01</xbrli:startdate><xbrli:enddate>2022-07-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">pfe:A1365ConsumerHealthcareJVLoanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">pfe:BiohavenMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-04</xbrli:startdate><xbrli:enddate>2022-01-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">pfe:BiohavenMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">pfe:BlackstoneMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-04-01</xbrli:startdate><xbrli:enddate>2023-04-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">pfe:BlackstoneMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">pfe:BlackstoneMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pfe:ClinicalTrialAgreementTermsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">pfe:BlackstoneMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pfe:NetSalesAndRoyaltyAgreementTermsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">pfe:BlackstoneMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringPlanAxis">pfe:RealigningOurCostBaseProgramMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringPlanAxis">pfe:RealigningOurCostBaseProgramMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringPlanAxis">pfe:RealigningOurCostBaseProgramMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-10-02</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringPlanAxis">pfe:ManufacturingOptimizationProgramPhaseOneMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringPlanAxis">pfe:ManufacturingOptimizationProgramMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringPlanAxis">pfe:ManufacturingOptimizationProgramMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringPlanAxis">pfe:RealigningOurCostBaseProgramMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RestructuringPlanAxis">pfe:RealigningOurCostBaseProgramMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-10-02</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringPlanAxis">pfe:RealigningOurCostBaseProgramMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringPlanAxis">pfe:TransformingToAMoreFocusedCompanyPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringPlanAxis">pfe:TransformingToAMoreFocusedCompanyPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:SeagenMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">pfe:RestructuringChargesAndAcquisitionRelatedCostsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-10-02</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArenaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">pfe:RestructuringChargesAndAcquisitionRelatedCostsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:GBTMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">pfe:RestructuringChargesAndAcquisitionRelatedCostsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-10-03</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:SeagenMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:TelavantHoldingsIncMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:CerevelTherapeuticsHoldingsIncMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:BioNTechMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:BioNTechAndCerevelTherapeuticsLLCMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-09-30</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:B7H4VFelmetatugVedotinMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-09-30</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:BrandMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:MedrolMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-09-30</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ZavzpretMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-09-30</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:TukysaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-09-30</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:DisitamabVedotinMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="pfe:IndefiniteLivedIntangibleAssetsAndFiniteLivedIntangibleAssetsByMajorClassAxis">pfe:OtherDevelopedTechnologyRightsInProcessResearchAndDevelopmentAndFiniteLivedLicensingAgreementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-10-02</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:EtrasimodVelsipityMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:Prevnar13Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="pfe:IndefiniteLivedIntangibleAssetsAndFiniteLivedIntangibleAssetsByMajorClassAxis">pfe:OtherInProcessResearchAndDevelopmentAndDevelopedTechnologyRightsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:HospiraMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:GenericSterileInjectableProductMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2024-07-01</xbrli:startdate><xbrli:enddate>2024-09-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:NimbusMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="pfe:AgreementAxis">pfe:TransitionServiceAgreementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ViiVMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:BrandMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:BrandMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:BrandMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:BrandMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:BrandMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:NoncurrentDeferredTaxLiabilitiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:NoncurrentDeferredTaxLiabilitiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:IncomeTaxesPayableMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:CurrentTaxAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:OtherTaxesPayableMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:IncomeTaxesPayableMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:CurrentTaxAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:OtherTaxesPayableMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-334"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-335"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-336"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-337"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-338"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-339"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-340"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-341"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-342"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-343"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-344"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-345"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-346"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-347"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-348"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-349"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-350"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-351"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-352"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-353"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-354"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-355"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-356"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-357"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-358"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-359"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-360"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-361"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-362"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-363"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-364"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-365"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-366"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-367"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-368"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-369"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-370"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-371"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-372"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-373"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-374"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-375"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-376"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-377"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-378"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-379"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-380"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-381"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-382"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-383"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-384"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-385"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-386"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">pfe:CreditFacilityMaturingOctober2025Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-387"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">pfe:CreditFacilityMaturingOctober2029Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-388"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-389"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2025Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-390"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2025Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-391"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2026Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-392"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2026Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-393"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2027Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-394"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2027Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-395"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2028Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-396"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2028Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-397"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2029Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-398"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2029Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-399"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2030Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-400"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2030Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue20312035Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue20312035Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue20362040Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue20362040Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue20412045Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue20412045Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue20462050Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue20462050Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue20512063Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-410"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue20512063Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-414"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-418"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-419"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-421"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="pfe:HedgedItemAxis">us-gaap:SalesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="pfe:HedgedItemAxis">us-gaap:SalesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-431"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-432"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-433"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-434"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-435"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">pfe:ForeignCurrencyDebtMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-436"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">pfe:ForeignCurrencyDebtMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-437"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-438"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-439"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-440"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-441"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-442"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-443"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-444"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-445"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-446"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-447"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-448"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-449"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-450"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-451"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-452"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-453"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-454"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-455"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-456"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-457"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-458"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-459"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-460"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-461"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-462"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-463"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-464"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-465"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">pfe:DevelopedMarketsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-466"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">pfe:DevelopedMarketsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-467"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">pfe:InternationalEmergingMarketsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-468"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">pfe:InternationalEmergingMarketsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-469"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-470"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-471"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-472"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-473"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-474"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-475"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-476"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-477"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-478"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:TalazoparibTalzennaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-479"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:TalazoparibTalzennaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-480"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:DepoMedrolMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-481"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-482"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-483"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-484"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-485"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-486"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-487"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-488"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-489"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-490"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-491"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-492"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-493"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-494"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-495"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-496"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-497"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-498"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-499"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-500"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-506"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-507"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-509"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-511"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-514"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-515"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-516"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-517"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-518"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-519"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-520"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-521"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-522"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-525"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-527"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-528"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-529"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-530"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-532"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-533"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-534"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-535"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-536"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-537"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-538"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-539"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-540"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-541"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-542"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-543"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-544"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-545"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-546"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-547"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-548"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-549"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-550"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-551"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-552"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-553"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-554"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-555"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-556"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-557"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-558"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-559"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-560"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-561"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-562"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-563"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-564"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-565"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-566"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-567"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-568"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-569"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-570"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-571"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-572"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-573"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-574"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-575"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:OtherCommingledFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-576"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:OtherCommingledFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-577"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:OtherCommingledFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-578"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:OtherCommingledFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-579"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:OtherCommingledFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-580"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:OtherCommingledFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-581"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:OtherCommingledFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-582"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:OtherCommingledFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-583"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-584"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-585"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-586"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-587"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-588"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-589"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-590"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-591"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-592"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-593"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-594"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-595"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-596"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-597"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-598"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-599"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-600"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-603"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-604"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-605"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-606"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-607"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-609"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-610"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-611"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-612"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-613"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-614"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-619"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-620"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-621"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-622"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-623"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-624"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-625"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-626"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-627"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-631"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-632"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-633"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-634"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-635"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-636"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-637"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-638"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-639"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-640"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-641"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-642"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-643"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-644"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-645"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-646"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-647"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-648"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-649"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-650"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-651"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-652"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-653"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-654"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-655"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-656"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-657"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-658"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-659"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-660"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-661"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-662"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-663"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-664"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-665"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-666"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-667"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-668"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-669"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-670"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-671"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-672"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-673"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-674"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-675"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-676"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-677"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-678"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-679"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-680"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-681"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-682"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-683"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-684"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-685"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-686"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-687"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-688"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-689"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-690"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-691"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-692"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-693"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-694"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-695"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-696"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-697"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-698"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-699"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-700"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-705"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-706"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-707"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-708"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-709"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-710"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-711"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDebtSecurityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-713"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDebtSecurityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-714"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanOtherInvestmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanOtherInvestmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-716"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-717"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-718"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-720"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDebtSecurityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-721"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDebtSecurityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-722"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanOtherInvestmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-723"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanOtherInvestmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-724"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-725"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-728"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">pfe:CommonESOPPlanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">pfe:CommonESOPPlanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-732"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">pfe:CommonESOPPlanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-733"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">pfe:BreakthroughPerformanceAwardsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-734"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">pfe:BreakthroughPerformanceAwardsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-735"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-736"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-737"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-738"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">pfe:PortfolioPerformanceSharesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-739"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">pfe:BreakthroughPerformanceAwardsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-740"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-741"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-742"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-743"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-744"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-745"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-746"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">pfe:PortfolioPerformanceSharesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-747"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">pfe:PortfolioPerformanceSharesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-748"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-749"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-750"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-751"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">pfe:BreakthroughPerformanceAwardsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-752"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">pfe:BreakthroughPerformanceAwardsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-753"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-754"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-755"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-756"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-757"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-758"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-759"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">pfe:PortfolioPerformanceSharesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-760"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">pfe:PortfolioPerformanceSharesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-761"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">pfe:PortfolioPerformanceSharesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-762"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-763"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-764"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-765"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-766"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-767"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-768"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-769"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-770"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-771"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-772"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">pfe:PortfolioPerformanceSharesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-773"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">pfe:PortfolioPerformanceSharesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-774"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">pfe:PortfolioPerformanceSharesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-775"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-776"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-777"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-778"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-779"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-780"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-781"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">pfe:ProfitUnitsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-782"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">pfe:ProfitUnitsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-783"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:VestingAxis">pfe:TotalShareholderReturnUnitsVestingPeriodOneMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-784"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:VestingAxis">pfe:TotalShareholderReturnUnitsVestingPeriodTwoMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-785"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:AwardDateAxis">pfe:CertainTSRUsGrantedIn2022And2023Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-786"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:AwardDateAxis">pfe:CertainTSRUsGrantedIn2022And2023Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-787"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:AwardDateAxis">pfe:RestrictedStockUnitsGrantedBefore2022Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-788"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-789"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-790"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-791"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:AwardDateAxis">pfe:PSAsGrantedIn2022And2023Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-792"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-793"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-794"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">pfe:PfizerAndVersusSeveralGenericManufacturersMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-08-01</xbrli:startdate><xbrli:enddate>2022-08-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-795"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="pfe:ExpirationPeriodAxis">pfe:Expiring2030Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">pfe:PfizerAndVersusSeveralGenericManufacturersMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-08-01</xbrli:startdate><xbrli:enddate>2022-08-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-796"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="pfe:ExpirationPeriodAxis">pfe:Expiring2033Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">pfe:PfizerAndVersusSeveralGenericManufacturersMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-08-01</xbrli:startdate><xbrli:enddate>2022-08-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-797"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">pfe:PfizerAndVersusSeveralGenericManufacturersMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-09-01</xbrli:startdate><xbrli:enddate>2022-09-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-798"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">pfe:PfizerAndVersusSeveralGenericManufacturersMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2025-01-01</xbrli:startdate><xbrli:enddate>2025-01-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-799"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="dei:LegalEntityAxis">pfe:TevaPharmaceuticalsIncMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInvalidityAndNonInfringementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">pfe:PfizerVersusTevaPharmaceuticalsIncMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-08-01</xbrli:startdate><xbrli:enddate>2022-08-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-800"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">pfe:PfizerVersusTevaPharmaceuticalsIncMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInvalidityAndNonInfringementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-06-01</xbrli:startdate><xbrli:enddate>2023-06-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">pfe:AlnylamPatentInfringementCaseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-05-01</xbrli:startdate><xbrli:enddate>2023-05-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-802"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">pfe:ModernaTXUSPatentInfringementCaseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-08-01</xbrli:startdate><xbrli:enddate>2022-08-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">pfe:ModernaTXUSPatentInfringementCaseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-03-01</xbrli:startdate><xbrli:enddate>2024-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-804"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">pfe:ModernaTXEuropeanPatentInfringementCaseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-08-01</xbrli:startdate><xbrli:enddate>2022-08-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">pfe:ModernaTXEuropeanPatentInfringementCaseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-09-01</xbrli:startdate><xbrli:enddate>2022-09-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2023-11-01</xbrli:startdate><xbrli:enddate>2023-11-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">pfe:ModernaTXEuropeanPatentInfringementCaseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-07-01</xbrli:startdate><xbrli:enddate>2024-07-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-808"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">pfe:ArbutusAndGenevantUSPatentInfringementCaseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-04-01</xbrli:startdate><xbrli:enddate>2023-04-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-809"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">pfe:GlaxoSmithKlineBiologicsSAAndGlaxoSmithKlineLLCUSPatentInfringementCaseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-04-01</xbrli:startdate><xbrli:enddate>2024-04-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-810"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">pfe:GlaxoSmithKlineBiologicsSAAndGlaxoSmithKlineLLCUSPatentInfringementCaseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-08-01</xbrli:startdate><xbrli:enddate>2024-08-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-811"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">pfe:GlaxoSmithKlineBiologicsSAAndGlaxoSmithKlineLLCUSPatentInfringementCaseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:AbrysvoMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-08-01</xbrli:startdate><xbrli:enddate>2023-08-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-812"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">pfe:GlaxoSmithKlineBiologicsSAAndGlaxoSmithKlineLLCUSPatentInfringementCaseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:AbrysvoMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-11-01</xbrli:startdate><xbrli:enddate>2023-11-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-813"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">pfe:GlaxoSmithKlineBiologicsSAAndGlaxoSmithKlineLLCUSPatentInfringementCaseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:AbrysvoMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-11-01</xbrli:startdate><xbrli:enddate>2024-11-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-814"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">pfe:GlaxoSmithKlineBiologicsSAAndGlaxoSmithKlineLLCUSPatentInfringementCaseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:AbrysvoMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-10-01</xbrli:startdate><xbrli:enddate>2024-10-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">pfe:PfizerBioNTechAndBioNTechManufacturingGmbHVersusCureVacJudgmentOfNonInfringementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-07-01</xbrli:startdate><xbrli:enddate>2022-07-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-816"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">pfe:PfizerBioNTechAndBioNTechManufacturingGmbHVersusCureVacJudgmentOfNonInfringementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-05-01</xbrli:startdate><xbrli:enddate>2023-05-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-817"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">pfe:GreenstoneAntitrustLitigationMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-818"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">pfe:GovernmentInquiresRelatingToBiohavenMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">pfe:U.S.AndParticipatingStatesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2025-01-01</xbrli:startdate><xbrli:enddate>2025-01-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-819"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">pfe:GovernmentInquiresRelatingToBiohavenMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">pfe:CaliforniaDepartmentOfInsuranceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2025-01-01</xbrli:startdate><xbrli:enddate>2025-01-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-820"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-822"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-824"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-825"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-826"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsAmortizationOfIntangibleAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-827"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsAmortizationOfIntangibleAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsAmortizationOfIntangibleAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-829"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsAcquisitionRelatedCostsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsAcquisitionRelatedCostsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsAcquisitionRelatedCostsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-832"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsOtherMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-833"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsOtherMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-834"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsOtherMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-835"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReclassificationTypeAxis">us-gaap:ReclassificationOtherMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-836"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReclassificationTypeAxis">us-gaap:ReclassificationOtherMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-837"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PaxlovidEUALabeledMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-838"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PaxlovidEUALabeledMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-839"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PaxlovidEUALabeledMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-840"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PaxlovidMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-841"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-842"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-843"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-844"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:HaleonMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-09-30</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-845"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-846"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-847"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-848"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PaxlovidMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-849"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PaxlovidMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-850"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PaxlovidMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-851"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ExcludingComirnatyAndPaxlovidMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-852"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ExcludingComirnatyAndPaxlovidMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-853"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ExcludingComirnatyAndPaxlovidMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-854"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-855"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-856"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-857"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">pfe:InternationalDevelopedMarketsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-858"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">pfe:InternationalDevelopedMarketsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-859"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">pfe:InternationalDevelopedMarketsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-860"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">pfe:InternationalEmergingMarketsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-861"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">pfe:InternationalEmergingMarketsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-862"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">pfe:InternationalEmergingMarketsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-863"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">pfe:NonUnitedStatesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-864"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">pfe:NonUnitedStatesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-865"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">pfe:NonUnitedStatesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-866"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-867"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-868"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-869"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-870"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-871"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-872"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PaxlovidEUALabeledMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-873"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PaxlovidEUALabeledMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-874"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PaxlovidEUALabeledMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-02-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-875"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PaxlovidNDALabeledUSStrategicNationalStockpileMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-876"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PaxlovidNDALabeledUSStrategicNationalStockpileMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-07-01</xbrli:startdate><xbrli:enddate>2024-09-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-877"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:MajorCustomersAxis">pfe:McKessonInc.Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-878"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:MajorCustomersAxis">pfe:McKessonInc.Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-879"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:MajorCustomersAxis">pfe:McKessonInc.Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-880"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:MajorCustomersAxis">pfe:CencoraInc.Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-881"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:MajorCustomersAxis">pfe:CencoraInc.Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-882"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:MajorCustomersAxis">pfe:CencoraInc.Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-883"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:MajorCustomersAxis">pfe:CardinalHealthInc.Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-884"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:MajorCustomersAxis">pfe:CardinalHealthInc.Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-885"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:MajorCustomersAxis">pfe:CardinalHealthInc.Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-886"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:MajorCustomersAxis">pfe:USGovernmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-887"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:MajorCustomersAxis">pfe:USGovernmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-888"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:MajorCustomersAxis">pfe:USGovernmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-889"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:MajorCustomersAxis">pfe:ThreeLargestUSWholesaleCustomersMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-890"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:MajorCustomersAxis">pfe:ThreeLargestUSWholesaleCustomersMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-891"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-892"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-893"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-894"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-895"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-896"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-897"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PrevnarPrevenarFamilyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-898"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PrevnarPrevenarFamilyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-899"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PrevnarPrevenarFamilyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-900"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:NurtecODTVyduraMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-901"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:NurtecODTVyduraMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-902"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:NurtecODTVyduraMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-903"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:AbrysvoMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-904"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:AbrysvoMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-905"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:AbrysvoMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-906"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PremarinFamilyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-907"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PremarinFamilyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-908"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PremarinFamilyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-909"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BMP2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-910"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BMP2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-911"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BMP2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-912"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:FSMEIMMUNTicoVacMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-913"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:FSMEIMMUNTicoVacMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-914"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:FSMEIMMUNTicoVacMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:OtherPrimaryCareProductsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-916"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:OtherPrimaryCareProductsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-917"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:OtherPrimaryCareProductsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-918"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-919"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-920"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-921"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:VyndaqelMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-922"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:VyndaqelMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-923"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:VyndaqelMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-924"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-925"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-926"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-928"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-929"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:SulperazonMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-931"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:SulperazonMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-932"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:SulperazonMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-933"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ZaviceftaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-934"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ZaviceftaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-935"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ZaviceftaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-936"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:OctagamMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-937"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:OctagamMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-938"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:OctagamMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-939"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:InflectraRemsimaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-940"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:InflectraRemsimaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-941"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:InflectraRemsimaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-942"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ZithromaxZmaxMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-943"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ZithromaxZmaxMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-944"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ZithromaxZmaxMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-945"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:GenotropinMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-946"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:GenotropinMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-947"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:GenotropinMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-948"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BeneFIXMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-949"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BeneFIXMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-950"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BeneFIXMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-951"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:CibinqoMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-952"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:CibinqoMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-953"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:CibinqoMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-954"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:OxbrytaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-955"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:OxbrytaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-956"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:OxbrytaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-957"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:OtherHospitalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-958"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:OtherHospitalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-959"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:OtherHospitalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-960"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:OtherSpecialtyCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-961"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:OtherSpecialtyCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-962"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:OtherSpecialtyCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-963"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-964"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-965"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-966"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:IbranceMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-967"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:IbranceMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-968"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:IbranceMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-969"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:XtandiMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-970"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:XtandiMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-971"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:XtandiMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-972"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PadcevMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-973"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PadcevMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-974"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PadcevMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-975"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:AdcetrisMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-976"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:AdcetrisMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-977"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:AdcetrisMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-978"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:OncologyBiosimilarsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-979"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:OncologyBiosimilarsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-980"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:OncologyBiosimilarsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-981"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:InlytaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-982"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:InlytaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-983"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:InlytaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-984"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:LorbrenaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-985"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:LorbrenaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-986"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:LorbrenaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-987"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-988"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-989"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-990"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BraftoviMektoviMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-991"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BraftoviMektoviMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-992"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BraftoviMektoviMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-993"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:TukysaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-994"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:TukysaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-995"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:TukysaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-996"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ElrexfioMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-997"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ElrexfioMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-998"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ElrexfioMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-999"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:TivdakMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-1000"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:TivdakMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-1001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:TivdakMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-1002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:TalzennaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-1003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:TalzennaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-1004"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:TalzennaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-1005"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:OtherOncologyProductsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-1006"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:OtherOncologyProductsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-1007"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:OtherOncologyProductsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-1008"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PfizerCentreOneMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-1009"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PfizerCentreOneMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-1010"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PfizerCentreOneMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-1011"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PfizerIgniteMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-1012"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PfizerIgniteMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-1013"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PfizerIgniteMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-1014"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsegmentsAxis">pfe:U.S.CommercialDivisionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-1015"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsegmentsAxis">pfe:U.S.CommercialDivisionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-1016"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsegmentsAxis">pfe:U.S.CommercialDivisionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-1017"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsegmentsAxis">pfe:OncologyDivisionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-1018"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsegmentsAxis">pfe:OncologyDivisionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-1019"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsegmentsAxis">pfe:OncologyDivisionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-1020"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsegmentsAxis">pfe:InternationalCommercialDivisionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-1021"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsegmentsAxis">pfe:InternationalCommercialDivisionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-1022"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsegmentsAxis">pfe:InternationalCommercialDivisionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-1023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:TotalAllianceBiopharmaceuticalsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-1024"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:TotalAllianceBiopharmaceuticalsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-1025"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:TotalAllianceBiopharmaceuticalsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-1026"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PaxlovidEUALabeledMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-1027"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">pfe:CommercializationPartnerMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:OctagamMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-1028"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PaxlovidMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1030"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PaxlovidAndComirnatyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PaxlovidAndComirnatyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1032"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PaxlovidNDALabeledUSStrategicNationalStockpileMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-1033"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PaxlovidAndComirnatyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2024-01-01</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="c-1034"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2024-09-30</xbrli:startdate><xbrli:enddate>2024-12-31</xbrli:enddate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-60 f-61 f-62" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-1" order="1"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-66 f-67 f-68 f-69 f-70 f-71 f-72 f-73 f-74" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-2" order="2"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-66 f-67 f-68" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-3" order="3"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-141 f-142 f-143" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-4" order="4"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-150 f-151 f-152" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-5" order="5"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-426 f-427 f-428 f-435 f-436 f-437" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-6" order="6"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-444 f-445 f-446" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-7" order="7"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-471 f-472 f-473 f-477 f-478 f-479" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-8" order="8"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-594 f-597 f-600 f-603 f-606 f-609 f-612 f-615 f-618 f-621 f-624" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-9" order="9"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-593 f-594 f-595" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-10" order="10"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-596 f-597 f-598" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-11" order="11"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-602 f-603 f-604" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-12" order="12"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-611 f-612 f-613" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-13" order="13"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-726 f-727" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-14" order="14"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-728 f-729 f-730 f-731 f-732 f-733" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-15" order="15"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-728 f-729" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-16" order="16"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-730 f-731" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-17" order="17"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-734 f-735" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-18" order="18"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-736 f-737" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-19" order="19"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-837 f-838 f-839" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-20" order="20"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-840 f-841 f-842" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-21" order="21"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-843 f-844 f-845" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-22" order="22"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-849 f-850 f-851" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-23" order="23"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-852 f-853 f-854" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-24" order="24"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-855 f-856 f-857" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-25" order="25"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-858 f-859 f-860" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-26" order="26"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-861 f-862 f-863" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-27" order="27"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-890 f-891 f-892" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-28" order="28"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-893 f-894 f-895" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-29" order="29"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-896 f-897 f-898" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-30" order="30"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-905 f-906 f-907 f-908 f-909 f-910 f-911 f-912 f-913" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-31" order="31"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-914 f-915 f-916 f-917 f-918 f-919 f-920 f-921 f-922 f-923 f-924 f-925" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-32" order="32"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-949 f-950 f-951 f-952 f-961 f-962 f-963 f-964" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-33" order="33"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-953 f-954 f-955 f-956" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-34" order="34"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-965 f-966 f-967 f-968" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-35" order="35"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-978 f-979 f-980" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-36" order="36"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-981 f-982 f-983" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-37" order="37"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-984 f-985 f-986" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-38" order="38"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-993 f-994 f-995" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-39" order="39"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-996 f-997 f-998" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-40" order="40"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-999 f-1000 f-1001" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-41" order="41"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1002 f-1003 f-1004" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-42" order="42"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1047 f-1048 f-1049 f-1050 f-1052 f-1053 f-1054 f-1055 f-1057 f-1058 f-1059 f-1060 f-1062 f-1063 f-1064 f-1065 f-1067 f-1068 f-1069 f-1070" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-43" order="43"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1034 f-1047 f-1048 f-1049 f-1050 f-1051 f-1052 f-1053 f-1054 f-1055 f-1056 f-1057 f-1058 f-1059 f-1060 f-1061 f-1062 f-1063 f-1064 f-1065 f-1066" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-44" order="44"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1083 f-1084 f-1085" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-45" order="45"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1083 f-1084 f-1085" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-46" order="46"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1131 f-1134 f-1137 f-1140 f-1143 f-1146 f-1149 f-1152 f-1155 f-1158 f-1161" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-47" order="47"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1133 f-1134 f-1135" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-48" order="48"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1133 f-1134 f-1135" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-49" order="49"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1136 f-1137 f-1138 f-1139 f-1140 f-1141" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-50" order="50"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1142 f-1143 f-1144" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-51" order="51"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1145 f-1146 f-1147" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-52" order="52"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1154 f-1155 f-1156" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-53" order="53"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1157 f-1158 f-1159" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-54" order="54"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1164 f-1165 f-1166 f-1167 f-1168 f-1169 f-1170 f-1171 f-1172 f-1173 f-1174 f-1175 f-1176 f-1177 f-1178 f-1179 f-1180 f-1181 f-1182 f-1183 f-1184 f-1185 f-1186 f-1187 f-1188 f-1189 f-1190 f-1191 f-1192 f-1193 f-1194 f-1195 f-1196 f-1197 f-1198 f-1199 f-1200 f-1201 f-1202 f-1203 f-1204 f-1205 f-1206 f-1207 f-1208 f-1209 f-1210 f-1211 f-1212 f-1213 f-1214 f-1215 f-1216 f-1217 f-1218 f-1219" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-55" order="55"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1164 f-1165 f-1166 f-1167" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-56" order="56"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1172 f-1173 f-1174 f-1175" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-57" order="57"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1176 f-1177 f-1178 f-1179" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-58" order="58"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1184 f-1185 f-1186 f-1187" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-59" order="59"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1192 f-1193" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-60" order="60"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1194 f-1195" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-61" order="61"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1218 f-1219" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-62" order="62"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1218 f-1219" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-63" order="63"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1240 f-1241 f-1242 f-1243 f-1244 f-1245 f-1249 f-1250 f-1251 f-1255 f-1256 f-1257" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-64" order="64"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1240 f-1241 f-1242" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-65" order="65"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1243 f-1244 f-1245 f-1246 f-1247 f-1248" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-66" order="66"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1246 f-1247 f-1248" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-67" order="67"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1255 f-1256 f-1257" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-68" order="68"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1258 f-1259 f-1260" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-69" order="69"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1280 f-1281 f-1282" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-70" order="70"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1318 f-1323 f-1328 f-1333 f-1338 f-1343 f-1348" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-71" order="71"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1323 f-1324 f-1325 f-1326 f-1327 f-1333 f-1334 f-1335 f-1336 f-1337 f-1343 f-1344 f-1345 f-1346 f-1347" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-72" order="72"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1355 f-1356 f-1357 f-1358 f-1359 f-1360 f-1515" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-73" order="73"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1403 f-1404 f-1405 f-1406 f-1407 f-1408" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-74" order="74"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1451 f-1452 f-1453 f-1454 f-1455 f-1456" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-75" order="75"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1523 f-1524 f-1541 f-1542" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-76" order="76"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1531 f-1532 f-1537 f-1538" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-77" order="77"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1617 f-1618" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-78" order="78"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1623 f-1624 f-1625" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-79" order="79"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1629 f-1630" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-80" order="80"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1633 f-1634" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-81" order="81"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1652 f-1653 f-1656 f-1657 f-1660 f-1661 f-1664 f-1665 f-1668 f-1669 f-1672 f-1673 f-1676 f-1677 f-1680 f-1681 f-1684 f-1685 f-1688 f-1689 f-1692 f-1693 f-1694 f-1695 f-1696 f-1698 f-1699 f-1700 f-1701 f-1703 f-1704" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-82" order="82"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1652 f-1653" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-83" order="83"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1711 f-1712 f-1713 f-1714 f-1715 f-1716" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-84" order="84"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1742 f-1743 f-1744 f-1745 f-1746 f-1747 f-1748 f-1749 f-1750 f-1751 f-1752 f-1753 f-1754 f-1755 f-1756 f-1757 f-1758 f-1759 f-1760 f-1761 f-1762 f-1763 f-1764 f-1765 f-1766 f-1767 f-1768 f-1769 f-1770 f-1771 f-1772 f-1773 f-1774 f-1775 f-1776 f-1777 f-1778 f-1779 f-1780 f-1781 f-1782" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-85" order="85"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1746 f-1747 f-1748 f-1749" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-86" order="86"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1750 f-1751 f-1752 f-1753 f-1762 f-1763 f-1764 f-1765" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-87" order="87"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1766 f-1767 f-1768 f-1769 f-1770 f-1771 f-1772 f-1773" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-88" order="88"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1792 f-1795" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-89" order="89"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1811 f-1812" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-90" order="90"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1813 f-1814" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-91" order="91"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1862 f-1863 f-1864 f-1865 f-1866 f-1867" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-92" order="92"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1868 f-1869 f-1870 f-1871 f-1872 f-1873 f-1886 f-1887 f-1888 f-1889" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-93" order="93"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1890 f-1891 f-1892 f-1893" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-94" order="94"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1902 f-1903 f-1904 f-1905 f-1906 f-1907" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-95" order="95"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1931 f-1932 f-1933 f-1934 f-1935 f-1936" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-96" order="96"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1932 f-1935" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-97" order="97"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-1976 f-1977 f-1978 f-1979 f-1980 f-1981 f-1982 f-1983 f-1984" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-98" order="98"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-2052 f-2053 f-2054 f-2064 f-2065 f-2066" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-99" order="99"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-2077 f-2078 f-2079 f-2080 f-2081 f-2082 f-2142 f-2143 f-2144 f-2145 f-2146 f-2147" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-100" order="100"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-2107 f-2108 f-2109 f-2110 f-2111 f-2112" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-101" order="101"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-2236 f-2237 f-2238 f-2239 f-2240 f-2241 f-2242 f-2243 f-2244 f-2245 f-2246 f-2247" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-102" order="102"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-2255 f-2260 f-2265 f-2269 f-2274 f-2279 f-2284 f-2292 f-2297 f-2301 f-2306 f-2310 f-2315 f-2320 f-2325 f-2329 f-2333 f-2339 f-2344 f-2349 f-2354 f-2359 f-2364 f-2369 f-2374 f-2379 f-2384 f-2389 f-2394 f-2399 f-2404 f-2409 f-2414 f-2419 f-2424 f-2430 f-2435 f-2443 f-2450 f-2459" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-103" order="103"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-2288 f-2289 f-2290 f-2291 f-2292 f-2293 f-2294 f-2295 f-2296 f-2297 f-2375 f-2376 f-2377 f-2378 f-2379 f-2380 f-2381 f-2382 f-2383 f-2384" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-104" order="104"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-2307 f-2308 f-2309 f-2310 f-2311 f-2312 f-2313 f-2314 f-2315 f-2395 f-2396 f-2397 f-2398 f-2399 f-2400 f-2401 f-2402 f-2403 f-2404" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-105" order="105"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-2326 f-2327 f-2328 f-2329 f-2330 f-2331 f-2332 f-2333 f-2415 f-2416 f-2417 f-2418 f-2419 f-2420 f-2421 f-2422 f-2423 f-2424" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-106" order="106"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-2436 f-2437 f-2438 f-2439 f-2440 f-2441 f-2442 f-2443 f-2444 f-2445 f-2446 f-2447 f-2448 f-2449 f-2450" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-107" order="107"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-2567 f-2568 f-2569 f-2570 f-2571 f-2572 f-2573 f-2574 f-2575 f-2576 f-2577 f-2578 f-2579 f-2580 f-2581" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-108" order="108"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-2678 f-2679 f-2687 f-2688 f-2696 f-2697 f-2707 f-2708 f-2716 f-2717" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-109" order="109"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-2721 f-2722 f-2723 f-2724 f-2725 f-2726 f-2727 f-2728 f-2729 f-2730 f-2731 f-2732 f-2733 f-2734 f-2735" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-110" order="110"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-2721 f-2722 f-2723 f-2724 f-2725 f-2726 f-2727 f-2728 f-2729 f-2730 f-2731 f-2732 f-2733 f-2734 f-2735" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-111" order="111"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-2724 f-2728 f-2732 f-2735" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-112" order="112"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-2729 f-2730 f-2731 f-2732" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-113" order="113"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-2755 f-2759 f-2763" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-114" order="114"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-2756 f-2757 f-2758 f-2759" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-115" order="115"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-2803 f-2804 f-2805" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-116" order="116"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-2852" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-117" order="117"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-2907 f-2908 f-2909 f-2916 f-2917 f-2918 f-2922 f-2923 f-2924 f-2928 f-2929 f-2930 f-2934 f-2935 f-2936 f-2943 f-2944 f-2945" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-118" order="118"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-2910 f-2911 f-2912 f-2919 f-2920 f-2921 f-2925 f-2926 f-2927 f-2931 f-2932 f-2933 f-2937 f-2938 f-2939 f-2946 f-2947 f-2948" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-119" order="119"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-2904 f-2905 f-2906 f-2907 f-2908 f-2909 f-2910 f-2911 f-2912" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-120" order="120"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-2913 f-2914 f-2915 f-2916 f-2917 f-2918 f-2919 f-2920 f-2921" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-121" order="121"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-2934 f-2935 f-2936 f-2937 f-2938 f-2939" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-122" order="122"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-3064 f-3065 f-3066" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-123" order="123"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-3070 f-3071 f-3072" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-124" order="124"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-3112 f-3113 f-3114" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-125" order="125"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-3130 f-3131 f-3132" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-126" order="126"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-3133 f-3134 f-3135" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-127" order="127"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-3145 f-3146 f-3147" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-128" order="128"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-3154 f-3155 f-3156" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-129" order="129"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-3166 f-3167 f-3168" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-130" order="130"><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="f-3184 f-3185 f-3186" linkrole="http://www.xbrl.org/2003/role/link" torefs="fn-131" order="131"></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:relationship></ix:resources></ix:header></div><div id="i8531e747ebb543f3bf818166f157d26a_1"></div><div style="min-height:22.5pt;width:100%"><div><span><br></span></div></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:399.75pt"><tbody><tr><td style="width:1.0pt"></td><td style="width:397.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></tbody></table></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">FORM <ix:nonnumeric contextref="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonnumeric> </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:399.75pt"><tbody><tr><td style="width:1.0pt"></td><td style="width:397.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></tbody></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:531.00pt"><tbody><tr><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:478.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(Mark One)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial Unicode MS&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="c-1" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="f-2">&#9746;</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE&nbsp;ACT OF 1934</span></td></tr></tbody></table></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonnumeric contextref="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3"><ix:nonnumeric contextref="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-4">December&nbsp;31</ix:nonnumeric>, 2024</ix:nonnumeric> </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:531.00pt"><tbody><tr><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:478.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial Unicode MS&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="c-1" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="f-5">&#9744;</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></tbody></table></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">For the transition period from</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">             </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">to           </span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%;text-decoration:underline">Commission file number <ix:nonnumeric contextref="c-1" name="dei:EntityFileNumber" id="f-6">1-3619</ix:nonnumeric> </span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:center"><img src="./PFIZER_files/pfe-20241231_g1.jpg" alt="Pfizer Logo.jpg" style="height:66px;margin-bottom:5pt;vertical-align:text-bottom;width:150px"></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonnumeric contextref="c-1" name="dei:EntityRegistrantName" id="f-7">PFIZER INC</ix:nonnumeric>.</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.548%"><tbody><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonnumeric contextref="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonnumeric contextref="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">13-5315170</ix:nonnumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(I.R.S. Employer Identification Number)</span></td></tr></tbody></table></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="c-1" name="dei:EntityAddressAddressLine1" id="f-10">66 Hudson Boulevard East</ix:nonnumeric>, <ix:nonnumeric contextref="c-1" name="dei:EntityAddressCityOrTown" id="f-11">New York</ix:nonnumeric>, <ix:nonnumeric contextref="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-12">New York</ix:nonnumeric>  <ix:nonnumeric contextref="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">10001-2192</ix:nonnumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address of principal executive offices)  (zip code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonnumeric contextref="c-1" name="dei:CityAreaCode" id="f-14">212</ix:nonnumeric>) <ix:nonnumeric contextref="c-1" name="dei:LocalPhoneNumber" id="f-15">733-2323</ix:nonnumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrants telephone number, including area code)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.548%"><tbody><tr><td style="width:1.0%"></td><td style="width:34.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.677%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-top:1pt solid #acacac;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&nbsp;12(b) of the Act:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Name&nbsp;of&nbsp;each&nbsp;exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="c-2" name="dei:Security12bTitle" id="f-16">Common Stock, $0.05 par value</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="c-2" name="dei:TradingSymbol" id="f-17">PFE</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="c-2" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">New York Stock Exchange</ix:nonnumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="c-3" name="dei:Security12bTitle" id="f-19">1.000% Notes due 2027</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="c-3" name="dei:TradingSymbol" id="f-20">PFE27</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="c-3" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-21">New York Stock Exchange</ix:nonnumeric></span></td></tr></tbody></table></div><div style="margin-bottom:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:276.00pt"><tbody><tr><td style="width:1.0pt"></td><td style="width:274.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="border-bottom:0.5pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&nbsp;12(g) of the Act: </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">None</span></div></td></tr></tbody></table></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. &nbsp;&nbsp;&nbsp;<ix:nonnumeric contextref="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-22">Yes</ix:nonnumeric>&nbsp;&nbsp;</span><span style="color:#000000;font-family:&#39;Arial Unicode MS&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;</span><span style="color:#000000;font-family:&#39;Arial Unicode MS&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.&nbsp;&nbsp;&nbsp;Yes&nbsp;</span><span style="color:#000000;font-family:&#39;Arial Unicode MS&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;&nbsp;</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;<ix:nonnumeric contextref="c-1" name="dei:EntityVoluntaryFilers" id="f-23">No</ix:nonnumeric>&nbsp;&nbsp;</span><span style="color:#000000;font-family:&#39;Arial Unicode MS&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;&nbsp;<ix:nonnumeric contextref="c-1" name="dei:EntityCurrentReportingStatus" id="f-24">Yes</ix:nonnumeric>&nbsp;&nbsp;&nbsp;</span><span style="color:#000000;font-family:&#39;Arial Unicode MS&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:&#39;Wingdings 2&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">No&nbsp;</span><span style="color:#000000;font-family:&#39;Arial Unicode MS&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files.)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<ix:nonnumeric contextref="c-1" name="dei:EntityInteractiveDataCurrent" id="f-25">Yes</ix:nonnumeric>&nbsp;&nbsp;</span><span style="color:#000000;font-family:&#39;Arial Unicode MS&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;</span><span style="color:#000000;font-family:&#39;Arial Unicode MS&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company and emerging growth company in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-26">Large Accelerated filer</ix:nonnumeric></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;Accelerated filer</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-accelerated filer</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;&nbsp;</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Smaller reporting company</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;&nbsp;</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="c-1" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="f-27">&#9744;</ix:nonnumeric></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">      </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Emerging growth company <ix:nonnumeric contextref="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-28">&#9744;</ix:nonnumeric></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;   &#9744;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its managements assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. &#8239;  </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" id="f-29">&#9746;</ix:nonnumeric></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.     <ix:nonnumeric contextref="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-30">&#9744;</ix:nonnumeric></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrants executive officers during the relevant recovery period pursuant to 240.10D-1(b).     &#9744;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<ix:nonnumeric contextref="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-31">&#9746;</ix:nonnumeric></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The aggregate market value of the voting stock held by non-affiliates of the registrant, computed by reference to the closing price as of the last business day of the registrants most recently completed second fiscal quarter was approximately $<ix:nonfraction unitref="usd" contextref="c-4" decimals="-9" name="dei:EntityPublicFloat" scale="9" id="f-32">158</ix:nonfraction> billion. This excludes shares of common stock held by directors and executive officers. Exclusion of shares held by any person should not be construed to indicate that such person possesses the power, directly or indirectly, to direct or cause the direction of the management or policies of the registrant, or that such person is controlled by or under common control with the registrant. The registrant has no non-voting common stock. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The number of shares outstanding of the registrants common stock as of February&nbsp;20, 2025 was <ix:nonfraction unitref="shares" contextref="c-5" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-33">5,667,340,414</ix:nonfraction> shares of common stock, all of one class.</span></div><ix:nonnumeric contextref="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-34" escape="true"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:489.75pt"><tbody><tr><td style="width:1.0pt"></td><td style="width:397.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:9pt"><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Portions of the Proxy Statement for the 2025 Annual Meeting of Shareholders</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Part III</span></td></tr></tbody></table></div></ix:nonnumeric><div style="height:22.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div></div></div><div id="i8531e747ebb543f3bf818166f157d26a_10"></div><hr style="page-break-after:always"><div style="min-height:38.25pt;width:100%"><div><span><br></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:36.111%"><tbody><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #006ebf;border-top:1pt dotted #006ebf;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></td></tr></tbody></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:93.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_13">Defined Terms</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_13">i</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_16">Available Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_16">iii</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_19">Forward-Looking Information and Factors that May Affect Future Results</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_19">1</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><a style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_22">PART I</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_25">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_25">ITEM&nbsp;1. BUSINESS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_28">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_28">About Pfizer</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_28">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_31">Commercial Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_31">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_34">Research and Development</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_34">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_37">Collaboration and Co-Promotion Agreements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_37">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_40">International Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_40">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_43">Sales and Marketing</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_43">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_46">Patents and Other Intellectual Property Rights</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_46">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_49">Competition</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_49">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_52">Pricing Pressures and Managed Care Organizations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_52">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_55">Raw Materials</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_55">10</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_58">Government Regulation and Price Constraints</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_58">10</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_61">Environmental Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_61">13</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_64">Our People</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_64">14</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67">ITEM&nbsp;1A. RISK FACTORS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67">15</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">ITEM&nbsp;1B. UNRESOLVED STAFF COMMENTS</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_70">ITEM 1C. CYBERSECURITY</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_70">24</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_73">ITEM&nbsp;2. PROPERTIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_73">25</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_76">ITEM&nbsp;3. LEGAL PROCEEDINGS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_76">25</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">ITEM&nbsp;4. MINE SAFETY DISCLOSURES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_79">INFORMATION ABOUT OUR EXECUTIVE OFFICERS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_79">26</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><a style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_82">PART II</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_82">27</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_85">ITEM&nbsp; 5. MARKET FOR THE COMPANYS COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_85">27</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_91">ITEM&nbsp;6. [RESERVED]</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_91">27</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_94">ITEM 7. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_94">28</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_151">ITEM&nbsp;7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_151">48</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_154">ITEM&nbsp;8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_154">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_292">ITEM&nbsp;9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_292">106</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_295">ITEM&nbsp;9A. CONTROLS AND PROCEDURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_295">106</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_304">ITEM&nbsp;9B. OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_304">109</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">ITEM&nbsp;9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">N/A</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><a style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_307">PART III</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_307">109</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_310">ITEM&nbsp;10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_310">109</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_313">ITEM&nbsp;11. EXECUTIVE COMPENSATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_313">109</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_316">ITEM&nbsp;12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_316">109</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_319">ITEM&nbsp;13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_319">109</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_322">ITEM&nbsp;14. PRINCIPAL ACCOUNTING FEES AND SERVICES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_322">109</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><a style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_325">PART IV</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_325">109</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_328">ITEM&nbsp;15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_328">109</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_331">15(a)(1) Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_331">109</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_334">15(a)(2) Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_334">110</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_337">15(a)(3) Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_337">110</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_340">ITEM 16. FORM 10-K SUMMARY</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_340">113</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_343">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_343">113</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">N/A = Not Applicable</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></tbody></table></div><div style="height:47.25pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div></div></div><div id="i8531e747ebb543f3bf818166f157d26a_13"></div><hr style="page-break-after:always"><div style="min-height:33.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:36.111%"><tbody><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #006ebf;border-top:1pt dotted #006ebf;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">DEFINED TERMS</span></td></tr></tbody></table></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unless the context requires otherwise, references to Pfizer, the Company, we, us or our in this Form 10-K (defined below) refer to Pfizer Inc. and its subsidiaries. For each year presented, Pfizers fiscal year-end for subsidiaries operating outside the U.S. is as of and for the year ended November&nbsp;30 and for U.S. subsidiaries is as of and for the year ended December 31. References to Notes in this Form 10-K are to the Notes to the consolidated financial statements in </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_154">Item 8. Financial Statements and Supplementary Data</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in this Form 10-K. We also have used several other terms in this Form 10-K, most of which are explained or defined below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:21.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.532%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">*</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Indicates calculation not meaningful or results are greater than 100%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Form 10-K</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K for the fiscal year ended December 31, 2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">2023 Form 10-K</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Our Annual Report on Form 10-K for the fiscal year ended December 31, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">340B Program</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">340B Drug Pricing Program</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Proxy Statement</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Proxy Statement for the 2025 Annual Meeting of Shareholders, which will be filed no later than 120 days after December 31, 2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">ABO</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Accumulated benefit obligation; represents the present value of the benefit obligation earned through the end of the year but does not factor in future compensation increases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">ACIP</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Advisory Committee on Immunization Practices</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">ADC</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Antibody-Drug Conjugate</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Alexion</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Alexion Pharma International Operations Limited, a subsidiary of AstraZeneca PLC</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">ALK</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">anaplastic lymphoma kinase</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenues</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Revenues from alliance agreements under which we co-promote products discovered or developed by other companies or us</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Arena</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5pt;padding-left:6.75pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Arena Pharmaceuticals, Inc.</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">AI</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">artificial intelligence</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Arvinas</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Arvinas, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Astellas</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Astellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">ATTR-CM</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">transthyretin amyloid cardiomyopathy</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Biohaven</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2pt;padding-left:6.75pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Biohaven Pharmaceutical Holding Company Limited</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">BioNTech</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">BioNTech SE</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Biopharma</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Global Biopharmaceuticals Business</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Blackstone</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Blackstone Life Sciences</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">BLA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Biologics License Application</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">BMS</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Bristol-Myers Squibb Company</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">BOD</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Board of Directors</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">CDC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">U.S. Centers for Disease Control and Prevention</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">cGMP</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt;padding-left:6.75pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">current Good Manufacturing Practices</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">CGRP</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">calcitonin gene-related peptide</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">CMS</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt;padding-left:6.75pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Centers for Medicare &amp; Medicaid Services</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">CODM</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Chief Operating Decision Maker</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt;padding-left:6.75pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Unless otherwise noted, refers to, as applicable, and as authorized or approved, the Pfizer-BioNTech COVID-19 Vaccine; Comirnaty (COVID-19 Vaccine, mRNA) original monovalent formula; the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5); the Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula); Comirnaty (COVID-19 Vaccine, mRNA) 2023-2024 Formula; Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula); Comirnaty (COVID-19 Vaccine, mRNA) 2024-2025 Formula; Comirnaty Original/Omicron BA.1; Comirnaty Original/Omicron BA.4/BA.5; Comirnaty Omicron XBB.1.5; Comirnaty JN.1 and Comirnaty KP.2.</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Consumer Healthcare JV</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">GSK Consumer Healthcare JV</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">COVID-19</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">novel coronavirus disease of 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">DEA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">U.S. Drug Enforcement Agency</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Developed Markets</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Includes, but is not limited to, the following markets: Western Europe, Japan, Canada, Central Europe, Australia, Scandinavian countries, South Korea, the Balkans, New Zealand and Finland</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">DMD</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Duchenne muscular dystrophy</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">EC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">European Commission</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">EMA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">European Medicines Agency</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Emerging Markets</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Africa, the Middle East, Eastern Europe (excluding the Balkans) and Turkey</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">EPS</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">earnings per share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">ESOP</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">employee stock ownership plan</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">EU</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">European Union</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">EUA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">emergency use authorization</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Exchange Act</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Securities Exchange Act of 1934, as amended</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">FASB</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Financial Accounting Standards Board</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">FCPA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">U.S. Foreign Corrupt Practices Act</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">FDA</span></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">U.S. Food and Drug Administration</span></td></tr></tbody></table></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">i</span></div></td></tr></tbody></table></div></div></div><hr style="page-break-after:always"><div style="min-height:33.75pt;width:100%"><div><span><br></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:21.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.532%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">FFDCA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">U.S. Federal Food, Drug and Cosmetic Act</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">GAAP</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">U.S. Generally Accepted Accounting Principles</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">GBT</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Global Blood Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">GDFV</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">grant-date fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Genmab</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Genmab A/S</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">GSK</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">GSK plc</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Haleon</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Haleon plc</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">HHS</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">U.S. Department of Health and Human Services</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">HIPAA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Health Insurance Portability and Accountability Act of 1996</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Hospira</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Hospira, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">IPR&amp;D</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">in-process research and development</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">IRA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Inflation Reduction Act of 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">IRC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Internal Revenue Code</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">IRS</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">U.S. Internal Revenue Service</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">IT</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">information technology</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">JV</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">joint venture</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">King</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">King Pharmaceuticals LLC (formerly King Pharmaceuticals, Inc.)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">mCC</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">metastatic cervical cancer</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">MCO</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">managed care organization</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">mCRC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">metastatic colorectal cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">mCRPC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">metastatic castration-resistant prostate cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">mCSPC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">metastatic castration-sensitive prostate cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">MD&amp;A</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Managements Discussion and Analysis of Financial Condition and Results of Operations</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">MDL</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Multi-District Litigation</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">MDPNP</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Medicare Drug Price Negotiation Program</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">MDRP</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Medicaid Drug Rebate Program</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Medicare Part B</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">a medical insurance plan that helps cover medically necessary services, outpatient care, and preventative services for people with Medicare</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Medicare Part D</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">a prescription drug coverage program for people with Medicare</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Meridian</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Meridian Medical Technologies, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Moodys</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Moodys Ratings (formerly Moodys Investors Service) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">mRNA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">messenger ribonucleic acid</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">MSA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Manufacturing Supply Agreement</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Mylan</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Mylan N.V.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">NAV</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">net asset value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">NDA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">New Drug Application</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Nimbus</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Nimbus Therapeutics, LLC</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">nmCRPC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">non-metastatic castration-resistant prostate cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">nmCSPC</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">non-metastatic castration-sensitive prostate cancer</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">NSCLC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">non-small cell lung cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">NYSE</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">New York Stock Exchange</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">ODT</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">oral disintegrating tablet</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Ono</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2pt;padding-left:6.75pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Ono Pharmaceutical Co., Ltd.</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">ORD</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Oncology Research and Development</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">OTC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">over-the-counter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Paxlovid</span><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">an oral COVID-19 treatment (nirmatrelvir tablets and ritonavir tablets)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">PBM</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">pharmacy benefit manager</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">PBO</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Projected benefit obligation; represents the present value of the benefit obligation earned through the end of the year and factors in future compensation increases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">PC1</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Pfizer CentreOne</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">PGS</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Pfizer Global Supply</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Pharmacia</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Pharmacia LLC (formerly Pharmacia Corporation)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">PIE</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Pfizer Investment Enterprises Pte. Ltd. (a wholly-owned finance subsidiary of Pfizer)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">PP&amp;E</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Property, plant and equipment</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Pierre Fabre</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Pierre Fabre Medicament SAS</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">PRAC</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Pharmacovigilance Risk Assessment Committee</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">PRD</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Pfizer Research and Development</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Prevnar family</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Includes Prevnar 20/Apexxnar (pediatric and adult) and Prevnar 13/Prevenar 13 (pediatric and adult)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">PsA</span></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">psoriatic arthritis</span></td></tr></tbody></table></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">ii</span></div></td></tr></tbody></table></div></div></div><hr style="page-break-after:always"><div style="min-height:33.75pt;width:100%"><div><span><br></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:21.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.532%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">QCE</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">quality consistency evaluation</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">RA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">rheumatoid arthritis</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">RCC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">renal cell carcinoma</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">R&amp;D</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">research and development</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">ReViral</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ReViral Ltd.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">ROU</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">right of use</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">RSV</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">respiratory syncytial virus</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">S&amp;P</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">S&amp;P Global (formerly Standard &amp; Poors)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Seagen</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Seagen Inc. and its subsidiaries</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">SEC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">U.S. Securities and Exchange Commission</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">SNS</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Strategic National Stockpile</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">SMPS</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Sumitomo Pharma Switzerland GMBH</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Takeda</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Takeda Pharmaceutical Company Limited</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Tax Cuts and Jobs Act or TCJA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Legislation commonly referred to as the U.S. Tax Cuts and Jobs Act of 2017</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">TSAs</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">transition service arrangements</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">UC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ulcerative colitis</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">U.K.</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">United Kingdom</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Upjohn Business</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Pfizers former global, primarily off-patent branded and generics business, which included a portfolio of 20 globally recognized solid oral dose brands, including Lipitor, Lyrica, Norvasc, Celebrex and Viagra, as well as a U.S.-based generics platform, Greenstone, that was spun-off on November 16, 2020 and combined with Mylan to create Viatris</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">United States</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">VBP</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">volume-based procurement</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Viatris</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Viatris Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">ViiV</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ViiV Healthcare Limited</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Vyndaqel family</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt;padding-left:6.75pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Includes Vyndaqel, Vyndamax and Vynmac</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">WHO</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">World Health Organization</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">WTO</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">World Trade Organization</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#2c2c2c;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Wyeth</span></div></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Wyeth LLC (formerly Wyeth)</span></div></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:2.65pt">Certain uses of Paxlovid and COVID-19 vaccines from BioNTech and Pfizer have not been approved or licensed by the FDA. Paxlovid has been authorized for emergency use by the FDA under an EUA for the treatment of mild-to-moderate COVID-19 in pediatric patients (12 years of age and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19, including hospitalization or death. Emergency uses of COVID-19 vaccines from Pfizer and BioNTech, including Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula), have been authorized for emergency use by the FDA under an EUA to prevent COVID-19 in individuals aged 6 months of age and older. The emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product during the COVID-19 pandemic under Section 564(b)(1) of the U.S. Federal Food, Drug and Cosmetics Act, unless the declaration is terminated or authorization revoked sooner. Please see the EUA Fact Sheets at </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">www.covid19oralrx.com</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">www.cvdvaccine-us.com</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">This Form 10-K includes discussion of certain clinical studies relating to various in-line products and/or product candidates. These studies typically are part of a larger body of clinical data relating to such products or product candidates, and the discussion herein should be considered in the context of the larger body of data. In addition, clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or efficacy of a product candidate or a new indication for an in-line product, regulatory authorities may not share our views and may require additional data or may deny approval altogether.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Some amounts in this Form 10-K may not add due to rounding. All percentages have been calculated using unrounded amounts. All trademarks mentioned are the property of their owners.</span></div><div id="i8531e747ebb543f3bf818166f157d26a_16"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%"><a style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_16">AVAILABLE INFORMATION</a></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our website is </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">www.pfizer.com</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">. This Form 10-K, our Quarterly Reports on Form 10-Q, our Current Reports on Form 8-K and our proxy statements, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act, are, or will be, available (free of charge) on our website, in text format and, where applicable, in interactive data file format</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> as soon as reasonably practicable after we electronically file this material with, or furnish it to, the SEC.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Throughout this Form 10-K, we incorporate by reference certain information from other documents filed or to be filed with the SEC, including our Proxy Statement. Please refer to this information. This Form 10-K will be available on our website on or about February&nbsp;27, 2025. Our Proxy Statement will be available on our website on or about March 13, 2025.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our annual Impact Report, which provides disclosures regarding our responsible business practices, is made available on our website. We also have a Pfizer Investor Insights website, which includes articles on the company, its products and its pipeline, located at </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">insights.pfizer.com</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Information in our Impact Report and on the Pfizer Investor Insights website are not incorporated by reference into this Form 10-K.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We may use our website as a means of disclosing material information and for complying with our disclosure obligations under Regulation Fair Disclosure promulgated by the SEC. These disclosures are included on our website in the AboutInvestors or Newsroom sections. Accordingly, investors should monitor these portions of our website, in addition to following our press releases, SEC filings, public conference calls and webcasts, as well as our social media channels (our Facebook page, Instagram account (@Pfizerinc), YouTube page, LinkedIn page, and X (formerly known as Twitter) accounts (@Pfizer and @Pfizer_News)). The information contained on our website, our Facebook, Instagram, YouTube and LinkedIn pages or our X (formerly known as Twitter) accounts, or any third-party website, is not incorporated by reference into this Form 10-K.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">iii</span></div></td></tr></tbody></table></div></div></div><hr style="page-break-after:always"><div style="min-height:33.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Information relating to corporate governance at Pfizer, including our Corporate Governance Principles; Director Qualification Standards; Pfizer Policies on Business Conduct (for all of our employees, including our Chief Executive Officer, Chief Financial Officer and Principal Accounting Officer); Code of Business Conduct and Ethics for Members of the Board of Directors; information concerning our Directors; ways to communicate by e-mail with our Directors; information concerning our Board Committees; Committee Charters; Charter of the Lead Independent Director; and transactions in Pfizer securities by Directors and Officers are available on our website. We will provide any of the foregoing information without charge upon written request to our Corporate Secretary, Pfizer Inc., 66 Hudson Boulevard East, New York, NY 10001-2192. We will disclose any future amendments to, or waivers from, provisions of the Pfizer Policies on Business Conduct affecting our Chief Executive Officer, Chief Financial Officer, Principal Accounting Officer and executive officers on our website as promptly as practicable, as may be required under applicable SEC and NYSE rules. Information relating to shareholder services, including the Computershare Investment Program, book-entry share ownership and direct deposit of dividends, is also available on our website.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">iv</span></div></td></tr></tbody></table></div></div></div><div id="i8531e747ebb543f3bf818166f157d26a_19"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">FORWARD-LOOKING INFORMATION AND FACTORS THAT MAY AFFECT FUTURE RESULTS</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">This Form 10-K contains forward-looking statements. We also provide forward-looking statements in other materials we release to the public, as well as public oral statements. Given their forward-looking nature, these statements involve substantial risks, uncertainties and potentially inaccurate assumptions. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">These statements may be identified by using words such as will, may, could, likely, ongoing, anticipate, estimate, expect, project, intend, plan, believe, assume, target, forecast, guidance, goal, objective, aim, seek, potential, hope and other words and terms of similar meaning or by using future dates.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We include forward-looking information in our discussion of the following, among other topics:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">our anticipated operating and financial performance, including financial guidance and projections;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">reorganizations, business plans, strategy, goals and prospects;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, launches, clinical trial results and other developing data; revenue contribution and projections; potential pricing and reimbursement; potential market dynamics, including demand, market size and utilization rates; and growth, performance, timing of exclusivity and potential benefits;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">strategic reviews, capital allocation objectives, dividends and share repurchases;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">plans for and prospects of our acquisitions, dispositions and other business development activities, and our ability to successfully capitalize on growth opportunities and prospects; </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">sales, expenses, interest rates, foreign exchange rates and the outcome of contingencies, such as legal proceedings;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">expectations regarding the impact of or changes to existing or new government regulations or laws;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">our ability to anticipate and respond to and our expectations regarding the impact of macroeconomic, geopolitical, health and industry trends, pandemics, acts of war and other large-scale crises; and</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">manufacturing and product supply. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">In particular, forward-looking information in this Form 10-K includes statements relating to specific future actions, performance and effects, including, among others, the expected benefits of the organizational changes to our operations; our anticipated operating and financial performance; our ongoing efforts to respond to COVID-19; our expectations regarding the impact of COVID-19 on our business; the expected revenue, seasonality of demand and phasing for certain of our products</span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">;</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> expected patent terms; the expected impact of patent expiries and generic and biosimilar competition; the expected pricing pressures on our products and the anticipated impact to our business; the benefits expected from our business development transactions, including our December 2023 acquisition of Seagen; the availability of raw materials; our efforts to develop plans to help mitigate the potential impact of tariffs on our business and operations; our anticipated cash flows and liquidity position; the anticipated costs, savings and potential benefits from certain of our initiatives, including our enterprise-wide Realigning our Cost Base Program, which we launched in October 2023, and our Manufacturing Optimization Program to reduce our cost of goods sold, which we announced in May 2024; our greenhouse gas emission reduction goals; our planned capital spending; and our capital allocation framework.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. Actual outcomes may vary materially from past results and those anticipated, estimated, implied or projected. These forward-looking statements may be affected by underlying assumptions that may prove inaccurate or incomplete, or by known or unknown risks and uncertainties, including those described in this section, in the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67">Item 1A. Risk Factors</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section or in MD&amp;A.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Therefore, you are cautioned not to unduly rely on forward-looking statements, which speak only as of the date of this Form 10-K. We undertake no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. You are advised, however, to consult any further disclosures we make on related subjects.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Some of the factors that could cause actual results to differ are identified below, as well as those discussed in the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67">Item 1A. Risk Factors</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section and within MD&amp;A. We note these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. The occurrence of any of the risks identified below, in the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67">Item 1A. Risk Factors</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section, or within MD&amp;A, or other risks currently unknown, could have a material adverse effect on our business, financial condition or results of operations, or we may be required to increase our accruals for contingencies. It is not possible to predict or identify all such factors. Consequently, you should not consider the following to be a complete discussion of all potential risks or uncertainties:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Risks Related to Our Business, Industry and Operations, and Business Development:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the outcome of R&amp;D activities, including the ability to meet anticipated pre-clinical or clinical endpoints, commencement and/or completion dates for our pre-clinical or clinical trials, regulatory submission dates, and/or regulatory approval and/or launch dates; the possibility of unfavorable pre-clinical and clinical trial results, including the possibility of unfavorable new pre-clinical or clinical data and further analyses of existing pre-clinical or clinical data; risks associated with preliminary, early stage or interim data; the risk that pre-clinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from our pipeline programs will be published in scientific journal publications, and if so, when and with what modifications and interpretations; and uncertainties regarding the future development of our product candidates, including whether or when our product candidates will advance to future studies or phases of development or whether or when regulatory applications may be filed for any of our product candidates;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">our ability to successfully address comments received from regulatory authorities such as the FDA or the EMA, or obtain approval for new products and indications from regulators on a timely basis or at all; </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">regulatory decisions impacting labeling, approval or authorization, including the scope of indicated patient populations, product dosage, manufacturing processes, safety and/or other matters, including decisions relating to emerging developments regarding potential product impurities; uncertainties regarding the ability to obtain or maintain, and the scope of, recommendations by technical or advisory committees, and the timing of, and ability to obtain, pricing approvals and product launches, all of which could impact the availability or commercial potential of our products and product candidates;</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">claims and concerns that may arise regarding the safety or efficacy of in-line products and product candidates, including claims and concerns that may arise from the conduct or outcome of post-approval clinical trials, pharmacovigilance or Risk Evaluation and Mitigation Strategies,</span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">which could impact marketing approval, product labeling, and/or availability or commercial potential;</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">1</span></div></td></tr></tbody></table></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#212529;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the success and impact of external business development activities, including the ability to identify and execute on potential business development opportunities; the ability to satisfy the conditions to closing of announced transactions in the anticipated time frame or at all; the ability to realize the anticipated benefits of any such transactions in the anticipated time frame or at all; the potential need for and impact of additional equity or debt financing to pursue these opportunities, which has in the past and could in the future result in increased leverage and/or a downgrade of our credit ratings and could limit our ability to obtain future financing; challenges integrating the businesses and operations; disruption to business or operations relationships; risks related to growing revenues for certain acquired or partnered products; significant transaction costs; and unknown liabilities;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">competition, including from new product entrants, in-line branded products, generic products, private label products, biosimilars and product candidates that treat or prevent diseases and conditions similar to those treated or intended to be prevented by our in-line products and product candidates;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the ability to successfully market both new and existing products, including biosimilars;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">difficulties or delays in manufacturing, sales or marketing; supply disruptions, shortages or stock-outs at our facilities or third-party facilities that we rely on; and legal or regulatory actions; </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the impact of public health outbreaks, epidemics or pandemics (such as COVID-19) on our business, operations and financial condition and results, including impacts on our employees, manufacturing, supply chain, sales and marketing, R&amp;D and clinical trials;</span></div><div style="margin-bottom:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">risks and uncertainties related to Comirnaty and Paxlovid or any potential future COVID-19 vaccines, treatments or combinations, including, among others, the risk that as the market for COVID-19 products remains endemic and seasonal, demand for our COVID-19 products has and may continue to be reduced or not meet expectations, which has in the past and may continue to lead to reduced revenues, excess inventory or other unanticipated charges; risks related to our ability to develop and commercialize variant adapted vaccines, combinations and/or treatments; uncertainties related to recommendations and coverage for, and the publics adherence to, vaccines, boosters, treatments or combinations; and potential third-party royalties or other claims related to Comirnaty and Paxlovid;</span></div><div style="margin-bottom:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">trends toward managed care and healthcare cost containment, and our ability to obtain or maintain timely or adequate pricing or favorable formulary placement for our products;</span></div><div style="margin-bottom:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">interest rate and foreign currency exchange rate fluctuations, including the impact of currency devaluations and monetary policy actions in countries experiencing high inflation or deflation rates;</span></div><div style="margin-bottom:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">any significant issues involving our largest wholesale distributors or government customers, which account for a substantial portion of our revenues;</span></div><div style="margin-bottom:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the impact of the increased presence of counterfeit medicines, vaccines or other products in the pharmaceutical supply chain;</span></div><div style="margin-bottom:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">any significant issues related to the outsourcing of certain operational and staff functions to third parties; </span></div><div style="margin-bottom:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">any significant issues related to our JVs and other third-party business arrangements, including modifications or disputes related to supply agreements or other contracts with customers including governments or other payors;</span></div><div style="margin-bottom:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">uncertainties related to general economic, political, business, industry, regulatory and market conditions including, without limitation, uncertainties related to the impact on us, our customers, suppliers and lenders and counterparties to our foreign-exchange and interest-rate agreements of challenging global economic conditions, such as inflation or interest rate fluctuations, and recent and possible future changes in global financial markets;</span></div><div style="margin-bottom:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the exposure of our operations globally to possible capital and exchange controls, economic conditions, expropriation, sanctions, tariffs and/or other restrictive government actions, changes in intellectual property legal protections and remedies, unstable governments and legal systems and inter-governmental disputes;</span></div><div style="margin-bottom:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the impact of disruptions related to climate change and natural disasters;</span></div><div style="margin-bottom:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">any changes in business, political and economic conditions due to actual or threatened terrorist activity, geopolitical instability, political or civil unrest or military action, including the ongoing conflicts between Russia and Ukraine and in the Middle East and the resulting economic or other consequences;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the impact of product recalls, withdrawals and other unusual items, including uncertainties related to regulator-directed risk evaluations and assessments, such as our ongoing evaluation of our product portfolio for the potential presence or formation of nitrosamines</span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">and our voluntary withdrawal of all lots of Oxbryta in all markets where it is approved and any regulatory or other impact on Oxbryta and other sickle cell disease assets;</span></div><div style="margin-bottom:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">trade buying patterns;</span></div><div style="margin-bottom:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the risk of an impairment charge related to our intangible assets, goodwill or equity-method investments;</span></div><div style="margin-bottom:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the impact of, and risks and uncertainties related to, restructurings and internal reorganizations, as well as any other corporate strategic initiatives and growth strategies, and cost-reduction and productivity initiatives, including any potential future phases, each of which requires upfront costs but may fail to yield anticipated benefits and may result in unexpected costs, organizational disruption, adverse effects on employee morale, retention issues or other unintended consequences;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the ability to successfully achieve our climate-related goals and progress our environmental sustainability and other priorities;</span></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Risks Related to Government Regulation and Legal Proceedings</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the impact of any U.S. healthcare reform or legislation or any significant spending reduction or cost control efforts affecting Medicare, Medicaid, the 340B Program or other publicly funded or subsidized health programs, including the IRA, or changes in the tax treatment of employer-sponsored health insurance that may be implemented;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">U.S. federal or state legislation or regulatory action and/or policy efforts affecting, among other things, pharmaceutical product pricing, intellectual property, reimbursement or access to or recommendations for our medicines and vaccines, taxes or other restrictions on U.S. direct-to-consumer advertising; limitations on interactions with healthcare professionals and other industry stakeholders; as well as pricing pressures for our products as a result of highly competitive biopharmaceutical markets;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">legislation or regulatory action in markets outside of the U.S., such as China or Europe, including, without limitation, laws related to pharmaceutical product pricing, intellectual property, medical regulation, environmental protections, reimbursement or access, </span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">2</span></div></td></tr></tbody></table></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">including, in particular, continued government-mandated reductions in prices and access restrictions for certain products to control costs in those markets;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">legal defense costs, insurance expenses, settlement costs and contingencies, including without limitation, those related to legal proceedings and actual or alleged environmental contamination;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the risk and impact of an adverse decision or settlement and risk related to the adequacy of reserves related to legal proceedings;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the risk and impact of tax related litigation and investigations;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">governmental laws, regulations and policies affecting our operations, including, without limitation, the IRA, as well as changes in such laws, regulations or policies, or their interpretation, including, among others, changes in tariffs, tax laws and regulations internationally and in the U.S., the adoption of global minimum taxation requirements outside the U.S. generally effective in most jurisdictions since January 1, 2024 and potential changes to existing tax laws, tariffs, or changes to other laws, regulations or policies in the U.S., including by the U.S. Presidential administration and Congress, as well as in other countries;</span></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Risks Related to Intellectual Property, Technology and Cybersecurity:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the risk that our currently pending or future patent applications may not be granted on a timely basis or at all, or any patent-term extensions that we seek may not be granted on a timely basis, if at all;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">risks to our products, patents and other intellectual property, such as: (i) claims of invalidity that could result in loss of patent coverage; (ii) claims of patent infringement, including asserted and/or unasserted intellectual property claims; (iii) claims we may assert against intellectual property rights held by third parties; (iv) challenges faced by our collaboration or licensing partners to the validity of their patent rights; or (v) any pressure from, or legal or regulatory action by, various stakeholders or governments that could potentially result in us not seeking intellectual property protection or agreeing not to enforce or being restricted from enforcing intellectual property rights related to our products, including Comirnaty and Paxlovid;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">any significant breakdown or interruption of our IT systems and infrastructure (including cloud services);</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">any business disruption, theft of confidential or proprietary information, security threats on facilities or infrastructure, extortion or integrity compromise resulting from a cyber-attack, which may include those using adversarial AI techniques, or other malfeasance by, but not limited to, nation states, employees, business partners or others; and</span></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">risks and challenges related to the use of software and services that include AI-based functionality and other emerging technologies.</span></div><div id="i8531e747ebb543f3bf818166f157d26a_22"></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:36.111%"><tbody><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #006ebf;border-top:1pt dotted #006ebf;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:11pt;font-weight:700;line-height:120%">PART I</span></td></tr></tbody></table></div><div id="i8531e747ebb543f3bf818166f157d26a_25"></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tbody><tr><td style="width:1.0%"></td><td style="width:10.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&nbsp;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:10pt;font-weight:700;line-height:120%">BUSINESS</span></td></tr></tbody></table></div><div id="i8531e747ebb543f3bf818166f157d26a_28"></div><div><img src="./PFIZER_files/pfe-20241231_g1.jpg" alt="Pfizer Logo.jpg" style="height:33px;margin-bottom:5pt;vertical-align:text-bottom;width:75px"></div><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">ABOUT PFIZER</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. is a research-based, global biopharmaceutical company. We apply science and our global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. We work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. We collaborate with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. The Company was incorporated under the laws of the State of Delaware on June 2, 1942. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Most of our revenues come from the manufacture and sale of biopharmaceutical products. We believe that our medicines and vaccines provide significant value for healthcare providers and patients through improved treatment of diseases and improvements in health, wellness and productivity as well as by reducing other healthcare costs, such as emergency room visits or hospitalizations. We seek to enhance the value of our medicines and vaccines and actively engage in dialogues about how we can best work with patients, physicians and payors to prevent and treat disease and improve outcomes. We seek to maximize patient access and evaluate our pricing arrangements and contracting methods with payors to minimize adverse impact on our revenues within the current legal and pricing structures. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We are committed to fulfilling our purpose: </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Breakthroughs that change patients lives</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Our purpose fuels everything we do and reflects both our passion for science and our commitment to patients. Our core business principles are: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.34pt">Trust is Everything</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.34pt">Science Will Win</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.34pt">Disruption Calls for Innovation</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.34pt">Time is Life</span></div><div style="margin-bottom:5pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">5.</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.34pt">Execution Makes the Difference.</span></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our 2025 key priorities are:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.34pt">Improve R&amp;D productivity with sharpened focus</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.34pt">Expand margins and maximize operational efficiency</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.34pt">Achieve commercial excellence in our key categories</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.34pt">Optimize capital allocation.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We are committed to strategically capitalizing on growth opportunities, primarily by advancing our own product pipeline and maximizing the value of our existing products, but also through various business development activities. We view our business development activity as an enabler of our strategies and seek to generate growth by pursuing opportunities and transactions that have the potential to strengthen our business and our </span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">3</span></div></td></tr></tbody></table></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">capabilities. We assess our business, assets and scientific capabilities/portfolio as part of our regular, ongoing portfolio review process and also continue to consider business development activities that will help advance our business strategy. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">For a discussion of our strategy and our business development initiatives, see the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_100">Overview of Our Performance, Operating Environment, Strategy and Outlook</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">section within MD&amp;A and </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_181">Note 2</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div id="i8531e747ebb543f3bf818166f157d26a_31"></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">COMMERCIAL OPERATIONS</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We manage our commercial operations through a global structure consisting of three operating segments, each led by a single manager: Biopharma, PC1 and Pfizer Ignite. Biopharma, our innovative science-based biopharmaceutical business, is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. PC1 is our contract development and manufacturing organization and a leading supplier of specialty active pharmaceutical ingredients. Pfizer Ignite is an offering that provides strategic guidance and end-to-end R&amp;D services to select innovative biotech companies that align with our R&amp;D focus areas. Biopharma is the only reportable segment. Our commercial divisions market, sell and distribute our products, and global operating functions are responsible for the research, development, manufacturing and supply of our products. </span><span style="background-color:#ffffff;color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The commercial structure within our Biopharma reportable segment in 2024 was comprised of the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="background-color:#ffffff;color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="background-color:#ffffff;color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Pfizer Oncology Division combined the U.S. Oncology commercial organizations, global Oncology marketing organizations and global and U.S. Oncology medical affairs from both Pfizer and Seagen (which we acquired in December 2023).</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="background-color:#ffffff;color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Pfizer U.S. Commercial Division included the U.S. Primary Care and U.S. Specialty Care customer groups, the Chief Marketing Office, the Global Chief Medical Affairs Office and Global Access &amp; Value.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="background-color:#ffffff;color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Pfizer International Commercial Division included the ex-U.S. commercial and medical affairs organizations covering Pfizers entire product portfolio in all international markets.</span></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">As part of our continued focus on commercial execution, at the beginning of 2025, we made changes in our commercial structure, which included the transition of all activities within the Pfizer Oncology Division to other parts of Biopharma, among other changes. Specifically, within our Biopharma reportable segment, the U.S. Oncology commercial organization and the global Oncology marketing organization, which were part of the former Pfizer Oncology Division, are now part of the Pfizer U.S. Commercial Division. In 2025, the commercial structure within our Biopharma reportable segment is as follows:</span></div><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.017%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Division</span></div></td><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Description</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:29pt"><td colspan="3" rowspan="12" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-right:9pt"><span style="color:#006ebf;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">Pfizer U.S. Commercial Division</span></div><div style="padding-right:9pt"><span><br></span></div></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;padding-right:9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Includes the U.S. commercial and medical affairs organizations covering Pfizers entire product portfolio (excluding Oncology medical affairs which is part of global R&amp;D), as well as the Global Access &amp; Value and Global Chief Marketing Office organizations.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Primary Care includes:</span></div></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:6.38pt">Internal medicine product portfolio of brands in cardiovascular metabolic, as well as brands that have experienced patent-based expirations or loss of regulatory exclusivity.</span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:6.38pt">Migraine product portfolio.</span></div></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:13pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:6.38pt">Vaccines product portfolio across all ages with a pipeline focus on infectious diseases with significant unmet medical need, including COVID-19.</span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:6.38pt">Treatment for COVID-19.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"><div><span><br></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Specialty Care includes:</span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:14pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:6.38pt">Inflammation &amp; immunology product portfolio of brands and biosimilars for chronic immune and inflammatory diseases.</span></div></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:6.38pt">Rare disease product portfolio of brands for a number of therapeutic areas with rare diseases, including amyloidosis, hemophilia and endocrine diseases.</span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:6.38pt">Hospital product portfolio of sterile injectable and immunoglobulin medicines.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Oncology includes:</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:6.38pt">Innovative oncology product portfolio of ADCs, small molecules, bispecifics and other immunotherapies that treat a wide range of cancers including certain types of breast cancer, genitourinary cancer and hematologic malignancies, as well as certain types of melanoma, gastrointestinal, gynecological and lung cancer.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:6.38pt">Oncology biosimilars.</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#006ebf;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">Pfizer International Commercial Division</span></div></td><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Includes the ex-U.S. commercial and medical affairs organizations covering Pfizers entire product portfolio in all international markets.</span></div></td></tr></tbody></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Select Primary Care, Specialty Care and Oncology products include: </span></div><div style="margin-bottom:3pt;margin-top:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#05497c;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:6.2pt">Primary Care: </span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">&#9702;</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.17pt">Internal medicine</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">: Eliquis, as well as other brands that have experienced patent-based expirations or loss of regulatory exclusivity.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.17pt">Migraine</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">: Nurtec ODT/Vydura and Zavzpret</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.17pt">Vaccines</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">: the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix and Trumenba </span></div><div style="margin-bottom:5pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.17pt">Treatment for COVID-19</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">: Paxlovid </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#05497c;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:6.2pt">Specialty Care: </span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">&#9702;</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.17pt">Inflammation &amp; immunology</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">: Xeljanz, Enbrel (outside the U.S. and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa and Velsipity</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.17pt">Rare disease</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">: the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla and Hympavzi</span></div><div style="margin-bottom:5pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.17pt">Hospital</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">: Sulperazon, Zavicefta, Octagam, Zithromax, Medrol and Panzyga</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#05497c;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:6.2pt">Oncology:</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna </span></div><div style="margin-bottom:8pt;margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">For additional information on our operating segments and products, including product revenues, see </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_271">Note 17</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">and for additional information on the key operational revenue drivers of our business, see the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_112">Analysis of the Consolidated Statements of Operations</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section within MD&amp;A. For a discussion of the risks associated with our dependence on certain of our major products, see the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67">Item 1A. Risk FactorsConcentration</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">4</span></div></td></tr></tbody></table></div></div></div><div id="i8531e747ebb543f3bf818166f157d26a_34"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">RESEARCH AND DEVELOPMENT</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">R&amp;D is at the heart of fulfilling our purpose to deliver breakthroughs that change patients lives as we work to translate advanced science and technologies into the medicines and vaccines that may be the most impactful for patients. In addition to discovering and developing new products, our R&amp;D efforts seek to add value to our existing products by improving their safety, efficacy and ease of dosing and by discovering potential new indications.</span></div><div style="margin-top:5pt"><span style="color:#006ebf;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Our R&amp;D Priorities and Strategy. </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our R&amp;D priorities include:</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">delivering a pipeline of highly differentiated medicines and vaccines where we have a unique opportunity to bring the most important new therapies to patients in need;</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">advancing our capabilities that can position us for long-term R&amp;D leadership; and</span></div><div style="margin-bottom:5pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">advancing new models for partnerships with creativity, flexibility and urgency to deliver innovation to patients as quickly as possible.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">To that end, our R&amp;D primarily focuses on our main therapeutic areas, which are oncology, internal medicine (including cardiovascular and migraine), vaccines and inflammation and immunology.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">While a significant portion of our R&amp;D is internal, we also seek promising chemical and biological lead molecules and innovative technologies developed by others to incorporate into our discovery and development processes or projects, as well as our portfolio. We do so by entering into collaboration, alliance and license agreements with universities, biotechnology companies and other firms as well as through acquisitions and investments. These arrangements allow us to share knowledge, risk and cost. They also enable us to access external scientific and technological expertise, as well as provide us the opportunity to advance our own products and in-licensed or acquired products. For information on certain of these collaborations, alliances and license arrangements and investments, see </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_181">Note 2</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt"><span style="color:#006ebf;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Our R&amp;D Operations.</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> In 2024, we continued to enhance our global R&amp;D operations and pursued strategies to improve R&amp;D productivity and advance a sustainable and value-creating pipeline. Oncology was organized in an end-to-end Oncology R&amp;D (ORD) organization, spanning discovery to late-phase clinical development. Pfizer Research and Development (PRD) managed the same for our remaining therapeutic areas in addition to certain platform organizations. Effective January 1, 2025, ORD and PRD were consolidated into a single R&amp;D organization to further strengthen Pfizers capabilities and leadership in discovering and developing breakthrough medicines and vaccines. As part of these changes, we are now evaluating how our simplified structure and sharpened focus might lead to improvements in productivity and potential efficiencies. We expect any potential savings identified through these efforts to be reinvested in our R&amp;D portfolio.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We manage R&amp;D operations on a total-company basis through the organizations described above. The Portfolio Management Team (PMT), currently chaired by our Chief Strategy and Innovation Officer, Executive Vice President, is accountable for aligning resources across R&amp;D, and for helping to ensure optimal capital allocation across the R&amp;D portfolio. We believe that this approach also serves to maximize accountability and flexibility. </span></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We do not disaggregate total R&amp;D expense by development phase or by therapeutic area since, as described above, we manage our R&amp;D strategy and operations collectively under the governance of the PMT and do not manage our R&amp;D operational spend independently by development phase or by therapeutic area. Further, as we are able to adjust a significant portion of our spending quickly, we believe that any prior-period information about R&amp;D expense by development phase or by therapeutic area would not necessarily be representative of future spending.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">For additional information on our R&amp;D operations, including R&amp;D related costs and expenses, see the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_124">Costs and Expenses</a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_124"></a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_124">Research and Development Expenses</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section within MD&amp;A and </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_271">Note 17</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt"><span style="color:#006ebf;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Our R&amp;D Pipeline. </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The process of drug, vaccine and biological product discovery from initiation through development and to potential regulatory approval is lengthy and can take more than ten years. As of February&nbsp;4, 2025, we had the following number of projects in various stages of R&amp;D:</span></div><div style="margin-bottom:5pt;text-align:center"><img src="./PFIZER_files/pfe-20241231_g2.jpg" alt="2024 Pipeline 10K.jpg" style="height:121px;margin-bottom:5pt;vertical-align:text-bottom;width:480px"></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Development of a single compound is often pursued as part of multiple programs. While our product candidates may or may not receive regulatory approval, new candidates entering clinical development phases are the foundation for future products. Information concerning several of our drug, vaccine and biological candidates in development, as well as supplemental filings for existing products, is set forth in the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_133">Product Developments</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section within MD&amp;A. The discovery and development of drugs, vaccines and biological products are time consuming, costly and unpredictable. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">For information on the risks associated with R&amp;D, see the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67">Item 1A. Risk FactorsResearch and Development</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section. </span></div><div id="i8531e747ebb543f3bf818166f157d26a_37"></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">COLLABORATION AND CO-PROMOTION AGREEMENTS</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We use collaboration and/or co-promotion arrangements to enhance our development, R&amp;D, sales and distribution of certain biopharmaceutical products, which include, among others, the following: </span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:6.2pt">Comirnaty</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> is an mRNA-based coronavirus vaccine to help prevent COVID-19, which is being jointly developed and commercialized with BioNTech. Pfizer and BioNTech equally share the costs of development for the Comirnaty program. Comirnaty has been granted an approval or an authorization in many countries around the world in populations varying by country. We also share gross profits equally from commercialization of Comirnaty (excluding China, Hong Kong, Macau and Taiwan, where we do not have rights), subject to regulatory authorizations or approvals market by market. For discussion on Comirnaty, see the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_100">Overview of Our Performance, Operating Environment, Strategy and OutlookCOVID-19</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">section within MD&amp;A.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">5</span></div></td></tr></tbody></table></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:6.2pt">Eliquis </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(apixaban) is part of the Novel Oral Anticoagulant market and was jointly developed and commercialized with BMS as an alternative treatment option to warfarin in appropriate patients. We fund between 50% and 60% of all development costs depending on the study, and profits and losses are shared equally except in certain countries where we commercialize Eliquis and pay a percentage of net sales to BMS. In certain smaller markets we have full commercialization rights and BMS supplies the product to us at cost plus a percentage of the net sales to end-customers.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:6.2pt">Xtandi </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(enzalutamide) is an androgen receptor inhibitor that blocks multiple steps in the androgen receptor signaling pathway within tumor cells that is being developed and commercialized in collaboration with Astellas. We share equally in the gross profits and losses related to U.S. net sales and also share equally all Xtandi commercialization costs attributable to the U.S. market, subject to certain exceptions. In addition, we share certain development and other collaboration expenses. For international net sales we receive royalties based on a tiered percentage.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:6.2pt">Orgovyx </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(relugolix) is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer that is being developed and commercialized with SMPS. The companies equally share profits and allowable expenses in the U.S. for Orgovyx. Pfizer does not have rights outside of this market. Separately, in December 2024, the companies terminated their collaboration with respect to the relugolix combination tablet.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:6.2pt">Padcev </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(enfortumab vedotin-ejfv) is a first-in-class ADC that is directed to Nectin-4, a protein located on the surface of cells and highly expressed in bladder cancer, that is being co-developed and jointly commercialized with Astellas. In the U.S., Padcev has been approved for use with Keytruda (pembrolizumab) for adult patients with locally advanced or metastatic urothelial cancer. Other approvals and indications for Padcev vary by market. In the U.S., Pfizer and Astellas jointly promote, and we record net sales and are responsible for all U.S. distribution activities for Padcev. The companies each bear the costs of their own sales organizations in the U.S., and equally share certain other costs associated with commercializing and any profits realized for Padcev in the U.S. Outside the U.S., we have commercialization rights in all countries in North and South America, and Astellas has commercialization rights in the rest of the world. The agreement between us and Astellas provides that the companies will effectively equally share in profits realized in markets outside of the U.S. through: (i) a costs-incurred and profit-sharing mechanism based on product sales and costs of commercialization in certain markets and (ii) a royalty-payment mechanism intended to approximate an equal profit share for both parties in the remaining markets. </span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:6.2pt">Adcetris</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> (brentuximab vedotin) is being developed and commercialized in collaboration with Takeda. Pfizer has commercialization rights for Adcetris in the U.S. and its territories and in Canada. Takeda has commercialization rights in the rest of the world and pays Pfizer a royalty based on a percentage of Takeda's net sales of Adcetris in its licensed territories, based on annual net sales tiers.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">In addition, we have collaboration and/or co-promotion arrangements with respect to certain other biopharmaceutical products, including, among others, certain of those described in the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_46">Item 1. BusinessPatents and Other Intellectual Property Rights</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revenues associated with these arrangements are included in </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenues</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> (except in certain markets where we have direct sales and except for the majority of revenues for Comirnaty and Padcev, which are included in </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Product revenues</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">). In addition, we have collaboration arrangements for the development and commercialization of certain pipeline products that are in development stage, including, among others certain of those described in the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_133">Product Developments</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section within MD&amp;A. For further discussion of collaboration and co-promotion agreements, see the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_46">Item 1. BusinessPatents and Other Intellectual Property Rights</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">the</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67">Item 1A. Risk FactorsCollaborations and Other Relationships with Third Parties</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">section and </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_181">Notes 2</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_271">17</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div id="i8531e747ebb543f3bf818166f157d26a_40"></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">INTERNATIONAL OPERATIONS</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our operations are conducted globally, and we supply our medicines and vaccines to approximately 200 countries and territories. Emerging markets are an important component of our strategy for global leadership, and our commercial structure recognizes that the demographics and rising economic power of the fastest-growing emerging markets are becoming more closely aligned with the profile found within developed markets. Urbanization and the rise of the middle class in emerging markets provide potential growth opportunities for our products.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revenues from operations outside the U.S. of $24.9 billion, $31.4 billion and $57.9 billion accounted for 39%, 53% and 57% of </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Total revenues</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in 2024, 2023 and 2022, respectively. Revenues exceeded $500 million in each of 11, 14 and 24 countries outside the U.S. in 2024, 2023 and 2022, respectively. The decrease in the number of countries exceeding $500 million in revenues from 2023 to 2024 was primarily driven by decreases in international revenues related to Comirnaty and Paxlovid. As a percentage of </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Total revenues</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">, China was our largest market outside the U.S. (representing 4% of total revenues) in 2024, and Japan was our largest market outside the U.S. in 2023 and 2022 (representing 6% and 8% of total revenues, respectively). For a geographic breakdown of </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Total revenues</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">, see the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_115">Total Revenues by Geography</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section within MD&amp;A and </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_277">Note 17B</a></span><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our international operations are subject to risks inherent in carrying on business in other countries. See the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67">Item 1A. Risk Factors</a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67"></a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67">Global Operations</a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67"> </a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">and </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_58">Item 1. Business</a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_58"></a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_58">Government Regulation and Price Constraints</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> sections.</span></div><div id="i8531e747ebb543f3bf818166f157d26a_43"></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">SALES AND MARKETING</span></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our prescription biopharmaceutical products are sold principally to wholesalers, but we also sell directly to retailers, hospitals, clinics, government agencies and pharmacies. Our vaccines in the U.S. are primarily sold directly to the federal government (including the CDC), wholesalers, individual provider offices, retail pharmacies and integrated delivery systems. Our vaccines outside the U.S. are primarily sold to government and non-government institutions. Certain of these government contracts may be renegotiated or terminated at the discretion of a government entity. For more information, see </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_178">Note </a><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_178">1G</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> and Note </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_280">17C</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We also seek to gain access for our products on formularies, which are lists of approved medicines available to members of healthcare programs or PBMs in the U.S. Insurers and PBMs who design and negotiate formularies on their behalf use various benefit designs, such as tiered co-pays for formulary products, to drive utilization of products in preferred formulary positions, typically in exchange for a discount off the price of the medicine in the form of a rebate agreement. We may also work with payors on disease management programs that help to develop tools and materials to educate patients and physicians on key disease areas. For information on our significant customers, see </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_280">Note 17C</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We promote our products to healthcare providers and patients consistent with applicable laws. Through our marketing organizations, we explain the approved uses, benefits and risks of our products to healthcare providers and patients and, in the U.S., to MCOs that provide insurance coverage, such as hospitals, integrated delivery systems, PBMs and health plans; and employers and government agencies who hire MCOs to provide health benefits to their employees. In the U.S. and select international markets, we market directly to consumers through direct-to-consumer advertising that seeks to communicate the approved uses, benefits and risks of our products while motivating people to have </span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">6</span></div></td></tr></tbody></table></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">meaningful conversations with their doctors. In addition, we sponsor general advertising to educate the public on disease awareness, prevention and wellness, important public health issues and our patient assistance programs. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">As part of our commitment to engaging our customers in a manner they prefer, we take an omnichannel approach, including both virtual and in person interactions, and see generally positive customer response to both approaches. </span></div><div id="i8531e747ebb543f3bf818166f157d26a_46"></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">PATENTS AND OTHER INTELLECTUAL PROPERTY RIGHTS</span></div><div style="margin-top:5pt"><span style="color:#006ebf;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Patents</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">. We own or have co-promotion and/or license rights related to a number of patents covering pharmaceutical and other products, their uses, formulations, and product manufacturing processes.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Patents for individual products extend for varying periods according to the date of patent filing or grant and the legal term of patents in the various countries where patent protection is obtained. The scope of protection afforded by a patent can vary from country to country and depends on the patent type, the scope of its patent claims and the availability of legal remedies. Patent term extensions (PTE) may be available in some countries to compensate for a loss of patent term due to delay in a products approval due to the regulatory requirements, while patent term adjustment may be available in some countries to compensate for administrative delays during prosecution of patents. One of the primary considerations in limiting our operations in some countries outside the U.S. is the lack of effective intellectual property protection for our products, although international and U.S. free trade agreements have included some global protection of intellectual property rights. See the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_58">Item 1. Business</a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_58"></a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_58">Government Regulation and Price Constraints</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">section.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">In various markets, a period of regulatory exclusivity may be provided for drugs or vaccines upon approval. The scope and term of such exclusivity will vary but, in general, the period will run concurrently with the term of any existing patent rights associated with the drug at the time of approval. </span></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Based on current sales and other factors, and considering the competition with products sold by our competitors, the patent rights we consider most significant in relation to our business as a whole, together with the year in which the basic product patent expires, are as follows: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:23.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.354%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S. Basic Product Patent Expiration Year</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Major Europe Basic Product Patent Expiration Year</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Japan Basic Product Patent Expiration Year</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Inlyta</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Xeljanz</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2026</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2028</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Prevnar 13/Prevenar 13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2029</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Eliquis</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Ibrance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2028</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2028</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Xtandi</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Vyndaqel/Vyndamax/Vynmac</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2025</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2028 pending PTE)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2026/2029</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(8)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Nurtec ODT/Vydura</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2030</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2034 pending PTE)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2035</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2030</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(9)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Braftovi</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(10)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2030</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2031 pending PTE)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(10)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(10)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Mektovi</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(10)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2026</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2027 pending PTE)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(11)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(10)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(10)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Talzenna</span></div></td><td colspan="3" style="border-top:1pt dotted #929292;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2029</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2032 pending PTE)</span></div></td><td colspan="3" style="border-top:1pt dotted #929292;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2034</span></div></td><td colspan="3" style="border-top:1pt dotted #929292;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2029</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2034 pending PTE)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lorbrena</span></td><td colspan="3" style="border-top:1pt dotted #929292;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2033</span></td><td colspan="3" style="border-top:1pt dotted #929292;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2034</span></td><td colspan="3" style="border-top:1pt dotted #929292;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2036</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Padcev</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(12)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2033</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(12)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(12)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tukysa</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(13)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2031</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2034 pending PTE) </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2031</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(9)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Zavzpret</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2031 </span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2034 pending PTE)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2031</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(9)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2031</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(9)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Velsipity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2030 </span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2035 pending PTE)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2029</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2034 pending SPC)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2029</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(9)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Prevnar 20/Apexxnar</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2033</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2035 pending PTE)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2037</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2033</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2038 pending PTE)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Ngenla</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(14)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2035</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2032</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2030</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cibinqo</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="background-color:#cceeff;color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2034</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2036 pending PTE)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2036</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2038</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tivdak</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(15)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2033</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(15)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(15)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Litfulo</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2034 </span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2037 pending PTE)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2038 </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2039</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Abrysvo</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2036 </span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2037 pending PTE)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(16)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2036</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2039 pending PTE)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Elrexfio</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2036 </span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2037 pending PTE)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2036 </span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2038 pending SPC)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2036</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2038 pending PTE)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt dotted #828282;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Hympavzi</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt dotted #828282;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2036</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2038 pending PTE)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt dotted #828282;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(16)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt dotted #828282;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2036</span></div></td></tr></tbody></table></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">7</span></div></td></tr></tbody></table></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:23.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.354%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S. Basic Product Patent Expiration Year</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Major Europe Basic Product Patent Expiration Year</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Japan Basic Product Patent Expiration Year</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Comirnaty</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(17)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2041</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(18)(19) </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2041</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt dotted #828282;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Paxlovid</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt dotted #828282;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2041</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt dotted #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2041</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt dotted #828282;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2041</span></td></tr></tbody></table></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:7.15pt">Unless otherwise indicated, the years pertain to the basic product patent expiration, including granted PTEs, supplementary protection certificates (SPC) or pediatric exclusivity periods. SPCs are included when granted in three out of five major European markets (France, Germany, Italy, Spain and the U.K.). Noted in parentheses is the projected year of expiry of the earliest pending patent term extension in the U.S. or Japan and/or SPC application in Europe, the term of which, if granted, may be shorter than originally requested due to a number of factors. In some instances, there are later-expiring patents relating to our products which may or may not protect our product from generic or biosimilar competition after the expiration of the basic patent.</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:7.15pt">Expiry is provided by regulatory exclusivity in this market.</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:7.15pt">The Europe patent that covers the combination of the 13 serotype conjugates of Prevenar</span><span style="color:#1f497d;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">13 was revoked following an opposition and has now been withdrawn. There are other Europe patents and pending applications covering the formulation, various aspects of the manufacturing process, and the combination of serotype conjugates of Prevenar</span><span style="color:#1f497d;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">13 that remain in force.</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:7.15pt">Eliquis was developed and is being commercialized in collaboration with BMS. In the U.S., we and BMS previously settled certain patent litigations with a number of generic companies permitting their launch of a generic version of Eliquis on April 1, 2028 (the settled generic companies). We continued to litigate against three remaining generic companies and following the resolution of the litigation in our favor, the three generic companies are not permitted to launch their products until the 2031 expiration date of the formulation patent.&#8239;Both the composition of matter patent expiring in November 2026 and the formulation patent expiring in 2031 may be subject to future challenges.&#8239;While we cannot predict the outcome of any potential future litigation, there are certain potential alternatives that might occur which could potentially permit generic launch prior to April 1, 2028: (i) if the formulation patent is held invalid or not infringed in future litigation, through appeal, the settled generic companies and any successful future litigant would be permitted to launch on November 21, 2026; or (ii) if both patents are held invalid or not infringed in future litigation, through appeal, the settled generic companies and any successful future litigant could launch products immediately upon such an adverse decision. Refer to </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_268">Note 16A1</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%"> for more information.</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:7.15pt">On October 31, 2023, the U.K. Supreme Court refused BMSs permission to appeal in relation to the judgment that found the apixaban basic product patent and associated SPC invalid. Additional challenges are pending in other jurisdictions. </span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:7.15pt">Xtandi is being developed and commercialized in collaboration with Astellas, which has exclusive commercialization rights for Xtandi outside the U.S. Pfizer receives tiered royalties as a percentage of international Xtandi net sales.</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:7.15pt">Interim patent term extension requests have been granted extending the expiry from December 2024 to December 2025 and Pfizer has filed applications for patent term extension to 2028.</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(8)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:7.15pt">Vyndaqel (tafamidis meglumine) basic patent expiry in Japan is August 2026 for treatment of polyneuropathy. Vynmac (tafamidis) was approved in Japan for treatment of cardiomyopathy with regulatory exclusivity expiring in March 2029.</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(9)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:7.15pt">Product not yet approved or authorized in this market.</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(10)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.26pt">We have exclusive rights to Braftovi and Mektovi in the U.S., Canada and certain emerging markets. Pierre Fabre has exclusive rights to commercialize both products in Europe and Ono has exclusive rights to commercialize both products in Japan. We receive royalties from Pierre Fabre and Ono on sales of Braftovi and Mektovi in a majority of markets outside the U.S.</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">(11)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:112%;padding-left:4.26pt">Mektovi U.S. expiry is provided by a composition of matter patent. Interim patent term extension requests have been granted extending the expiry from March 2025 to March 2026 and Pfizer has filed an application for patent term extension to 2027. Other U.S. patents remain in force beyond the composition of matter patent expiry. Those patents have been challenged in litigation. Refer to </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:112%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_268">Note 16A1</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:112%"> for more information.</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(12)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.26pt">Padcev is being commercialized in collaboration with Astellas. Pfizer has co-promotion rights in the U.S. Outside the U.S., Pfizer has commercialization rights in all countries in North and South America, and Astellas has commercialization rights in the rest of the world, including Europe, Asia, Australia and Africa.</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(13)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.26pt">In September 2020, Seagen and Merck began a collaboration to commercialize Tukysa. As of December 31, 2023, this collaboration ended and all commercialization rights were returned to Seagen (Pfizer).</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(14)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.26pt">Ngenla is being developed in collaboration with OPKO Health, Inc.</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(15)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.26pt">Tivdak is commercialized in collaboration with Genmab. Pfizer has co-promotion rights in the U.S. Outside the U.S., Genmab has the sole right to promote Tivdak for second-line plus mCC and has co-promotion rights for other indications in all territories except certain territories where Zai Lab Limited (Zai Lab) has commercialization rights (mainland China, Hong Kong, Macau, and Taiwan). Pfizer and Genmab equally share all costs and profits for Tivdak in the U.S., Europe, China (including the payments from Zai Lab described below), and Japan; provided that Genmab will be solely responsible for all costs of development, manufacturing and commercialization of second-line plus mCC outside the U.S. and the Zai Lab territories. Genmab will pay Pfizer a royalty-based percentage of aggregate net sales of Tivdak for second-line plus mCC outside the U.S. and the Zai Labs territories. In markets outside the U.S. other than Europe, China, and Japan, Pfizer will pay Genmab a royalty based on a percentage of aggregate net sales of Tivdak for indications other than second-line plus mCC.</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">Further, pursuant to the agreement with Zai Lab, Pfizer is entitled to receive potential development, regulatory and commercial milestone payments, and tiered royalties on net sales of Tivdak in the Zai Lab territories, which will be shared equally with Genmab.</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(16)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.26pt">The basic product patent application has been filed in this market. If granted, a full term is expected in this market.</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(17)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.26pt">Product is being commercialized in collaboration with BioNTech. The Comirnaty trademark covers marketed variants.</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(18)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.26pt">The basic product patent has been granted in the U.K. and expires in 2041. In the other major markets, a patent application has been filed. If granted, a full term is expected. </span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(19)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.26pt">Pfizer does not have co-promotion rights for this product in Germany.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">For information regarding profit sharing and royalty arrangements for certain of these products, see </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_37">Item 1. BusinessCollaboration and Co-Promotion Agreements</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:5pt"><span style="color:#006ebf;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Loss of Intellectual Property Rights. </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The loss, expiration or invalidation of intellectual property rights, patent litigation settlements and judgments and the expiration of co-promotion and licensing rights can have a material adverse effect on our revenues. Once patent protection has expired or has been lost prior to the expiration date as a result of a legal challenge, we typically lose market exclusivity on these products, and generic and biosimilar pharmaceutical manufacturers generally produce identical or highly similar products and sell them for a lower price. The date at which generic or biosimilar competition commences may be different from the date that the patent or regulatory exclusivity expires. However, when generic or biosimilar competition does commence, the resulting price competition can substantially decrease our revenues for the impacted products, often in a very short period of time. Also, if one of our product-related patents is found to be invalid by judicial, court, regulatory or administrative proceedings, generic or biosimilar products could be introduced, resulting in the erosion of sales of our existing products. Additionally, we could be subject to claims that our intellectual property rights infringe third party patents.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain of our products have experienced patent-based expirations or loss of regulatory exclusivity in certain markets in the last few years, and we expect certain products to face increased generic competition over the next few years. While additional patent-based or regulatory exclusivity </span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">8</span></div></td></tr></tbody></table></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">expiries will continue, we expect a moderate impact of reduced revenues due to patent expiries in 2025 and anticipate a more significant impact of reduced revenues from patent-based or regulatory exclusivity expiries in 2026 through 2030 as several of our in-line products experience these expirations. There is no assurance that a particular product will maintain market exclusivity for the full time period that appears in the estimates included in this Form 10-K or that we assume when we provide our financial guidance. For additional information on the impact of loss of patent-based exclusivity or regulatory exclusivity on our revenues, see the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_100">Overview of Our Performance, Operating Environment, Strategy and OutlookOur 2023 Performance</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">section within MD&amp;A.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We continue to vigorously defend our patent rights against infringement, and we will continue to support efforts that strengthen worldwide recognition of patent rights while taking necessary steps to help ensure appropriate patient access. See the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67">Item 1A. Risk Factors</a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67"></a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67">Competitive Products, </a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67"></a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67">Intellectual Property Protection</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67"> </a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67">and</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67"> </a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67"></a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67">Third-Party Intellectual Property Claims</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">sections and </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_268">Note 16A1</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:5pt"><span style="color:#006ebf;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Trademarks</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Our products are sold under brand-name and logo trademarks and trade dress. Registrations generally are for fixed, but renewable, terms and protection is provided in some countries for as long as the mark is used while in others, for as long as it is registered. Protecting our trademarks is of material importance to us.</span></div><div id="i8531e747ebb543f3bf818166f157d26a_49"></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">COMPETITION</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our business is conducted in intensely competitive and highly regulated markets. Many of our products face competition in the form of branded or generic drugs or biosimilars that treat similar diseases or indications. The principal forms of competition include efficacy, safety, ease of use and cost. Though the means of competition vary among our products, demonstrating the value of our products is a critical factor for success.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We compete with other companies that manufacture and sell products that treat or prevent diseases or indications similar to those treated or prevented by our major products. These competitors include other worldwide research-based biopharmaceutical companies, smaller research companies with more limited therapeutic focus and generic drug and biosimilar manufacturers. Our competitors also may devote substantial funds and resources to R&amp;D and their successful R&amp;D could result in erosion of the sales of our existing products and potential sales of our products in development, as well as product obsolescence. In addition, several of our competitors operate without large R&amp;D expenses and make a regular practice of challenging our product patents before their expiration.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">To help address competitive trends we continually emphasize innovation, which is underscored by our multi-billion-dollar investment in R&amp;D, as well as our business development transactions, both designed to result in a strong and differentiated product pipeline. Our investment in research continues even after drug or vaccine approval as we seek to further demonstrate the value of our products for the conditions they treat or prevent, as well as investigating potential new applications. We educate patients, physicians, payors and global health authorities on the benefits and risks of our medicines and vaccines, and seek to continually enhance the organizational effectiveness of our biopharmaceutical functions, including our efforts to effectively launch and market our products to our customers.</span></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Operating conditions have also shifted as a result of increased global competitive pressures, industry regulation and cost containment. We continue to evaluate, adapt and improve our organization and business practices in an effort to better meet customer and public needs. We believe that we have taken an industry-leading role in evolving our ethical approaches to U.S. direct-to-consumer advertising, interactions with, and payments to, healthcare professionals and medical education grants. We also continue to support programs to help address patient affordability and access barriers, as we strive to advance fundamental health system change through our support for better healthcare solutions. For example, our </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Accord for a Healthier World </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">program aims to provide our full portfolio of patented and off-patent medicines and vaccines for which Pfizer holds global rights on a not-for-profit basis to 1.2 billion people living in 45 lower-income countries around the world.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our vaccines have and may continue to face competition, including from the introduction of alternative vaccines or next-generation vaccines prior to or after the expiration of their patents, which may adversely affect our future results.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our biosimilars, which include biosimilars of certain inflammation &amp; immunology and oncology biologic medicines, compete with branded products from competitors, as well as other generics and biosimilars manufacturers. We seek to maximize the opportunity to establish a first-to-market or early market position for our biosimilars to provide customers a lower-cost alternative immediately when available and also to potentially provide us with higher levels of sales and profitability until other competitors enter the market. </span></div><div style="margin-top:5pt"><span style="color:#006ebf;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Generic Products</span><span style="color:#006ebf;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Generic pharmaceutical manufacturers pose one of the biggest competitive challenges to our branded small molecule products because they can market a competing version of our product after the expiration or loss of our patent protection and often charge much less. Several competitors regularly challenge our product patents before their expiration. Generic competitors often operate without large R&amp;D expenses, as well as without costs of conveying medical information about products to the medical community. In addition, the approval process in the U.S. and in the EU exempts generics from costly and time-consuming clinical trials to demonstrate their safety and efficacy, allowing generic manufacturers to rely on the safety and efficacy data of the innovator product. In China, for example, given the expansion of the QCE process and continuation of the VBP program, we expect to continue to face intensified competition by certain generic manufacturers in 2025 and beyond, which has and may continue to result in price cuts and volume loss of some of our products. In addition, generic versions of competitors branded products have and may continue to compete with our products.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial and government payors typically encourage the use of generics as alternatives to brand-name drugs in their healthcare programs, including Medicaid in the U.S., and U.S. laws generally allow, and in some cases require, pharmacists to substitute generic drugs for brand-name drugs. In a small subset of states, prescribing physicians are able to expressly prevent such substitution. Similar rules also apply in several EU member states, where national authorities typically encourage and incentivize the use of generic products.</span></div><div style="margin-top:5pt"><span style="color:#006ebf;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Biosimilars. </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain of our biologic products, including Enbrel (we market Enbrel outside the U.S. and Canada), already face, or may face in the </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">future, competition from biosimilars (also referred to as follow-on biologics). Biosimilars are versions of biologic medicines that have been developed and proven to be highly similar to the original biologic in terms of safety and efficacy and that have no clinically meaningful differences in safety, purity or potency. Biosimilars have the potential to offer high-quality, lower-cost alternatives to innovative biologic medicines. In the U.S., biosimilars referencing innovative biologic products are approved by the FDA under the U.S. Public Health Service Act, whereas in the EU the EMA is responsible for evaluating the majority of applications for biosimilars through the centralized procedure.</span></div><div id="i8531e747ebb543f3bf818166f157d26a_52"></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">PRICING PRESSURES AND MANAGED CARE ORGANIZATIONS</span></div><div style="margin-top:5pt"><span style="color:#006ebf;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Commercial Pricing Pressures. </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pricing and access pressures in the commercial sector continue to be significant. Overall, there is increasing pressure on U.S. providers to deliver healthcare at a lower cost and to ensure that those expenditures deliver demonstrated value in terms of health outcomes. Many employers have adopted or make available high deductible health plans, which can increase out-of-pocket costs for </span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">9</span></div></td></tr></tbody></table></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">medicines, or are using utilization management tools or limiting access on formularies. This trend is likely to continue. Private third-party payors, such as health plans, increasingly challenge pharmaceutical product pricing, which could result in lower prices, lower reimbursement rates for payors and a reduction in demand for our products, including denial of coverage of our products, if lower cost alternatives are available. Payors often require significant discounts, or rebates, from our prices in exchange for more favorable formulary placement. Pricing pressures also may occur as a result of highly competitive biopharmaceutical markets and increasing concentration of insurers and PBMs. Healthcare provider purchasers, directly or through group purchasing organizations, are seeking enhanced discounts or implementing more rigorous bidding or purchasing review processes.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We believe medicines and vaccines are the most efficient and effective use of healthcare dollars based on the value they deliver to the overall healthcare system. We work with law makers and advocate for solutions that effectively improve patient health outcomes, lower costs to the healthcare system, and help ensure access to medicines and vaccines within an efficient and affordable healthcare system. This includes assessing our go-to market model to help address patient affordability challenges. We have engaged with major payors and the U.S. government to explore opportunities to improve access and reimbursement in an effort to drive pro-patient policies. In addition, in response to the evolving U.S. and global healthcare spending landscape, we work with health authorities, health technology assessment and quality measurement bodies and major U.S. payors throughout the product-development process to better understand how these entities value our compounds and products. Further, we are developing stronger support designed to demonstrate the value of the medicines and vaccines that we discover or develop, register and manufacture.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">For information on government pricing pressures, see the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_58">Item 1. Business</a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_58"></a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_58">Government Regulation and Price Constraints</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67">Item 1A. Risk Factors</a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67"></a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67">Pricing and Reimbursement</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">sections. </span></div><div style="margin-top:5pt"><span style="color:#006ebf;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Managed Care Organizations. </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The evolution of managed care in the U.S. has been a major factor in the competitiveness of the healthcare marketplace. Approximately 317 million people in the U.S. now have some form of health insurance coverage, and the marketing of prescription drugs and vaccines to both consumers and the entities that manage coverage in the U.S. continues to grow in importance. In particular, the influence of MCOs has increased in recent years due to the growing number of patients receiving coverage through MCOs. At the same time, consolidation in the MCO industry has resulted in fewer, even larger MCOs, which enhances those MCOs ability to negotiate lower pricing and further increases their importance to our business. Since MCOs purport to seek to contain and reduce healthcare expenditures, their growing influence has increased downward pressure on drug prices, as well as negatively impacted revenues.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">MCOs and their PBMs typically negotiate prices with pharmaceutical providers by using formularies (which are lists of approved medicines available to MCO members), clinical protocols (which require prior authorization for a branded product if a generic product is available or require the patient to first fail on one or more generic products before permitting access to a branded medicine), long-term contracts and their ability to influence volume and market share of prescription drugs. In addition, by placing branded medicines on higher-tier or non-preferred status in their formularies, MCOs transfer to the patient higher patient out-of-pocket expenses. This financial disincentive is a tool for MCOs to manage drug costs and channel patients to medicines preferred by the MCOs. We expect payment reforms for MCOs will continue to evolve with increased emphasis on expanded participation and on removing barriers to equitable healthcare. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The breadth of the products covered by formularies can vary considerably from one MCO to another, and many formularies include alternative and competitive products for treatment of particular medical problems. MCOs emphasize primary and preventive care, out-patient treatment and procedures performed at doctors offices and clinics as ways to manage costs. Hospitalization and surgery, typically the most expensive forms of treatment, are carefully managed, and drugs that can help in chronic care management and reduce the need for hospitalization, professional therapy or surgery may become favored first-line treatments for certain diseases. At the same time, MCOs may seek to exclude high-cost drugs from formularies in their efforts to manage and lower their costs.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Exclusion of a product from a formulary or other restrictions can significantly impact drug usage in the MCO or PBM managed patient population and beyond. Consequently, pharmaceutical companies compete to gain access to formularies for their products, typically on the basis of unique product features, such as greater efficacy, better patient ease of use, or fewer side effects, as well as the overall cost of the therapy. We continue to seek to ensure that our major products are included on MCO formularies. However, our branded products are increasingly being placed on the higher tiers or in a non-preferred status. Continuing efforts by managed care entities to contain or reduce costs of healthcare and/or impose price controls may adversely affect demand for our products and our financial performance. See the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67">Item 1A. Risk Factors</a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67"></a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67">Managed Care Trends</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section. </span></div><div id="i8531e747ebb543f3bf818166f157d26a_55"></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">RAW MATERIALS</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We procure raw materials essential to our business from numerous suppliers worldwide. In general, these materials have been available in sufficient quantities to support our demand and in many cases are available from multiple suppliers. We do not anticipate the availability of raw materials to have a significant impact on our operations in 2025, but are monitoring potential supply chain disruptions as a result of ongoing geopolitical and trade negotiations, which could, among other things, impact costs. We are continuing to monitor and implement mitigation strategies to reduce any potential risk or impact including active supplier management, qualification of additional suppliers and advanced purchasing to the extent possible.</span></div><div id="i8531e747ebb543f3bf818166f157d26a_58"></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">GOVERNMENT REGULATION AND PRICE CONSTRAINTS</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We are subject to extensive regulation by government authorities in the countries in which we do business. This includes laws and regulations governing the operations of biopharmaceutical companies, such as the approval, manufacturing and marketing of products, pricing (including discounts and rebates) and price reporting, interactions with healthcare professionals, institutions, and referral sources, reporting of remuneration provided to healthcare providers and academic medical centers, financial assistance provided to patients, clinical research, data privacy and information security, among others. These laws and regulations may require administrative guidance for implementation, and a failure to comply could subject us to legal and/or administrative actions. Enforcement measures may include substantial fines and/or penalties, orders to stop non-compliant activities, criminal charges, warning letters, product recalls or seizures, delays in product approvals, exclusion from participation in government programs or contracts as well as limitations on conducting business in applicable jurisdictions, and could result in harm to our reputation and business. See </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_268">Note 16A</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Compliance with these laws and regulations is costly, and requires significant technical expertise and capital investment to ensure compliance. </span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">10</span></div></td></tr></tbody></table></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:8pt"><span style="color:#006ebf;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">In the U.S.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Drug and Biologic Regulation</span><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The FDA, pursuant to the FFDCA, the Public Health Service Act and other federal statutes and regulations, extensively regulates pre- and post-marketing activities related to our biopharmaceutical products and devices. The statutes and regulations govern areas such as safety and efficacy, clinical trials, advertising and promotion, quality control, manufacturing, labeling, distribution, post-marketing safety surveillance and reporting, and record keeping. Other U.S. federal agencies, including the DEA, may also regulate certain of our products and activities. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">For a biopharmaceutical company to market a drug or a biologic product, including vaccines, the FDA must evaluate whether the product is safe and effective for its intended use. Absent statutory exclusivity for a competing product, if the FDA determines that the drug or biologic is safe and effective, the FDA generally will approve the products NDA or BLA (or supplemental NDA or supplemental BLA), as appropriate.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">A drug or biologic may be subject to post marketing commitments, which are studies or clinical trials that the product sponsor agrees to conduct, or post marketing requirements, which are studies or clinical trials that are required as a condition of approval. In addition, we are also required to report adverse events and comply with cGMPs (the FDA regulations that govern all aspects of manufacturing quality for pharmaceuticals) and the Drug Supply Chain Security Act (the law that, among other things, sets forth requirements related to product tracing, product identifiers and verification for manufacturers, wholesale distributors, third-party logistics providers, re-packagers and dispensers to facilitate the tracing of product through the pharmaceutical distribution supply chain), as well as advertising and promotion regulations. See the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67">Item 1A. Risk Factors</a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67"></a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67">Development, Regulatory Approval and Marketing of Products</a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67"> </a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67">and</a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67"> </a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67"></a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67">Post-Authorization/Approval Data</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">sections.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We are also responsible for monitoring, reviewing, and the periodic reporting of adverse drug experience, or pharmacovigilance, including information received from any source, such as commercial marketing experience, postmarketing clinical investigations, postmarketing epidemiological or surveillance studies, reports in the scientific literature, and unpublished scientific papers.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">In the context of public health emergencies, like the COVID-19 pandemic, we may apply to the FDA for an EUA which, if granted, allows for the distribution and use of our products during the declared emergency, in accordance with the conditions set forth in the EUA, unless the EUA is terminated by the government. Although the criteria for an EUA differ from the criteria for approval of an NDA or BLA, EUAs nevertheless require the development and submission of data to satisfy the relevant FDA standards, and a number of ongoing obligations. The FDA generally expects EUA holders to work toward submission of full applications, such as a BLA or an NDA, as soon as possible.</span></div><div style="margin-top:5pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Biosimilar Regulation.</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The FDA is responsible for approval of biosimilars. Innovator biologics, or reference products, are entitled to certain exclusivity periods. Applications for biosimilars may not be submitted until four years after the date on which the reference product was first licensed and may not be approved until 12 years after the reference product was first licensed.</span></div><div style="margin-top:5pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Sales and Marketing Regulations</span><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Our marketing practices are subject to federal and state laws, such as the Anti-Kickback Statute (AKS), Civil Monetary Penalties Law and False Claims Act, intended to prevent fraud and abuse in the healthcare industry. These laws can apply to both our direct-to-consumer marketing practices as well as our marketing to clinicians and healthcare facilities. The AKS prohibits soliciting, offering, receiving, or paying anything of value to generate business that may be paid for, in whole or in part, by a federal healthcare program. The Civil Monetary Penalties Law covers a variety of conduct, often violations under other laws, and includes penalties for AKS violations as well as causing the submission of false claims. The False Claims Act generally prohibits anyone from knowingly and willingly presenting, or causing to be presented, any claims for payment for goods or services, including to government payors, such as Medicare and Medicaid, that are false or fraudulent including false certifications of compliance with applicable law. The federal government and states also regulate sales and marketing activities and financial interactions between manufacturers and healthcare providers and academic medical centers, requiring disclosure to government authorities and the public of such interactions, and the adoption of compliance standards or programs. State attorneys general have also taken action to regulate the marketing of prescription drugs under state consumer protection and false advertising laws. </span></div><div style="margin-top:5pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Pricing, Reimbursement and Access Regulations.</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Pricing and reimbursement for our products depend in part on government regulation. Any significant efforts at the federal or state levels to reform the healthcare system by changing the way healthcare is provided or funded or to expand controls on drug pricing, government reimbursement, and access to medicines and vaccines on public and private insurance plans could have a material impact on us. </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We must offer discounts or rebates on purchases of pharmaceutical products under various government programs including Medicare, Medicaid, the Veterans Administration and the 340B Program. We also must report specific prices to state and federal government agencies. The calculations necessary to determine the prices reported are complex and the failure to do so accurately may expose us to enforcement measures. See the discussion regarding rebates in the</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_118">Product Revenue Deductions</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">section within MD&amp;A and </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_178">Note 1G</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The drug pricing provisions of the IRA are being implemented over the next several years. The IRA includes several provisions to lower prescription drug costs for Medicare patients and to reduce drug spending by the federal government. Among other things, the IRA enhances the Medicare Part D benefit by eliminating the coverage gap (donut hole) beginning in 2025, adds a maximum out-of-pocket cap for Medicare beneficiaries (set at $2,000 for 2025), and creates a new program, the Medicare Prescription Payment Plan, that allows patients to pay their cost-sharing over time. These changes also include a new Medicare Part D Manufacturer Discount Program, which will change our discounting obligations for Medicare Part D utilization of our drugs. Specifically, this program requires manufacturers to provide a 10% discount on branded prescriptions in the initial coverage phase and a 20% discount in the catastrophic phase. The IRA also imposes rebates under Medicare Part B and Medicare Part D on drug price increases that outpace inflation, and directs HHS to set the prices of certain high-expenditure, single-source drugs and biologics covered under Medicare, known as the MDPNP. In August 2023, CMS published the first ten medicines subject to the MDPNP, which included Eliquis. In August 2024, the government released the new Medicare price for Eliquis, which, effective January 1, 2026, will be required to be offered to all Medicare beneficiaries and to covered entities participating in the 340B Program that dispense Eliquis to a Medicare beneficiary if that maximum fair price is lower than the discounted price such entities are offered under the 340B Program ceiling price calculation. The Eliquis Medicare price is factored into our long-term financial planning, in accordance with our standard financial reporting and forecasting protocols. On January 17, 2025, CMS announced the selection of another 15 drugs from Medicare Part D for the maximum fair price, with prices to be set and effective on January 1, 2027. Ibrance and Xtandi were included in the list of 15 drugs selected. Another 15 drugs from Medicare Part B or Medicare Part D will be selected by February 1, 2026, for the maximum price to be set and in effect by January 1, 2028. It is possible that more of our products could be selected in future years, which could, among other things, lead to lower revenues prior to expiry of intellectual property protections. The MDPNP is currently subject to legal challenges and therefore, the outcome of the MDPNP remains uncertain. We continue to evaluate the impact of the IRA on our business, operations and financial condition and results as the full effect of the IRA on our business and the pharmaceutical industry remains uncertain. We anticipate a net unfavorable impact to revenue in 2025 of approximately $1 billion, year-over-year, related to the Medicare Part D redesign changes that take effect in 2025. See the discussion regarding </span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">11</span></div></td></tr></tbody></table></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">changes to the IRA in the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_100">Overview of Our Performance, Operating Environment, Strategy and OutlookOur Operating Environment</a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_100"> </a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">section within MD&amp;A.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Changes to the MDRP or the 340B Program could have a material impact on our business. For example, certain changes finalized by CMS in a December 2020 final rule, including which products qualify as so-called line extension drugs subject to increased rebate liability, may have a material adverse impact on our business. Additionally, in September 2024, CMS finalized a new rule that, among other items, expands the scope of medications considered to be covered outpatient drugs that could be subject to rebates under the MDRP and imposes penalties on covered outpatient drugs that CMS determines to be misclassified. Many pharmaceutical manufacturers believe the 340B Program continues to expand beyond the original intent of serving low-income/uninsured patients. There has been limited government intervention to control this unintended growth. Various potential changes impacting the scope of the 340B Program are undergoing review or are the subject of litigation, and their status is unclear. In 2022, we implemented a policy to help improve contract pharmacy integrity. The HHS Health Resources and Services Administration (HRSA), which administers the 340B Program, sent letters to numerous manufacturers (not including Pfizer) that have also implemented contract pharmacy policies and integrity initiatives; the letters expressed HRSAs view that those manufacturers policies were in violation of the 340B Program statute. Several manufacturers have challenged HRSAs enforcement letters in federal court and litigation is ongoing in certain of those cases, and were resolved in favor of the manufacturers in others. We believe that our policy is consistent with the statute. In addition, some states have enacted laws opposing manufacturer restrictions on contract pharmacy transactions in their states. At least one state has begun to pursue enforcement proceedings under its law. Several stakeholders have challenged such laws and litigation is ongoing in certain jurisdictions. Additionally, other states have considered and could enact similar laws going forward, although any such laws also may be subject to legal challenges. Additional legal or legislative developments at the federal or state level with respect to the 340B Program may have an adverse impact on our integrity initiative, and we may face enforcement action or penalties, depending upon such developments. The 340B Program continues to be a subject of congressional scrutiny and inquiries, litigation, and other developments, any or all of which could affect the scope of the 340B Program and Pfizers obligation to offer discounts to 340B Program-covered entities under the 340B Program. See the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67">Item 1A. Risk Factors</a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67"></a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67">Pricing and Reimbursement</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">States seek to control healthcare costs related to Medicaid and other state regulated healthcare programs. A majority of states use preferred drug lists to manage access to pharmaceutical products under Medicaid, including some of our products. States may seek to negotiate supplemental rebate agreements that are larger than the minimum federal requirement for preferred formulary access. Preferred access to our products under the Medicaid managed care programs are often determined by the managed care health plans contracted by the state to administer benefits, which may also require supplemental rebates for preferred formulary access. We expect states will continue to seek cost cutting, which may focus on managed care capitation payments, supplemental rebates, and/or formulary management.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">In the U.S., we expect to see continued focus by the U.S. government on regulating pricing and access to medicine, in addition to actions already taken, which could result in legislative and regulatory changes. Government and private payors routinely seek to manage utilization and control the costs of our products. There is considerable public and government scrutiny of pharmaceutical pricing and intellectual property and actions being taken at the state and federal level. Further efforts by states and the federal government to regulate prices or payment for pharmaceutical products, including proposed actions to facilitate drug importation or establish upper pricing limits that cap reimbursement to lower reference prices, require deep discounts, impose financial penalties related to pricing practices, and require manufacturers to report and make public price increases and sometimes a written justification for the increase, could adversely affect our business if implemented. Further, commercial payors often follow Medicare coverage and reimbursement policies when setting their own payment rates. Any reduction in cost or other containment measures may similarly be adopted by commercial plans. Payors may continue to promote generic drugs and biosimilars more aggressively to generate savings and attempt to stimulate additional price competition. In addition, we expect that consolidation and integration among pharmacy chains, wholesalers and PBMs will increase pricing pressures in the industry. See the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67">Item 1A. Risk Factors</a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67"></a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67">Managed Care Trends</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section.</span></div><div style="margin-bottom:5pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Anti-Corruption. </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The FCPA prohibits U.S. corporations and their representatives from offering, promising, authorizing or making payments to any foreign government official, government staff member, political party or political candidate to obtain or retain business abroad. The scope of the FCPA includes interactions with certain healthcare professionals in many countries. Other countries have enacted similar anti-corruption laws and/or regulations.</span></div><div style="margin-bottom:5pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Data Privacy. </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The number of privacy and data security laws and regulations in the U.S. to which we are subject on the federal and state level continues to increase. We routinely collect and use sensitive personal information relating to health. The legislative, regulatory and litigation landscape for privacy and data protection requirements is rapidly evolving and changing, and may limit our ability to use data globally or across borders. Data protection requirements are not universal and can conflict between jurisdictions. Compliance with those laws and regulations is made more complex by the lack of consistent standards, common definitions, or clear regulatory expectations. At the same time, enforcement of these laws and regulations is increasing and litigation is becoming more common. Any failure or perceived failure by us to comply with applicable privacy and data protection laws and regulations, including cybersecurity breaches or incidents, could subject us to significant fines and penalties, and/or litigation, as well as negatively impact our reputation.</span></div><div style="margin-bottom:8pt"><span style="color:#006ebf;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Outside the U.S.</span></div><div style="margin-bottom:5pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">New Drug Approvals</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">. In the EU, the EMA conducts the scientific evaluation, supervision and safety monitoring of our innovative medicinal products that are eligible for the centralized marketing authorization procedure. Through the centralized procedure, pharmaceutical companies may submit to the EMA a single application for a marketing authorization valid in all the EU and the European Economic Area (EEA) countries. The EC makes a legally binding decision based on the EMA's recommendation. The centralized procedure is mandatory for certain new products and optional for others. In the U.K., the Medicines and Healthcare Products Regulatory Agency is the sole regulatory authority. In Japan, the Pharmaceuticals and Medical Device Agency is involved in a wide range of regulatory activities, including clinical studies, approvals, post-marketing reviews and pharmaceutical safety. In China, the National Medical Product Administration is the primary regulatory authority for approving and supervising medicines. Health authorities in many middle- and lower-income countries might require marketing approval or scientific opinions by a recognized regulatory authority (e.g., the FDA or EMA/EC) before they begin reviewing or approving applications. By way of example, the EMA, in cooperation with the WHO, can provide scientific opinions on high priority human medicines, including vaccines, for markets outside the EU.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">In April 2023, the EC adopted a proposal to revise the EU pharmaceutical legislation. In April 2024, the European Parliament introduced amendments to the EC's proposal. The EU legislative process remains ongoing, with several stages still required before the reform can receive final approval. Once completed, the reform is likely to be the most comprehensive overhaul of EU medicines regulation in over 20 years, with a wide range of impacts including on approval procedures, regulatory data protection, and environmental protection measures. Once approved, certain provisions of the reform could potentially have an adverse impact on our business.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">12</span></div></td></tr></tbody></table></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:5pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Pharmacovigilance.</span><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">In the EU, the EMAs PRAC is responsible for reviewing and making recommendations on product safety issues. Specifically, the PRAC focuses on detecting, assessing and communicating the risks associated with adverse reactions of medicinal products, while considering their therapeutic effects. It also evaluates post-authorization safety studies and conducts pharmacovigilance audits. Outside developed markets, pharmacovigilance requirements vary and are generally not as extensive, but there is a trend toward increasing regulation.</span></div><div style="margin-top:5pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Pricing and Reimbursement</span><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain governments, including in the different EU member states, the U.K., Japan, China and Canada, provide healthcare at low-to-zero direct cost to consumers at the point of care and have significant power to regulate pharmaceutical prices or patient reimbursement levels to control costs for the government-sponsored healthcare system, particularly under recent global financing pressures. Governments globally may use a variety of measures to control costs, including, among others, legislative or regulatory pricing reforms, cross country collaboration and procurement, price cuts, mandatory rebates, health technology assessments, forced localization as a condition of market access, international reference pricing (i.e., the practice of a country linking its regulated medicine prices to those of other countries), QCE processes and VBP. In addition, the international patchwork of price regulation, differing economic conditions and incomplete value assessments across countries has led to varying access to quality medicines in many markets and some third-party trade in our products between countries. Several important multilateral organizations such as the WHO scrutinize international pharmaceutical pricing through policy recommendations and sponsorship of programs, such as The Oslo Medicines Initiative (OMI) which aimed to ensure affordability for high-priced medicines. The OMI concluded its work in September 2022, and the WHO/Europe Access to Novel Medicines Platform was established to enhance affordable and equitable access to effective, innovative and high-priced medicinal products in the region.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">In China, pricing pressures have increased in recent years because of an overall focus on healthcare cost containment with the central government emphasizing improved health outcomes and decreased drug prices as key indicators of progress towards its healthcare reform. State owned hospitals and the state insurance program account for the vast majority of all drug purchases. For patented innovative products, drug prices have decreased dramatically as a result of adding innovative drugs (including oncology medicines and medicines for chronic diseases) to the National Reimbursement Drug List via access-price negotiation. A centralized VBP program with a tendering process implemented at both the national level and the provincial level aims to contain healthcare costs by driving utilization of generics that have passed QCE. This has resulted in further lowering the price of medicines, especially off-patent medicines; this trend is expected to continue. China is continuing its use of Health Technology Assessment and is controlling mark-ups within the country using a two-invoice limited system, aiming to regulate the pricing of pharmaceutical products and certain types of medical devices. Pfizer, along with most off-patent originators, has mostly not been successful in the VBP bidding process. The government has indicated that additional drugs which are past patent-based exclusivity expiry (including biological products) could be subjected to VBP qualification in future rounds. Certain of our products, such as Xeljanz, Unasyn, Hemabate and Ibrance, were included as candidates in the tenth national VBP round in 2024, and Pfizer was not successful in the bidding process for such products. While certain details of future QCE expansion have been made available, we are unable to determine the impact on our business of the various pricing measures underway.</span></div><div style="margin-top:5pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Healthcare Provider Transparency and Disclosures.</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Several countries have implemented laws requiring (or industry trade associations have recommended) disclosure of transfers of value made by pharmaceutical companies to healthcare providers and/or healthcare organizations, such as academic teaching hospitals. </span></div><div style="margin-top:5pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Intellectual Property</span><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Reliable patent protection and enforcement around the world are among the key factors we consider for continued business and R&amp;D investment. The WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (WTO-TRIPS) requires participant countries to provide patent and other intellectual property-related protection for pharmaceutical products by law, with a time-limited exemption provided for least-developed countries. While some countries have made improvements, we still face patent grant, enforcement and other intellectual property challenges in many countries. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">While the global intellectual property policy environment has generally improved following implementation of WTO-TRIPS and bilateral/multilateral trade agreements, our growth and ability to bring new product innovation to patients depends on maintaining those standards and further progress in intellectual property protection. In certain developed international markets, governments maintain relatively effective intellectual property policies. However, in the EU, ongoing review of pharmaceutical legislation may reduce the basic period of regulatory data protection. In several emerging market countries and multilateral institutions, governments continue to address the role of intellectual property in the context of, for example, access to medicines. </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Considerable political and economic pressure has weakened current intellectual property protection in some countries and has led to policies such as more restrictive standards for obtaining patents and more difficult procedures for patenting biopharmaceutical inventions, restrictions on patenting certain types of inventions, revocation of patents, laws or regulations that promote or provide broad discretion to issue a compulsory license, weak intellectual property enforcement and failure to implement effective regulatory data protection. Our industry advocacy efforts focus on seeking a fair and transparent business environment for foreign manufacturers, underscoring the importance of strong intellectual property systems for all innovative industries (both domestic and foreign) and helping improve patients access to innovative medicines and vaccines.</span></div><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Data Privacy. </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We are subject to extensive privacy and data protection laws and regulations around the world concerning the collection, use and sharing of personal data. We routinely collect and use sensitive personal information relating to health. The legislative, regulatory and litigation landscape for privacy and data protection requirements is rapidly evolving and changing, and may limit our ability to use data globally or across borders. Data protection requirements are not universal and can conflict between jurisdictions. Compliance with those laws and regulations is made more complex by the lack of consistent standards, common definitions, or clear regulatory expectations. At the same time, enforcement of these laws and regulations is increasing and fines and penalties are also increasing. Any failure or perceived failure by us to comply with applicable privacy and data protection laws and regulations, including cybersecurity breaches or incidents, could subject us to significant fines and penalties, and/or litigation, as well as negatively impact our reputation.</span></div><div id="i8531e747ebb543f3bf818166f157d26a_61"></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">ENVIRONMENTAL MATTERS</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our operations are affected by national, state and/or local environmental laws. We have made, and intend to continue to make, the expenditures necessary for compliance with applicable laws. We also are cleaning up environmental contamination from past industrial activity at certain sites. We incurred capital and operational expenditures in 2024 for environmental compliance purposes and for the clean-up of certain past industrial activity as follows: $100 million in environment-related capital expenditures and $174 million in other environment-related expenses.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">While capital expenditures or operating costs for environmental compliance cannot be predicted with certainty, we do not currently anticipate they will have a material effect on our capital expenditures or financial position. See also </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_268">Note 16A3</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">13</span></div></td></tr></tbody></table></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">As a science guided organization, we take a proactive approach to our environmental sustainability initiatives. In 2022, we announced a goal to further reduce greenhouse gas (GHG) emissions and achieve the Science Based Target Initiatives voluntary Net-Zero Standard by 2040. As part of this goal, Pfizer aims to decrease its GHG emissions by 95% and its value chain emissions by 90% from 2019 levels by 2040. To support our goal, we are developing and implementing our emission reduction plan, which will include strategies to achieve reductions throughout our value chain including investing in new technologies and innovative climate solutions, and setting expectations for our suppliers to establish science-aligned GHG emission reduction goals. Our emission reduction plan-related expenses and capital spending incurred for 2024 were not material to our consolidated financial statements. While we expect to incur incremental capital and operational expenditures to meet our goal, we do not currently anticipate they will have a material effect on our financial position in the near term. Longer term uncertainties such as the likelihood of commercially available technologies make it difficult to predict the financial impact of meeting the goal, and we will continue to assess and monitor the financial impact of the emission reduction plan. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">For a discussion of the risks associated with climate change, see the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67">Item 1A. Risk FactorsClimate Change and Sustainability</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section.</span></div><div id="i8531e747ebb543f3bf818166f157d26a_64"></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">OUR PEOPLE</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our purpose is: </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Breakthroughs that change patients lives</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">. These breakthroughs are delivered through the collaboration of our talented workforce. As of December 31, 2024, we employed approximately 81,000 people worldwide. Our ability to successfully deliver on our purpose is dependent on our people. We work to create an environment that prioritizes colleagues' health and wellness. Our people-centric approach touches every aspect of the employee experience  including recruiting, benefits, compensation and development. Creating a purpose-driven workplace that attracts, nurtures, and retains top talent is a priority. Our vibrant and supportive work culture is designed to empower colleagues to innovate, collaborate, and contribute meaningfully to improving global health. We invest in comprehensive development programs, provide merit-based opportunities for advancement, and encourage work-life integration through flexible work arrangements.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Culture.</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> We cultivate community in our workplace and our purpose of delivering breakthroughs that change patients lives. As we work to bring together people with different perspectives and experiences we foster a collaborative environment based on merit. We continue to execute a merit-based talent approach, focusing on identifying candidates with the right qualifications and ensuring they are considered for the opportunities based on their skills, abilities, and performance. We aim to provide everyone with an opportunity to demonstrate their merit. Our leaders set the tone for the company, embracing accountability and transparency, while promoting a vibrant culture in which colleagues are free to speak up and are encouraged to share views and raise concerns without fear of retaliation.</span></div><div style="margin-bottom:5pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Colleague Engagement</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Open communication and feedback are essential elements of our commitment to performance, colleague engagement, and teamwork. Pfizer managers discuss colleague performance and leadership assessments regularly, with the intent to encourage breakthrough goals and foster leadership. We understand that communication goes both ways: equally important is our commitment to listening and responding to colleague feedback, to foster a healthy work environment with the power to attract and retain top talent. We are passionate about creating safe spaces at work, so our colleagues feel able and encouraged to provide the company with feedback and raise concerns and questions. The Office of the Ombuds is a resource colleagues, at any level, can connect with to get information and guidance to help them address and resolve work-related issues. We also host company-wide safe space calls and provide various other public, private, and anonymous channels for colleagues to speak up without fear of retaliation. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our annual engagement survey, Pfizer Pulse, provides a forum for our colleagues to give structured feedback and allows us to measure and track priority areas and equip leaders with actionable insights. In addition, we ask for feedback at various points in the employee lifecycle through focus groups, surveys, and colleague forums. The information we receive helps enable us to adapt to the real-time needs of our colleagues and continuously improve our ways of working.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer prioritizes colleague recognition to drive engagement, a sense of belonging, motivation, and productivity. Our global rewards and recognition program, Bravo, lets colleagues celebrate and acknowledge each other for demonstrating Pfizer values in a way that makes an impact on the company, a colleague, a team or a patient.</span></div><div style="margin-bottom:5pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Performance and Leadership.</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">In 2024, we introduced our Actionable Attitudes leadership mindset: anchor in trust, challenge convention, embrace uncertainty, engage with compassion, progress over perfection, and rise above. Complementing our Pfizer values and behaviors, our Actionable Attitudes leadership mindset embodies the attitudes every colleague should aspire to demonstrate, to foster a more dynamic, innovative, and compassionate place to work. In addition, in 2024, we expanded our Project-Based Ways of Working, which is designed to empower cross-functional teams to drive decisions within established guardrails and provides access to leadership for removing roadblocks, allowing colleagues to take on leadership roles and decision responsibilities through training, coaching, and a robust support network.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We are committed to helping our colleagues reach their full potential by rewarding both their performance and leadership skills and by providing opportunities for growth and development. Our performance management approachcalled Performance and Leadership Insightsis based on six-month semesters during which our colleagues and their managers set goals, receive feedback and meet to discuss performance. These conversations are meant to help colleagues grow and develop by evaluating performance (what the colleague achieved, measured by outcomes), leadership (how they achieved it, taking into account Pfizers values of courage, excellence, equity and joy), and identifying areas of growth that help move colleagues towards fulfilling their career goals and their potential. </span></div><div style="margin-bottom:5pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Growth and Development</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Supporting colleagues ongoing growth not only supports their individual success but also cultivates a resilient and adaptable workforce that can thrive in the face of change. As we navigate the evolving landscape of our industry, we recognize that providing our colleagues with opportunities for learning, skill-building, and growth is essential to their engagement, productivity, and overall job satisfaction. Investing in career growth and development reaffirms our commitment to our colleagues, demonstrates our belief in their potential, and supports them in being motivated, agile, and equipped with the necessary skills to tackle new challenges and seize emerging opportunities. Our perspective on career growth continues to shift from a traditional, linear view to one that is built on aspirations and embraces a variety of experiences. We actively encourage growth opportunities and part-time or temporary projects that allow colleagues to expand their expertise and build new skills while remaining in their current roles. We also promote diagonal moves, where colleagues pursue new roles in different job functions to gain a holistic understanding of the enterprise. By fostering an environment that encourages continuous learning, embraces flexibility, and empowers decision-making at all levels, we are not just preparing our workforce for the futurewe are actively shaping it. We believe this approach helps ensure that Pfizer remains at the forefront of innovation, ready to tackle the health challenges of tomorrow with a skilled, adaptable, and purpose-driven team. </span></div><div style="margin-bottom:5pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Health, Safety and Well-Being</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">. At Pfizer, protecting the health, safety, and well-being of colleagues and contingent workers, all of whom are essential to driving our business forward, is an integral part of how we operate. Pfizer's Global Environment, Health &amp; Safety (EHS) Policy and </span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">14</span></div></td></tr></tbody></table></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">supporting standards outline our approach to assessment, evaluation, elimination, and mitigation of EHS risks across our operations globally. Our leadership is accountable for EHS compliance and risk management. Colleagues and contingent workers receive EHS training relevant to their job roles, including measures to prevent workplace incidents and injuries. In addition, we conduct workplace assessments, inspections, and audits to evaluate and continuously improve our EHS arrangements.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We are committed to supporting and encouraging our colleagues' well-being. We use results from Pfizer Pulse and other colleague feedback forums to inform the wellness services we offer, such as (i) a Wellness Day for every colleague; (ii) on-site health clinics for colleagues in select locations, with access to certain vaccinations, where allowed by law; (iii) digital accessibility cafs providing colleagues with disabilities tools and equipment to do their jobs effectively; (iv) measures to assist those with neurodiverse conditions, such as sensory rooms and noise cancelling headphones; (v) a toolkit to aid in accommodation needs, education for managers and additional tools to help those who need any type of assistance to perform their roles; this includes on demand American Sign Language (ASL) services; (vi) mental health resources, including a manager/team toolkit designed to facilitate conversations, actively support coworkers, and provide local resources for colleagues to access services; (vii) programming through Employee Assistance Program (EAP) providers, including our mental health partner, THRIVE, our fitness partner, Exos, and our healthcare partner, Kepro; (viii) financial support, including short-term loans and natural disaster relief; and (ix) work policies to help enable colleagues to work effectively from home and their local offices, including our "Flex10" program that offers colleagues in hybrid roles 10 workdays per year to work from a different location within their country. </span></div><div style="margin-bottom:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Pay Equity.</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Our commitment to pay equity for all colleagues is based in our values and our intention to continue to build a highly motivated workforce.</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We are committed to equitable pay practices at Pfizer for employees based on role, education, experience, performance, and location and we conduct and report publicly on pay equity on an annual basis.</span></div><div id="i8531e747ebb543f3bf818166f157d26a_67"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tbody><tr><td style="width:1.0%"></td><td style="width:10.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&nbsp;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTORS</span></td></tr></tbody></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">This section describes the material risks to our business, which should be considered carefully in addition to the other information in this report and our other filings with the SEC. Investors should be aware that it is not possible to predict or identify all such factors and that the following is not meant to be a complete discussion of all potential risks or uncertainties. Additionally, our business is subject to general risks applicable to any company, such as economic conditions, geopolitical events, extreme weather and natural disasters. If known or unknown risks or uncertainties materialize, our business operations, financial condition, operating results (including components of our financial results), cash flows, prospects, reputation or credit ratings could be adversely affected now and in the future, potentially in a material way. The following discussion of risk factors contains forward-looking statements, as discussed in the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_19">Forward-Looking Information and Factors that May Affect Future Results</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> section.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">RISKS RELATED TO OUR BUSINESS, INDUSTRY AND OPERATIONS:</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">MANAGED CARE TRENDS</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Private payors, such as health plans, and other managed care entities, such as PBMs, continue to take action to manage the utilization and costs of drugs in the U.S., the single largest market for biopharmaceutical products. The negotiating power of MCOs, PBMs and other private third-party payors has increased due to consolidation, and they, along with state and federal governments, increasingly employ formularies to control costs and encourage utilization of certain drugs, including through the use of deductibles, utilization management tools, cost sharing or formulary placement. They may demand rebates and/or fees from biopharmaceutical manufacturers for preferred placement on a drug formulary. The growing availability and use of higher cost innovative specialty pharmaceutical medicines that treat rare or life threatening conditions also has generated increased payor interest in the development of cost-containment strategies. These initiatives have increased consumers interest in drug prices and input in medication choices, as they pay for a larger portion of their prescription costs and may cause them to favor lower-cost generic alternatives. We may fail to obtain or maintain timely or adequate pricing or formulary placement of our products, or fail to obtain such formulary placement at favorable pricing net of rebates.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Third-party payors also use additional measures such as new-to-market blocks, exclusion lists, indication-based pricing and value-based pricing/contracting to improve their cost containment efforts and cost efficiency. Such payors are also increasingly imposing utilization management tools requiring prior authorization for a branded product or requiring the patient to first fail on one or more other products before permitting access to a particular branded medicine. As the U.S. private third-party payor market consolidates further, and as the IRA prices become publicly available, we may face greater pricing pressure from private third-party payors as they continue to drive more of their patients to use lower cost alternatives or seek even larger rebates to control costs or offset losses from the IRA. For additional information on the IRA, see the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_52">Item 1. Business</a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_52"></a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_52">Pricing Pressures and Managed Care Organizations</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">and </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_58">Government Regulation and Price Constraints</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67">Item 1A. Risk Factors</a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67"></a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67">Pricing and Reimbursement</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">sections.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Also, business arrangements in this area are subject to a high degree of government scrutiny, and available safe harbors under applicable federal and state fraud and abuse laws are subject to change through legislative and regulatory action, as well as evolving judicial interpretations. Our approach to these arrangements may also be informed by such government and industry guidance.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">COMPETITIVE PRODUCTS</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Competitive product launches have and may erode future sales of our products, including our existing products and those currently under development, or result in product obsolescence. Such launches continue to occur, and potentially competitive products are in various stages of development. We cannot predict with accuracy the timing or impact of the introduction of competitive products that treat or prevent diseases and conditions like those treated or prevented by our in-line products and product candidates.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Some of our competitors may have competitive, technical or other advantages over us for the development of technologies and processes or greater experience in particular therapeutic areas, and consolidation among certain pharmaceutical and biotechnology companies can enhance such advantages. These advantages may make it difficult for us to compete with them successfully to discover, develop and market new products and for our current products to compete with new products or indications they may bring to market. Our products and product candidates compete, and may compete in the future, against products or product candidates that offer higher rebates or discounts, exclusionary contracting, lower prices, equivalent or superior efficacy, better safety profiles, easier administration, earlier market availability or other competitive features, including potential preference to prescribe existing competitor treatments over our novel therapies. For example, with the growing competition in the vaccine space, we are subject to increasing discounts to meet competitive dynamics and to help ensure our vaccines are available in retail pharmacies. If we are unable to compete effectively, this could reduce actual or anticipated future sales, which could negatively impact our results of operations.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">15</span></div></td></tr></tbody></table></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">In addition, competition from manufacturers of generic drugs, including from generic versions of competitors branded products that lose their market exclusivity, is a major challenge for our branded products. Certain of our products have experienced significant generic competition over the last few years. We anticipate a more significant impact of reduced revenues from patent-based or regulatory exclusivity expiries in 2026 through 2030 as several of our in-line products experience these expirations. See the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_46">Item 1. BusinessPatents and Other Intellectual Property Rights</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">section. In China, we expect to continue to face intense competition by certain generic manufacturers, which has resulted, and may result in the future, in price cuts and volume loss of some of our products.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">In addition, our patented products may face generic or biosimilar competition before patent-based and/or regulatory exclusivity expires, including from at-risk launch (despite pending patent infringement litigation against the generic or biosimilar product) by a manufacturer of a generic or biosimilar version of one of our patented products. Generic and biosimilar manufacturers have filed or could file applications with the FDA seeking approval of product candidates that they claim do not infringe our or our collaboration and licensing partners patents or claim that our or our collaboration and licensing partners patents are not valid. We and our licensing and collaboration partners also face challenges in various jurisdictions by generic drug manufacturers to patents covering products for which we have patent rights, licenses or co-promotion rights. See </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_268">Note 16A1</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We may become subject to competition from biosimilars referencing our biologic products if competitors are able to obtain marketing approval for such biosimilars.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We also commercialize biosimilar products that compete with products of others, including other biosimilar products. The number of current and forthcoming competing biosimilars, coupled with Medicares average sales price-based provider reimbursement methodology, is expected to increase pricing pressures on our biosimilar products. Uptake of our biosimilars may be lower due to various factors, such as access challenges where our product may not receive appropriate coverage/reimbursement access or remains in a disadvantaged position relative to an innovator product. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">For additional information on competition our products face, see the</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_49">Item 1. Business</a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_49"></a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_49">Competition</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">section.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">CONCENTRATION</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We recorded revenues of more than $1 billion for each of 11 products that collectively accounted for 66% of </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Total revenues</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in 2024. For example, Eliquis accounted for 12% of </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Total revenues</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in 2024. See </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_178">Notes 1</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_271">17</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">. If these products or any of our other major products were to, or continue to (if applicable), experience loss of patent protection (if applicable), changes in prescription or vaccination purchasing or growth rates, reduced product demand, material product liability litigation, unexpected side effects or safety concerns, regulatory proceedings or investigations, lower governmental and/or regulatory confidence, negative publicity affecting doctor or patient confidence, pressure from competitive products, changes in recommendations and coverage, changes in labeling, pricing and access pressures, including those related to the IRA, or supply shortages or if a new, more effective product should be introduced, the adverse impact on our revenues could be significant and our revenue forecasts and expectations could prove to be inaccurate and we may fail to meet these expectations. In particular, certain of our products have experienced patent-based expirations or loss of regulatory exclusivity in certain markets in the last few years, and we expect certain products to face increased generic competition over the next few years. While additional patent-based or regulatory exclusivity expiries will continue, we expect a moderate impact of reduced revenues due to patent expiries in 2025 and anticipate a more significant impact of reduced revenues from patent-based or regulatory exclusivity expiries in 2026 through 2030 as several of our in-line products experience these expirations. In addition, patents covering a number of our best-selling products are, or have been, the subject of pending legal challenges. For additional information on our patents, see the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_46">Item 1. Business</a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_46"></a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_46">Patents and Other Intellectual Property Rights</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section. For Comirnaty and Paxlovid, while we believe that these products have the potential to provide ongoing stable revenue streams for Pfizer for the foreseeable future, revenues of these products have decreased substantially over time. For Paxlovid, utilization is expected to follow infection trends, and revenues may fluctuate based on the timing, duration and severity of COVID-19 infections. For information on risks associated with Comirnaty and Paxlovid, see the </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">section below.</span></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">In addition, certain of our customers account for a significant portion of our revenues. If one of our significant customers should encounter financial or other difficulties, it might decrease the amount of business such customer does with us and/or we might be unable to timely collect all the amounts that such customer owes us or at all, which could negatively impact our results of operations. In addition, we expect that consolidation and integration of pharmacy chains and wholesalers will increase competitive and pricing pressures on pharmaceutical manufacturers, including us. See </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_280">Note 17C</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">for a discussion of our significant customers.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">RESEARCH AND DEVELOPMENT </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The discovery and development of new products, as well as the development of additional uses for existing products, are necessary for the continued strength of our business. Our product lines must be replenished over time to offset revenue losses when products lose exclusivity or market share or to respond to healthcare and innovation trends, as well as to provide for earnings growth, primarily through internal R&amp;D or through collaborations, acquisitions, JVs, licensing or other arrangements. Growth depends in large part on our ability to identify and develop new products or new indications for existing products that address unmet medical needs and receive reimbursement from payors. However, balancing current growth, investment for future growth and the delivery of shareholder return remains a major challenge. The costs of product development continue to be high and are growing, as are regulatory requirements in many therapeutic areas, which may affect the complexity of drug trials, and the number of candidates we are able to fund as well as the sustainability of the R&amp;D portfolio. Decisions made early in the development process of a drug or vaccine candidate can have a substantial impact on the marketing strategy and payor reimbursement possibilities if the candidate receives regulatory approval. We try to plan clinical trials prudently and to reasonably anticipate and address challenges, but there is no assurance that an optimal balance between trial conduct, speed and desired outcome will be achieved. In addition, potential quality issues may be identified in the course of a clinical trial that cannot be remediated to the satisfaction of a regulatory authority that may take actions within the scope of its enforcement authority, including excluding data and placing restrictions on future clinical trials.</span></div><div style="margin-bottom:8pt;margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Additionally, our product candidates can fail at any stage of the R&amp;D process, and may not receive regulatory approval even after many years of R&amp;D. We may fail to correctly identify compounds or indications for which our science is promising or allocate R&amp;D investment resources efficiently, and failure to invest in the right technology platforms, therapeutic areas, product classes, geographic markets and/or licensing opportunities could adversely impact the productivity of our pipeline. Further, even if we identify areas with the greatest commercial potential, the scientific approach may not succeed despite the significant investment required for R&amp;D, and the product may not be as competitive as expected because of the highly dynamic regulatory and market environments and the hurdles in terms of access, coverage and reimbursement. </span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">16</span></div></td></tr></tbody></table></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:5pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">GLOBAL OPERATIONS</span></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We operate on a global scale and could be affected by currency and interest rate fluctuations; capital and exchange controls; local and global economic conditions including inflation, recession, volatility and/or lack of liquidity in capital markets; expropriation and other restrictive government actions; changes in intellectual property; legal protections and remedies; trade regulations; tariffs; tax laws and regulations; and procedures and actions affecting approval, production, pricing, and marketing of, reimbursement for and access to our products, as well as impacts of political or civil unrest or military action, including the ongoing conflicts between Russia and Ukraine and in the Middle East and their economic consequences, geopolitical instability, terrorist activity, unstable governments and legal systems, inter-governmental disputes, public health outbreaks, epidemics, pandemics, natural disasters or disruptions related to climate change. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Some emerging market countries may be particularly vulnerable to periods of financial, economic or political instability or significant currency fluctuations or may have limited resources for healthcare spending. As a result of these and other factors, our strategy to grow in emerging markets may not be successful, and any growth rates in these markets may not be sustainable. Additionally, local economic conditions may adversely affect the ability of payors, as well as our distributors, customers, suppliers and service providers, to pay for our products, or otherwise to buy necessary inventory or raw materials, and to perform their obligations under agreements with us.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Government financing and economic pressures can lead to negative pricing pressure in various markets where governments take an active role in setting prices, access criteria (e.g., through health technology assessments) or other means of cost control. For additional information on government pricing pressures, see the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_58">Item 1. BusinessGovernment Regulation and Price Constraints</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section. </span></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We continue to monitor the global trade environment and potential trade conflicts, sanctions and impediments that could impact our business. If trade restrictions or tariffs reduce global economic activity, potential impacts could include declining sales; increased costs; volatility in foreign exchange rates; a decline in the value of our financial assets and pension plan investments; required increases of our pension funding obligations; increased government cost control efforts; delays or failures in the performance of customers, suppliers and other third parties on whom we may depend for the performance of our business; and the risk that our allowance for doubtful accounts may not be adequate. In addition, issued or future executive orders or other new or changes in laws, regulations or policy regarding tariffs, could have a material adverse effect on our business, earnings and financial guidance. The actual impact of the new tariffs on our business is subject to a number of factors including, but not limited to, restrictions on trade, the effective date and duration of such tariffs, countries included in the scope of tariffs, changes to amounts of tariffs, and potential retaliatory tariffs imposed by other countries. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We operate in many countries and transact in many different currencies. Changes in the value of those currencies relative to the U.S. dollar, or high inflation or deflation in those countries, can impact our revenues, costs and expenses and our financial guidance. Significant portions of our revenues, costs and expenses, as well as our substantial international net assets, are exposed to exchange rate changes. In 2024, 39% of our total revenues were derived from international operations, including 19% from Europe and 13% from China, Japan and the rest of the Asia Pacific region. Future changes in exchange rates or economic conditions and the impact they may have on our results of operations, financial condition or business are difficult to predict. For additional information about our exposure to foreign currency risk, see the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_145">Analysis of Financial Condition, Liquidity, Capital Resources and Market Risk</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section within MD&amp;A.</span></div><div style="margin-bottom:8pt;margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">In addition, our borrowing, pension benefit and postretirement benefit obligations and interest-bearing investments are subject to risk from changes in interest and exchange rates. The risks related to interest-bearing investments and borrowings and the measures we have taken to help contain them are discussed in the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_145">Analysis of Financial Condition, Liquidity, Capital Resources and Market Risk</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section within MD&amp;A and </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_229">Note 7E</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">. For additional details on critical accounting estimates and assumptions for our benefit plans, see the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_109">Significant Accounting Policies and Application of Critical Accounting Estimates and AssumptionsBenefit Plans</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section within MD&amp;A and</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_244">Note 11</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">PRODUCT MANUFACTURING, SALES AND MARKETING RISKS</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We could encounter difficulties, delays or inefficiencies in our supply chain, product manufacturing and distribution networks, as well as sales or marketing, due to regulatory actions, shut-downs, work stoppages or strikes, approval delays, withdrawals, recalls, penalties, supply disruptions, shortages or stock-outs at our facilities or third-party facilities that we rely on, reputational harm, the impact to our facilities due to health pandemics or natural or man-made disasters, including as a result of climate change, product liability or unanticipated costs. Examples of such difficulties or delays include the inability to increase or maintain production capacity commensurate with demand; challenges related to component materials to maintain supply and/or appropriate quality standards throughout our supply network and/or comply with applicable regulations; inability to supply certain products due to voluntary product recalls or withdrawals, including, for example, our voluntary withdrawal of all lots of Oxbryta in all markets where it is approved; and supply chain disruptions at our facilities or at a supplier or vendor. In addition, we engage contract manufacturers, and, from time to time, our contract manufacturers may face difficulties or are unable to manufacture our products at the necessary quantity or quality levels.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Regulatory agencies periodically inspect our manufacturing facilities, as well as third-party facilities that we rely on, to evaluate compliance with cGMP or other applicable requirements. Failure to comply with these requirements may subject us to possible legal or regulatory actions, such as warning letters, suspension of manufacturing, seizure of product, injunctions, debarment, product recalls, delays or denials of product approvals, import bans or denials of import certifications. </span><span style="background-color:#ffffff;color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">In response to requests from various regulatory authorities, manufacturers across the pharmaceutical industry, including Pfizer, are evaluating their product portfolios for the potential presence or formation of nitrosamines and we are actively engaging with regulatory authorities on this topic. If nitrosamines are detected above certain levels in our products, this may lead to market action for such products. For example, i</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">n 2021, Pfizer recalled all lots of Chantix due to the presence of a nitrosamine, N-nitroso-varenicline, at or above the acceptable intake limits communicated by various regulatory authorities. Regulatory authorities have since issued updated guidance on nitrosamine acceptable intake levels. With this guidance, which included an updated intake level for N-nitroso-varenicline, we have started making regulatory submissions to potentially enable Chantix to return to market in the U.S. and in certain international markets.</span></div><div style="margin-bottom:8pt;margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">See the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_100">Overview of Our Performance, Operating Environment, Strategy and Outlook</a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_100"></a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_100">Our Operating Environment </a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">section within MD&amp;A.</span></div><div style="margin-bottom:5pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">COLLABORATIONS AND OTHER RELATIONSHIPS WITH THIRD PARTIES </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We depend on third-party collaborators, service providers, and others in the research, development, manufacturing and commercialization of our products and product candidates and also enter into JVs and other business development transactions. To achieve expected longer-term benefits, we may make substantial upfront payments as part of these transactions, which may negatively impact our earnings or cash flows. We rely heavily on these parties for multiple aspects of our drug development, manufacturing and commercialization activities, but we do not control many aspects of those activities. We also outsource certain services, including activities related to transaction processing, accounting, IT, manufacturing, clinical trial recruitment and execution, clinical lab services, non-clinical research, safety services, integrated facilities </span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">17</span></div></td></tr></tbody></table></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">management and other areas. In conducting clinical trials, we may depend on contract research organizations to handle regulatory filings, monitor site performance and raise potential quality matters relating to clinical trials. Failure by one or more of the third-party collaborators, service providers and others to complete activities on schedule or in accordance with our expectations or to meet their contractual or other obligations to us; failure of one or more of these parties to comply with applicable laws or regulations; disruptions in one or more of these parties businesses, including unexpected demand for or shortage of raw materials or components, cyber-attacks on supplier systems, labor disputes or shortage and inclement weather, as well as natural or man-made disasters or pandemics; or any disruption in the relationships between us and these parties have or could delay or prevent the development, approval, manufacturing or commercialization of our products and product candidates, expose us to suboptimal quality of service delivery or deliverables, result in repercussions such as missed deadlines or other timeliness issues, erroneous data and supply disruptions, and could also result in non-compliance with legal or regulatory requirements or industry standards, including Good Clinical Practice (GCP) and other requirements, or subject us to reputational harm, all with potential negative implications for our product pipeline and business. Further, our revenues will be adversely affected by the termination or expiration of collaboration and co-promotion agreements that we have entered into and that we may enter into from time to time.</span></div><div style="margin-bottom:5pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">COUNTERFEIT PRODUCTS</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our reputation, in-line and pipeline portfolios render our medicines and vaccines prime targets for counterfeiters. Counterfeits pose a significant risk to patient health and safety because of the conditions under which they are manufacturedoften in unregulated, unlicensed, uninspected, and unsanitary sitesas well as the lack of regulation of their contents. Failure to mitigate this threat could adversely impact consumers who use our products, potentially causing them harm. This situation, in turn, may result in the loss of patient confidence in the Pfizer name and in the integrity of our medicines and vaccines, and potentially impact our business through lost sales, product recalls, and possible litigation. The prevalence of counterfeit medicines is an industry-wide issue due to a variety of factors, including the adoption of e-commerce. As consumers increasingly turn to the internet as a source for many products including medicines, they are at the same time increasingly exposed to fake medicines via the internet as criminals increasingly distribute counterfeit and substandard medicines through rogue online pharmacies. The internet exposes patients to greater risk as it is a preferred vehicle for dangerous counterfeit offers and scams that target unsuspecting consumers. Traffic to these generally deceptive pharmacy sites is largely driven by misplaced trust in sophisticated internet retailers and social media offers coupled with the convenience e-commerce affords consumers. Counterfeiters generally target any medicine or vaccine boasting strong demand and we have observed heightened counterfeit and fraud attempts to our internal medicine portfolio, as well as products utilized in the treatment of COVID-19.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We consistently invest in an enterprise-wide strategy to aggressively combat counterfeit threats by educating patients and healthcare providers about the risks, investing in innovative technologies to detect and disrupt sophisticated internet offers and scams, proactively monitoring and interdicting supply with the help of law enforcement, and advising legislators and regulators. However, our efforts and those of others may not be entirely successful, and the presence of counterfeit medicines may continue to increase.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">RISKS RELATED TO GOVERNMENT REGULATION AND LEGAL PROCEEDINGS:</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">PRICING AND REIMBURSEMENT</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our future results could be adversely affected by changes in U.S. and international governmental regulations that mandate price controls, create coverage criteria, or limit patient access to our products. In addition to the expansion of price controls in the U.S. in the IRA, the adoption of more restrictive coverage policies and price controls in new and existing jurisdictions, or the failure to obtain or maintain coverage and pricing could also adversely impact revenue. We expect pricing pressures and other cost containment measures for drugs and vaccines will continue.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">In the U.S., pharmaceutical product pricing is subject to government and public scrutiny and calls for reform, and many of our products are subject to increasing pricing pressures as a result. We expect to see continued focus by the U.S. government on regulating pricing and access to medicine. For example, the drug pricing provisions of the IRA are being implemented over the next several years. The IRA directs HHS to set the prices of certain high-expenditure, single-source drugs and biologics covered under Medicare. The IRA also imposes rebates under Medicare Part B and Medicare Part D which require manufacturers to pay rebates if price increases outpace inflation relative to a benchmark period, and replaces the Medicare Part D coverage gap discount program with a new discounting program. The drug pricing provisions of the IRA began to be implemented in 2022 and implementation efforts will continue in coming years. In August 2023, CMS published the first ten medicines subject to the MDPNP, which included Eliquis. In August 2024, the government released the new Medicare price for Eliquis, which will become effective January 1, 2026. On January 17, 2025, CMS announced the selection of another 15 drugs from Medicare Part D for the maximum fair price, with prices to be set and effective on January 1, 2027. Ibrance and Xtandi were included in the list of 15 drugs selected. Another 15 drugs from Medicare Part B or Medicare Part D will be selected by February 1, 2026, for the maximum price to be set and in effect by January 1, 2028. It is possible that more of our products could be selected in future years, which could, among other things, lead to lower revenues prior to expiry of intellectual property protections. Health plans may also require rebates in addition to the maximum fair price for preferred placement on a Medicare plan formulary. The MDPNP is currently subject to legal challenges and therefore, the outcome remains uncertain. We continue to evaluate the impact of the IRA on our business, operations and financial condition and results as the full effect of the IRA on our business and the pharmaceutical industry remains uncertain. For additional information, see the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_58">Item 1. Business</a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_58"></a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_58">Government Regulation and Price Constraints</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">section.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Payors may give preference to generic drugs and biosimilars more aggressively to generate savings and attempt to stimulate additional price competition. In addition, we expect that consolidation and integration among pharmacy chains, wholesalers and PBMs will increase pricing pressures in the industry. Some states have implemented, and others are considering, patient access constraints or cost cutting under state regulated programs including the Medicaid program. States have continued to focus on addressing drug costs, generally by increasing price transparency or attempting to limit drug price increases for state-regulated insurance. Measures to regulate prices or payment for pharmaceutical products, including legislation on drug importation and prescription drug affordability boards (PDABs) that seek to impose reimbursement limits for certain drugs, could adversely affect our business. For additional information on U.S. pricing and reimbursement, see the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_58">Item 1. Business</a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_58"></a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_58">Government Regulation and Price Constraints</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">section.</span></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We encounter similar regulatory and legislative issues in most other countries in which we operate. In certain markets, such as in EU member states, the U.K., Japan, China, Canada, Australia and New Zealand, governments have significant power as large single payors to regulate prices, access criteria, or impose other means of cost control, particularly as a result of recent global financing pressures. For example, the QCE and VBP tender process in China has resulted in significant price cuts for off-patent medicines. Additionally, in the EU, the EC proposed the largest reform of EU pharmaceutical legislation in 20 years. In April 2024, the European Parliament introduced amendments to the ECs proposal. The EU legislative process remains ongoing, with several stages still required before the reform can receive final approval. This reform may alter </span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">18</span></div></td></tr></tbody></table></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">regulatory exclusivity periods for our products and may add burdensome obligations that impact access. In addition, with the European Regulation on Health Technology Assessment (EU HTA-R) taking effect in January 2025, we are engaging and monitoring application of the EUs new clinical assessment program to new oncology products and certain biologic products submitted to the EMA. For additional information regarding these government initiatives, see the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_58">Item 1. Business</a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_58"></a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_58">Government Regulation and Price Constraints</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section. We anticipate that these and similar initiatives will continue to increase pricing and access pressures globally. In addition, in many countries, with respect to our vaccines, we participate in a tender process for selection in national immunization programs. Failure to win national immunization tenders or to obtain acceptable pricing, as well as recent entry of additional competitors, could adversely affect our business.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S. HEALTHCARE REGULATION</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The U.S. healthcare industry is highly regulated and subject to frequent and substantial changes. Any significant additional efforts at the U.S. federal or state levels to reform the healthcare system by changing the way healthcare is provided or funded could have a material impact on us. For additional information on U.S. healthcare regulation, see the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_58">Item 1. BusinessGovernment Regulation and Price Constraints</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section. Other U.S. federal or state legislative or regulatory action and/or policy efforts could adversely affect our business, including, among others, general budget control actions, changes in patent laws, the importation of prescription drugs to the U.S. at prices that are regulated by foreign governments, revisions to reimbursement of biopharmaceuticals under government programs that could reference international prices or require new discounts, limitations on interactions with healthcare professionals and other industry stakeholders, restrictions on pharmaceutical advertising, or the use of comparative effectiveness methodologies that could be implemented in a manner that focuses primarily on cost differences and minimizes the therapeutic differences among pharmaceutical products and restricts access to innovative medicines. In addition, we may face increased risks to, among other things, our business, revenue, earnings, reputation or financial guidance, as a result of potential changes to vaccine or other healthcare policy in the U.S. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Any additional reduction of U.S. federal spending on entitlement programs beyond the IRA, including Medicare, Medicaid, or any other publicly funded or subsidized health programs, and the 340B Program, may affect payment for our products or services provided using our products. Any other significant spending reductions or cost controls affecting Medicare, Medicaid or other publicly funded or subsidized health programs that may be implemented could have an adverse impact on our results of operations. The IRA is being implemented largely through government guidance and as its effect on Medicare and commercial markets evolve, we will continue to evaluate the potential impacts to our business.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We expect additional drug cost containment efforts at both the federal and state levels. Further, commercial payors often follow Medicare coverage policy and payment limitations when setting their own payment rates. Any reduction in cost or other containment measures may similarly be adopted by commercial plans. Coverage policies and reimbursement rates for commercial plans may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">DEVELOPMENT, REGULATORY APPROVAL AND MARKETING OF PRODUCTS</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The discovery and development of drugs, vaccines and biological products are time consuming, costly and unpredictable. The outcome is inherently uncertain and involves a high degree of risk due to the following factors, among others: </span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">The process from early discovery to design and adequate implementation of clinical trials to regulatory approval can take many years and have high costs.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">We may have difficulties recruiting and enrolling patients for clinical trials on a consistent basis.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Product candidates can and do fail at any stage of the process, including as the result of unfavorable pre-clinical and clinical trial results, or unfavorable new pre-clinical or clinical data and further analyses of existing pre-clinical or clinical data, including results that may not support further clinical development of the product candidate or indication. </span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">We may need to amend our clinical trial protocols or conduct additional clinical trials under certain circumstances, for example, to further assess appropriate dosage or collect additional safety data.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">We may not be able to meet anticipated pre-clinical or clinical endpoints, commencement and/or completion dates for our pre-clinical or clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates. </span></div><div style="margin-bottom:5pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">We may not be able to successfully address all the comments received from regulatory authorities such as the FDA and the EMA, or be able to obtain approval for new products and indications from regulators. </span></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Regulatory approvals of our products depend on myriad factors, including regulatory determinations as to the products safety and efficacy. In the context of public health emergencies like the COVID-19 pandemic, regulators evaluate various factors and criteria to potentially allow for marketing authorization on an emergency or conditional basis. Additionally, clinical trial and other product data are subject to differing interpretations and assessments by regulatory authorities. As a result of regulatory interpretations and assessments or other developments that may occur during the review process, or even after a product is authorized or approved for marketing, a products commercial potential could be adversely affected by potential emerging concerns or regulatory decisions regarding or impacting the scope of indicated patient populations, labeling or marketing, manufacturing processes, safety issues and/or other matters, including decisions relating to emerging developments regarding potential product impurities. Also, certain of our products have received and may in the future receive approvals under accelerated approval pathways where continued approval may be contingent upon confirmatory studies demonstrating the anticipated clinical benefit and/or safety profile.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We may not be able to receive or maintain favorable recommendations by technical or advisory committees, such as the ACIP or an FDA Advisory Committee, which may impact the availability or commercial potential of our products and product candidates. Further, claims and concerns that may arise regarding the safety and/or efficacy of in-line products and product candidates can negatively impact current or future product sales, as applicable, and potentially lead to regulator-directed risk evaluations and assessments, asset impairments, and/or consumer fraud, product liability and other litigation and claims, as well as product recalls or withdrawals, including our voluntary withdrawal of all lots of Oxbrtya in all markets where it is approved, and any regulatory or other impact on Oxbryta or other sickle cell disease assets. Regulatory requirements may also result in a more challenging, expensive and lengthy regulatory approval process than anticipated due to requests for, among other things, additional or more extensive clinical trials prior to granting approval, or increased post-approval requirements. For these and other reasons discussed in this </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section, we may not obtain the approvals we expect within the timeframe we anticipate, or at all. </span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">19</span></div></td></tr></tbody></table></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">POST-AUTHORIZATION/APPROVAL DATA</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">As a condition to granting marketing authorization or approval of a product, the FDA may require, or the sponsor may voluntarily agree to undertake, post-marketing commitments such as additional clinical trials or other studies. The results generated in these trials have in the past impacted certain of our products and could impact our products in the future, such as by resulting in the loss of marketing approval, changes in labeling, and/or new or increased concerns about safety and/or efficacy, including newly discovered adverse events. Regulatory agencies in countries outside the U.S. often have similar regulations and may impose comparable requirements, although there are differences between the U.S., the EU and other international regulatory requirements, which may contribute to inconsistency or uncertainty in the marketability of our products across different jurisdictions. Post-marketing studies and clinical trials, whether conducted by us or by others, whether mandated by regulatory agencies or conducted voluntarily, and other emerging data about products, such as adverse event reports, may also adversely affect the availability or commercial potential of our products. Further, if safety or efficacy concerns are raised about a product in the same class as one of our products, those concerns could implicate the entire class; and this, in turn, could have an adverse impact on the availability or commercial viability of our product(s) or product candidates as well as other products in the class. The potential regulatory, commercial or other implications of post-marketing study results typically cannot immediately be determined. In September 2024, we made the decision to voluntarily withdraw Oxbryta in all markets where it is approved based on the totality of clinical data that indicated at that time the overall benefit of Oxbryta no longer outweighs the risk in the approved sickle cell patient population. For more information, see the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_133">Product Developments</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section within MD&amp;A.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The terms of our EUA for Comirnaty require that we conduct post-observational studies to evaluate the association between the Pfizer-BioNTech COVID-19 Vaccine (Original monovalent), Pfizer-BioNTech COVID-19 Vaccine, Bivalent, and the Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula), and a pre-specified list of adverse events of special interest, including myocarditis and pericarditis, along with deaths and hospitalizations, and severe COVID-19. The required study populations include individuals specified in our September 2023 authorization letter (reissued) as well as populations of interest, such as healthcare workers, pregnant women, immunocompromised individuals and subpopulations with specific comorbidities. Additionally, in relation to the FDA approval for Comirnaty, we are required to complete certain post marketing study requirements and commitments through 2024 and beyond.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">LEGAL MATTERS</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We are and may be involved in various legal proceedings, including patent litigation, product liability and other product-related litigation, including personal injury, consumer fraud, off-label promotion, securities, antitrust and breach of contract claims, commercial and other asserted and unasserted matters, environmental, government and tax investigations, employment litigation, tax litigation and other legal proceedings that arise from time to time in the ordinary course of our business. Litigation is inherently unpredictable, and excessive verdicts do occur. Although we believe that our claims and defenses in matters in which we are a defendant are substantial, we have in the past and could in the future incur judgments, enter into settlements or revise our expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on our results of operations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Claims against our patents include challenges to the coverage and/or validity of our patents on various products or processes. There can be no assurance as to the outcome of these matters, and a loss in any of these cases could result in a loss of patent protection for the product at issue, which could lead to a significant loss of sales of that product and could materially affect future results of operations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We are also involved in government investigations that arise in the ordinary course of our business. There continues to be a significant volume of government investigations and litigation against companies operating in our industry, both in the U.S. and around the world. Government investigations and actions have and could result in substantial criminal and civil fines and/or criminal charges, limitations on our ability to conduct business in applicable jurisdictions, corporate integrity or deferred prosecution agreements and other disciplinary actions, as well as reputational harm, including as a result of increased public interest in the matter. In addition, in a</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> qui tam</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> lawsuit in which the government declines to intervene, the relator may still pursue a suit for the recovery of civil damages and penalties on behalf of the government. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our sales and marketing activities, the pricing of our products and other aspects of our business are subject to extensive regulation under the FFDCA, the MDRP, the FCPA and other federal and state statutes, including those discussed elsewhere in this Form 10-K, as well as the AKS, anti-bribery laws, the False Claims Act, consumer protection statutes and similar laws in international jurisdictions. In addition to the potential for changes to relevant laws, the compliance and enforcement landscape is informed by government litigation, settlement precedent, advisory opinions, and special fraud alerts. Our approach to certain practices may evolve over time in light of these types of developments.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Requirements or industry standards in the U.S. and certain jurisdictions abroad require pharmaceutical manufacturers to track and disclose financial interactions with healthcare professionals and healthcare providers and can increase government and public scrutiny of such financial interactions. If an interaction is found to be improper, government enforcement actions and penalties could result. Like many companies in our industry, we have from time to time received, and may receive in the future, inquiries and subpoenas and other types of information demands from government authorities. In addition, we have been and may in the future be subject to claims and other actions related to our business activities, brought by governmental authorities, as well as consumers and private payors. In some instances, we have incurred significant expense, civil payments, fines and other adverse consequences as a result of these claims, actions and inquiries. Such claims, actions and inquiries may relate to alleged non-compliance with laws and regulations associated with the dissemination of product (approved and unapproved) information, potentially resulting in government enforcement action and reputational damage. These risks may be heightened by the use of AI in our operations as well as in our digital marketing, including social media, mobile applications and blogger outreach, as well as direct-to-consumer marketing and digital platform offerings.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">In connection with the resolution of a U.S. government investigation concerning independent copay assistance organizations that provide financial assistance to Medicare patients, in 2018, we entered into a Corporate Integrity Agreement with the Office of the Inspector General of the HHS (OIG), which expired in May 2023. Pfizer submitted its final annual report in October 2023 and the OIG officially closed the matter in January 2025.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We and certain of our subsidiaries are also subject to numerous contingencies arising in the ordinary course of business relating to legal claims and proceedings, including environmental contingencies. Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. While we have accrued for worldwide legal liabilities, no guarantee exists that additional costs will not be incurred or additional payments will not be required beyond the amounts accrued. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">For additional information, including information regarding certain legal proceedings in which we are involved in, see </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_268">Note 16A</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">20</span></div></td></tr></tbody></table></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">RISKS RELATED TO INTELLECTUAL PROPERTY, TECHNOLOGY AND SECURITY:</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">INTELLECTUAL PROPERTY PROTECTION</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our success largely depends on our ability to market technologically competitive products. We rely and expect to continue to rely on a combination of intellectual property, including patent, trademark, trade dress, copyright, trade secret and domain name protection laws, as well as confidentiality and license agreements, to protect our intellectual property and proprietary rights. If we fail to obtain and maintain adequate intellectual property protection, we may not be able to prevent third parties from launching generic or biosimilar versions of our branded products, from using our proprietary technologies or from marketing products that are very similar or identical to ours. Our currently pending or future patent applications may not result in issued patents or be granted on a timely basis. Similarly, any term extensions that we seek may not be granted on a timely basis, if at all, and any term adjustments related to patent office delays in obtaining a patent may be reduced or eliminated entirely due to risks associated with changes in law relating to patent terms. In addition, our issued patents may not contain claims sufficiently broad to protect us against claims regarding validity, enforceability, scope and effective term made by parties with similar technologies or products or provide us with any competitive advantage, including patent-based exclusivity in a particular technology or product area. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Further, legal or regulatory action by various stakeholders or governments could potentially result in us not seeking intellectual property protection for or agreeing not to enforce or being restricted from enforcing intellectual property related to our products. For example, the WTOs June 2022 Ministerial Decision on the Agreement on Trade-Related Aspects of Intellectual Property Rights seeks to make it easier for certain WTO members to issue a compulsory license on COVID-19 vaccines. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The scope of our patent claims also may vary between countries, as individual countries have distinct patent laws, and our ability to enforce our patents depends on the laws of each country, its enforcement practices, and the extent to which certain countries engage in policies or practices that weaken a countrys intellectual property framework (e.g., laws or regulations that promote or provide broad discretion to issue a compulsory license). In countries that provide some form of regulatory exclusivity, mechanisms exist permitting some form of challenge to our patents by competitors or generic drug marketers prior to or immediately following the expiration of such regulatory exclusivity, and generic companies are employing aggressive strategies, such as at-risk launches that challenge our patent rights. Most of the suits involve claims by generic drug manufacturers that patents covering our products, uses, processes or dosage forms are invalid and/or do not cover the product of the generic or biosimilar drug manufacturer. Independent actions have been filed alleging that our assertions of, or attempts to enforce, patent rights with respect to certain products constitute unfair competition and/or violations of antitrust laws. Such claims may also be brought as counterclaims to actions we bring to enforce our patents. We are also party to other patent damages suits in various jurisdictions pursuant to which generic drug manufacturers, payors, governments or other parties are seeking damages from us for alleged delay of generic entry. We also are often involved in other proceedings, such as inter partes review, post-grant review, re-examination or opposition proceedings, before the U.S. Patent and Trademark Office, the European Patent Office, or other foreign counterparts relating to our intellectual property or the intellectual property rights of others. Also, if one of our patents or a competitors patents is found to be invalid in such proceedings, generic or biosimilar products could be introduced into the market resulting in the erosion of sales of our existing products. For additional information, including information regarding certain legal proceedings in which we are involved, see </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_268">Note 16A1</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Further, if we are unable to maintain our existing license agreements or other agreements pursuant to which third parties grant us rights to intellectual property, our operating results and financial condition could be adversely affected. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We currently hold trademark registrations and have trademark applications pending in many jurisdictions, any of which may be the subject of a governmental or third-party objection, which could prevent the maintenance or issuance of the trademark. As our products mature, our reliance on our trademarks and trade dress to differentiate us from our competitors increases and, as a result, our business could be adversely affected if we are unable to prevent third parties from adopting, registering or using trademarks and trade dress that infringe, dilute or otherwise violate our rights. We seek to protect our proprietary information, including our trade secrets and proprietary know-how, by requiring our employees, consultants, other advisors and other third parties to execute proprietary information and confidentiality agreements upon the commencement of their relationship with us. Despite these efforts and precautions, we may be unable to prevent a third-party from copying or otherwise obtaining and using our trade secrets or our other intellectual property without authorization, and legal remedies may not adequately compensate us for the damages caused by such unauthorized use. Further, others may independently and lawfully develop substantially similar or identical products that circumvent our intellectual property by means of alternative designs or processes or otherwise.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">THIRD-PARTY INTELLECTUAL PROPERTY CLAIMS</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">A properly functioning intellectual property regime is essential to our business model. We are committed to respecting the valid intellectual property rights of other companies, but the patent granting process is imperfect. Accordingly, the pursuit of valid business opportunities may require us to challenge intellectual property rights held by others that we believe were improperly granted, including challenges through negotiation and litigation, and such challenges may not always be successful.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Part of our business depends upon identifying biosimilar opportunities and launching products to take advantage of those opportunities, which may involve litigation, associated costs and time delays, and may ultimately not be successful. These opportunities may arise in situations where patent protection of equivalent branded products has expired or been declared invalid, or where products do not infringe the patents of others. In some circumstances we may take action, such as litigation, asserting that our products do not infringe patents of existing products or that those patents are invalid or unenforceable in order to achieve a first-to-market or early market position for our products.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Third parties may claim that our products infringe one or more patents owned or controlled by them. Claims of intellectual property infringement can be costly and time-consuming to resolve, may delay or prevent product launches, and may result in significant royalty payments or damages or potential licensing agreements. For example, our R&amp;D in a therapeutic area may not be first and another company or entity may have obtained relevant patents before us. We are involved in patent-related disputes with third parties over our attempts to market pharmaceutical products, including related to Abrysvo, Comirnaty and Paxlovid. As we expand our mRNA portfolio, patent-related disputes may increase. Once we have final regulatory approval of the related products, we may decide to commercially market these products even though associated legal proceedings (including any appeals) have not been resolved (i.e., at-risk launch). If one of our marketed products (or a product of our collaboration/licensing partners to which we have licenses or co-promotion rights) is found to infringe valid patent rights of a third party, such third party may be awarded significant damages or royalty payments, or we may be prevented from further sales of that product. Such damages may be enhanced as much as three-fold if we or one of our subsidiaries is found to have willfully infringed valid patent rights of a third party.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">21</span></div></td></tr></tbody></table></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">INFORMATION TECHNOLOGY AND SECURITY </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Significant disruptions of IT systems or breaches of information security could adversely affect our business. We extensively rely upon sophisticated IT systems (including cloud services) to operate our business. We produce, collect, process, store and transmit large amounts of confidential information (including personal information and intellectual property), and we deploy and operate an array of technical and procedural controls to maintain the confidentiality, integrity and availability of such confidential information. We develop and operate digital systems to engage patients, healthcare providers, governments, payors and supply chain partners to conduct business and deliver medicines, digital diagnostics, clinical trials and digital therapies. Such systems include mobile applications, wearable devices, internet websites and other digital technologies that may be targets of attack. We have outsourced significant elements of our operations, including significant elements of our IT infrastructure and, as a result, we manage relationships with many third-party providers who may or could have access to our confidential information. We rely on technology developed, supplied and/or maintained by third-parties that may make us vulnerable to supply chain style cyber-attacks. Further, technology and security vulnerabilities of acquisitions, business partners or third-party providers may not be identified during due diligence or soon enough to mitigate exploitation. The size and complexity of our IT and information security systems, and those of our third-party providers (and the large amounts of confidential information that is present on them), make such systems potentially vulnerable to service interruptions or to security breaches from inadvertent or intentional actions by, but not limited to, our employees, contingent workers, service providers, business partners, customers or malicious attackers. As a global pharmaceutical company, our systems and assets are the target of frequent cyber-attacks. Such cyber-attacks are of ever-increasing levels of sophistication, including the use of adversarial AI techniques, and are made by groups and individuals with a wide range of motives (including, but not limited to, industrial espionage, extortion, property destruction and personal information theft) and expertise, including, but not limited to, organized criminal groups, hacktivists, nation states, employees, business partners and others. Due to the nature of some of these attacks, there is a risk that they may remain undetected for a period of time. While we have invested in the protection of data and IT and develop and maintain systems and controls, our efforts, like those of other similar companies, have not always and may not in the future prevent service interruptions, extortion, theft of confidential, personal or proprietary information, compromise of data integrity or unauthorized information disclosure. Any technology service interruption or breach of our systems could adversely affect our business operations and/or result in potential legal liability, the loss of personal data, confidential information or intellectual property. Such incidents could require disclosure to government authorities and/or regulators and could require notification to impacted individuals and any incident could result in financial, legal, business and reputational harm to us. We maintain cyber liability insurance; however, this insurance may not be sufficient to cover the financial, legal, business or reputational losses that may result from an interruption or breach of our systems.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">AI is increasingly being used in the biopharmaceutical and global healthcare industries. As with many developing technologies, AI presents risks and challenges. For example, algorithms may be flawed or trained on content without the necessary intellectual property rights or other legal rights or permissions; data sets may not be appropriate for the intended use, of poor quality, contain biased information, or become corrupted during a cyber-attack; and inappropriate or controversial data practices by data scientists, engineers, and end-users could impair results. If the outputs that AI produces or assists in producing are deficient or inaccurate, we could be subjected to competitive harm, potential legal liability and brand or reputational harm. Furthermore, use of AI may lead to the release of confidential information which may impact our ability to realize the benefits of our data, including intellectual property.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">GENERAL RISKS</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">BUSINESS DEVELOPMENT ACTIVITIES AND STRATEGIC GOALS</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We have established significant growth goals, which we plan to achieve, in part, by not only advancing our own product pipelines and maximizing the value of our existing products, but also through various forms of business development activities, which can include alliances, licenses, JVs, collaborations, equity- or debt-based investments, dispositions, divestments, mergers and acquisitions. We view our business development activity as an enabler of our strategies and seek to generate growth by pursuing opportunities and transactions that have the potential to strengthen our business and our capabilities. The success of our business development activities is dependent on the availability and accurate evaluation of appropriate opportunities, competition from others that are seeking similar opportunities and our ability to successfully identify, structure and execute transactions, including the ability to satisfy closing conditions in the anticipated timeframes or at all, and our ability to successfully integrate acquired businesses and develop and commercialize acquired products. Pursuing, executing and consummating these transactions may require substantial investment, which may require us to obtain additional equity or debt financing, which has in the past and could in the future result in increased leverage and/or a downgrade of our credit ratings and could limit our ability to obtain future financing. We have incurred substantial indebtedness to fund our acquisition of Seagen. We financed a portion of the transaction with the proceeds from the $31 billion of long-term debt issued in May 2023, plus additional short-term indebtedness issued prior to the acquisition. The amount of debt that we have incurred could have significant consequences including, among other things, reducing our operating or financial flexibility, requiring a portion of our cash flow from operations to make interest payments and reducing the cash flow available to fund capital expenditures and other corporate purposes and to grow our business. To the extent we incur additional indebtedness or interest rates increase, these risks could increase further.</span></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The success of our business development transactions depends on our ability to realize the anticipated benefits of these transactions and is subject to numerous risks and uncertainties, many of which are outside of our control. Unsuccessful clinical trials, regulatory hurdles, new information and commercialization challenges, among other factors, may adversely impact revenue and income contribution from business development transactions, including from acquired products and businesses, and may lead to impairment of acquired assets. We may fail to generate expected revenue growth for our existing products, product pipeline and contribution from these transactions or from acquired products or businesses or we may fail to achieve anticipated cost savings, within expected time frames or at all, which may impact our ability to meet our growth objectives. </span><span style="color:#212529;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">In certain transactions, we may agree to provide certain transition services for an extended period of time, which may divert our focus and resources that would otherwise be invested into maintaining or growing our business. </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Similarly, the accretive impact anticipated from certain transactions may not be realized or may be delayed. Integration of acquired products or businesses may result in the loss of key employees, the disruption of ongoing business, including third-party relationships, or inconsistencies in standards, controls, procedures and policies. Further, while we seek to mitigate risks and liabilities through, among other things, due diligence, we may be exposed to risks and liabilities as a result of business development transactions. There is no assurance that we will be able to acquire attractive businesses or enter into strategic business relationships on favorable terms ahead of our competitors, or that such acquisitions or strategic business development relationships will be accretive to earnings or improve our competitive position.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Where we invest in or otherwise obtain debt or equity securities of third parties in connection with business development transactions, such as our ownership interest in Haleon, we may be unable to direct or influence the management, operational decisions and policies of such companies </span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">22</span></div></td></tr></tbody></table></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">and the value of the acquired securities will fluctuate and may lose value. Any future distribution or sale of such securities will be subject to prevailing market conditions and other factors, including the size of our ownership stake, at the time of such distribution or sale and there is no assurance as to the price that such securities will ultimately be sold or that such securities will be sold at all.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">PANDEMICS</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pandemics, such as the COVID-19 pandemic, have impacted and may in the future impact our business, operations and financial condition and results. Related risks and challenges for our business include, among others: uncertainty regarding the severity and duration of a pandemic; impacts to business operations; decreased demand for certain of our products; increased costs of doing business; manufacturing disruptions and delays; supply chain disruptions and shortages, including challenges related to reliance on third-party suppliers resulting in reduced availability of materials or components used in the development, manufacturing, distribution or administration of our products; evolving macroeconomic factors and conditions, including general economic uncertainty, unemployment rates and recessionary pressures; changes in labor markets, including challenges related to our human capital and talent development; unknown consequences on our business performance and initiatives stemming from the substantial investment of time and other resources to any potential pandemic response; increased difficulty and uncertainty regarding predicting or estimating future performance; pace of post-pandemic recovery, disruption and volatility within the financial or credit markets; and our financial performance in general.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">COVID-19</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We face risks and uncertainties related to our COVID-19 products, including Comirnaty and Paxlovid or any potential future COVID-19 vaccines, treatments or combinations, including, among others, the risk that as the market for COVID-19 products remains endemic and seasonal, demand for our COVID-19 products has and may continue to be reduced or not meet expectations, which has and may continue to lead to reduced revenues, excess inventory or other unanticipated charges; risks related to our ability to develop and commercialize variant adapted vaccines, combinations and/or treatments; uncertainties related to recommendations and coverage for, and the publics adherence to, vaccines, boosters, treatments or combinations; risks related to our ability to accurately predict revenue for Comirnaty and Paxlovid or any potential future COVID-19 vaccines or treatments; whether and when EUA or biologics license applications or amendments to any such applications may be filed in particular jurisdictions for Comirnaty or any other potential vaccine or vaccine candidates, including those related to potential future annual boosters, re-vaccinations, or vaccines in additional populations, and if obtained, whether or when such EUA or licenses, or existing EUAs, will expire or terminate; whether and when additional supply or purchase agreements will be reached or existing agreements will be modified; potential third-party royalties or other claims related to Comirnaty or Paxlovid; and the other risks and uncertainties discussed throughout this Item 1A. Risk Factors.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">RESPONSIBLE BUSINESS GROWTH</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer is subject to transitional and physical risks related to climate change. Transitional risks include, for example, a disorderly global transition away from fossil fuels that may result in increased energy prices; customer preference for low or no-carbon products; stakeholder pressure to decarbonize assets; or new legal or regulatory requirements that result in new or expanded carbon pricing, taxes, restrictions on GHG emissions, and increased GHG disclosure and transparency. These risks could increase operating costs, including the cost of our electricity and energy use, or otherwise increase compliance costs. Physical risks to our operations include water stress and drought; flooding and storm surge; wildfires; extreme temperatures and storms, which could impact pharmaceutical production, increase costs, or disrupt supply chains of medicines for patients. For example, our manufacturing facility in Rocky Mount, NC was damaged by a tornado in July 2023. For additional details on the impact of the tornado in Rocky Mount, NC, see the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_100">Overview of Our Performance, Operating Environment, Strategy and Outlook</a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_100"></a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_100">Our Operating Environment</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">section within MD&amp;A. Our supply chain is subject to these same transitional and physical risks and would likely pass along any increased costs to us. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">In June 2022, Pfizer established our fourth consecutive GHG reduction goal with new near- and long-term targets to achieve the Science Based Target Initiatives voluntary Net-Zero Standard by 2040. While we are working to develop and implement emission reduction plans to achieve our voluntary climate goals, various factors, including the long time horizons and commercial availability of new technologies to enable the emission reductions, in the time and scale needed, may present inherent risk in our ability to meet these goals. Additionally, success may depend on the actions of governments and third parties and may require, among other things, significant capital investment; R&amp;D; and government policies and incentives to foster innovation and reduce costs of technologies that may not currently exist or be available at scale.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain governmental authorities, non-governmental organizations, customers, investors, employees, and other stakeholders are increasingly sensitive to matters perceived to be related to responsible business growth, such as equitable access to medicines and vaccines, product quality and safety, human capital, diversity, equity and inclusion, environmental stewardship, support for local communities, value chain environmental and social due diligence, and corporate governance and transparency. In addition, governments and the public expect companies like us to report on our business practices with respect to human rights, responsible sourcing and environmental impact, as well as the actions of our third-party contractors and suppliers around the world. This focus may lead to new expectations or requirements that could result in increased costs associated with research, development, manufacture, or distribution of our products. Our ability to compete could also be affected by changing customer preferences and requirements, such as growing demand for companies to establish validated Net Zero targets or offer more sustainable products. While we are committed to responsible business growth, if we do not meet, or are perceived not to meet, our goals or other stakeholder expectations in these key areas, we risk negative stakeholder reaction, including from proxy advisory services, as well as damage to our brand and reputation, reduced demand for our products or other negative impacts on our business and operations. While we monitor a broad range of corporate responsibility matters, we cannot be certain that we will manage such matters successfully, or that we will successfully meet the expectations of investors, employees, consumers, governments and other stakeholders.</span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">MARKET FLUCTUATIONS IN OUR EQUITY AND OTHER INVESTMENTS</span></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Changes in the fair value of certain equity investments that are recognized in net income may result in increased volatility of our income. See </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_202">Note 4</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">and the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_145">Analysis of Financial Condition, Liquidity, Capital Resources and Market Risk</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">section within MD&amp;A.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our pension benefit obligations and postretirement benefit obligations are subject to volatility from changes in the fair value of equity investments and other investment risk in the assets funding these plans, as well as changes in the appropriate discount rate. See the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_109">Significant Accounting Policies and Application of Critical Accounting Estimates and Assumptions</a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_109"></a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_109">Benefit Plans</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">section within MD&amp;A and </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_244">Note 11</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">23</span></div></td></tr></tbody></table></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">COST AND EXPENSE CONTROL AND UNUSUAL EVENTS</span></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Growth in costs and expenses, changes in product and geographic mix and the impact of acquisitions, divestitures, restructurings, internal reorganizations, product withdrawals, recalls and other unusual events that could result from evolving business strategies, evaluation of asset realization and organizational restructuring could adversely affect future results. Such risks and uncertainties include, in particular, our ability to realize the projected benefits of our cost-reduction and productivity initiatives, including our enterprise-wide cost realignment program and manufacturing optimization program, other corporate strategic initiatives and any acquisitions, divestitures or other initiatives, as well as potential disruption of ongoing business, such as potential impacts on our ability to deliver on our pipeline as planned. Additionally, as a result of these initiatives, we may experience a loss of continuity, loss of accumulated knowledge or intellectual property and/or inefficiency, adverse effects on employee morale, loss of key employees and/or other retention issues during transitional periods. Reorganizations and restructurings can require a significant amount of time and focus, which may divert attention from operating and growing our business. If we fail to achieve some or all of the expected benefits of restructuring, it could have a material adverse effect on our competitive position, business, financial condition, results of operations and cash flows.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">INTANGIBLE ASSETS, GOODWILL AND EQUITY-METHOD INVESTMENTS</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our consolidated balance sheet contains significant amounts of intangible assets, including IPR&amp;D and goodwill. For IPR&amp;D assets, the risk of failure is significant, and there can be no certainty that these assets ultimately will yield successful products. Our ability to realize value on these significant investments is often contingent upon, among other things, regulatory approvals and market acceptance. As such, IPR&amp;D assets may become impaired and/or be written off in the future if the associated R&amp;D effort is abandoned or is curtailed. For goodwill, all reporting units can confront events and circumstances that can lead to a goodwill impairment charge such as, among other things, unanticipated competition, an adverse action or assessment by a regulator, a significant adverse change in legal matters or in the business climate and/or a failure to replace the contributions of products that lose market exclusivity. Our other intangible assets, including developed technology rights and brands, face similar risks for impairment. Our equity-method investments may also be subject to impairment charges that may result from the occurrence of unexpected adverse events or management decisions that impact our estimates of expected cash flows to be generated from these investments. We may recognize impairment charges as a result of a weak economic environment, challenging market conditions, decisions by management, or events related to particular customers or asset types, such as the development of competing assets by us or others, regulatory actions or product recalls or withdrawals. Any such impairment charge of our intangible assets, goodwill and equity-method investments may be significant. See </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_202">Note 4</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">for a discussion of recent impairments of intangible assets. For additional details, see the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_109">S</a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_109">ignificant Accounting Policies and Application of Critical Accounting Estimates and Assumptions</a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_109"></a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_109">Asset Impairments</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section within MD&amp;A.</span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">CHANGES IN LAWS AND ACCOUNTING STANDARDS</span></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our future results could be adversely affected by changes in laws, regulations or policies, or their interpretation, including, among others, changes in accounting standards, tariffs, tax laws and regulations internationally and in the U.S., including, without limitation, the IRA, the adoption of global minimum taxation requirements outside the U.S. generally effective in most jurisdictions since January 1, 2024 and potential changes to existing tax laws, tariffs, competition laws, privacy laws and environmental laws or changes to other laws, regulations and policies in the U.S., including by the U.S. Presidential administration and Congress, as well as in other countries. For example, issued or future executive orders or other new or changes in laws, regulations or policy regarding tariffs, could have a material adverse effect on our business, earnings and financial guidance. The actual impact of the new tariffs on our business is subject to a number of factors including, but not limited to, restrictions on trade, the effective date and duration of such tariffs, countries included in the scope of tariffs, changes to amounts of tariffs, and potential retaliatory tariffs imposed by other countries. See </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation and Price Constraints</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> for additional information regarding privacy and other laws. For additional information on changes in tax laws or rates or accounting standards, see the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_127">Provision/(Benefit) for Taxes on Income</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_148">New Accounting Standards</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> sections within MD&amp;A and</span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_178"> </a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_178">Note 1B</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div id="i8531e747ebb543f3bf818166f157d26a_70"></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tbody><tr><td style="width:1.0%"></td><td style="width:10.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&nbsp;1C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:10pt;font-weight:700;line-height:120%">CYBERSECURITY</span></div></td></tr></tbody></table></div><ix:nonnumeric contextref="c-1" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="f-39" continuedat="f-39-1" escape="true"><ix:nonnumeric contextref="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="f-40" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Managing cybersecurity risk is a crucial part of our overall strategy for safely operating our business. We <ix:nonnumeric contextref="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true" id="f-41">incorporate</ix:nonnumeric> cybersecurity practices into our Enterprise Risk Management (ERM) program. Management is responsible for assessing and managing risk, including through the ERM program, subject to oversight by our BOD. Our cybersecurity policies and practices are aligned with NIST (National Institute of Standards and Technology) industry standards.</span></div></ix:nonnumeric><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Consistent with our overall ERM program and practices, our cybersecurity program includes:</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">Vigilance</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">: We maintain a global cybersecurity operation that endeavors to detect, prevent, contain, and respond to cybersecurity threats and incidents in a prompt and effective manner with the goal of minimizing business disruptions.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">External Collaboration</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">: We collaborate with public and private entities, including intelligence and law enforcement agencies, industry groups and third-party service providers to identify, assess and mitigate cybersecurity risks.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">Systems Safeguards</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">: We deploy technical safeguards that are designed to protect our information systems, products, operations and sensitive information from cybersecurity threats. These include firewalls, intrusion prevention and detection systems, disaster recovery capabilities, malware and ransomware prevention, access controls and data protection. We continuously conduct vulnerability assessments to identify new risks and periodically test the efficacy of our safeguards through both internal and external penetration tests.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">Education</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">: We provide periodic training for all personnel regarding cybersecurity threats, with such training appropriate to the roles, responsibilities and access of the relevant Company personnel. Our policies require all workers to report any real or suspected cybersecurity events.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">Supplier Ecosystem Management</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">: We extend our cybersecurity management control expectations to our supply chain ecosystem, as appropriate. This includes identifying cybersecurity risks presented by third parties.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">Incident Response Planning</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">: We have established, and maintain and periodically test, incident response plans that direct our response to cybersecurity events and incidents. Such plans include the protocol by which certain significant or potentially material incidents would be communicated to executive management, our BOD, external regulators and shareholders, as appropriate.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">Enterprise-Wide Coordination</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">: We engage relevant stakeholders from across the Company to identify emerging risks and respond to cybersecurity threats. This cross-functional approach includes personnel from our R&amp;D, manufacturing, commercial, technology, legal, compliance, internal audit and other business functions.</span></div></ix:nonnumeric><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">24</span></div></td></tr></tbody></table></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><ix:continuation id="f-39-1"><div style="margin-bottom:5pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><ix:nonnumeric contextref="c-1" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="f-42" escape="true"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">Governance</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">: Our BODs oversight of cybersecurity risk management is led by the Audit Committee, which oversees our ERM program. Cybersecurity threats, risks and mitigation are periodically reviewed by the Audit Committee and such reviews include both internal and independent assessment of risks, controls and effectiveness.</span></ix:nonnumeric></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our risk assessment efforts have indicated that we are a target for theft of intellectual property, financial resources, personal information, and trade secrets from a wide range of actors including nation states, organized crime, malicious insiders and activists. The impacts of attacks, abuse and misuse of Pfizers systems and information could include, without limitation, loss of assets, operational disruption and damage to Pfizers reputation. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">A key element of managing cybersecurity risk is the ongoing assessment and testing of our processes and practices through auditing, assessments, drills and other exercises focused on evaluating the sufficiency and effectiveness of our risk mitigation. We regularly engage <ix:nonnumeric contextref="c-1" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true" id="f-43">third parties</ix:nonnumeric> to perform assessments of our cybersecurity measures, including information security maturity assessments and independent reviews of our information security control environment and operating effectiveness. Certain results of such assessments and reviews are reported by the Chief Information Security Officer (CISO) to certain senior leaders, the Audit Committee and the BOD, as appropriate, and we make adjustments to our cybersecurity processes and practices as necessary based on the information provided by the <ix:nonnumeric contextref="c-1" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true" id="f-44">third-party assessments and reviews</ix:nonnumeric>.</span></div></ix:continuation><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="c-1" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-45" escape="true">The Audit Committee oversees cybersecurity risk management, including the policies, processes and practices that management implements to prevent, detect and address risks from cybersecurity threats.</ix:nonnumeric> <ix:nonnumeric contextref="c-1" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-46" escape="true">The <ix:nonnumeric contextref="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true" id="f-47">Audit Committee</ix:nonnumeric> receives periodic briefings on, and discusses with our CISO, cybersecurity risks and risk management practices, including, for example, recent developments in the external cybersecurity threat landscape, evolving standards, vulnerability assessments, third-party and independent reviews, technological trends and considerations arising from our supplier ecosystem. The Audit Committee may also promptly receive information regarding certain significant or potentially material cybersecurity incidents that may occur, including any ongoing updates regarding the same.</ix:nonnumeric> </span></div><ix:nonnumeric contextref="c-1" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="f-48" escape="true"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="f-49" escape="true">Our <ix:nonnumeric contextref="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true" id="f-50">CISO</ix:nonnumeric> is a member of our management team who is principally responsible for overseeing our cybersecurity risk management program, in partnership with other business leaders across the Company.</ix:nonnumeric> <ix:nonnumeric contextref="c-1" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="f-51" escape="true">We believe our CISO and the information security organization have the appropriate expertise, background and depth of experience relating to monitoring the prevention, mitigation, detection and remediation of cybersecurity incidents to manage risks arising from cybersecurity threats.</ix:nonnumeric> <ix:nonnumeric contextref="c-1" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" id="f-52" continuedat="f-52-1" escape="true">The CISO works in coordination with other members of the management team, including, among others, the Chief Digital Officer, the Chief Financial Officer and the Chief Legal Officer and their designees. </ix:nonnumeric></span></div><ix:continuation id="f-52-1"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our CISO, along with leaders from our privacy and corporate compliance functions, collaborate to implement a program designed to manage our exposure to cybersecurity risks and to promptly respond to cybersecurity incidents. Prompt response to incidents is delivered by multi-disciplinary teams in accordance with our incident response plan. Through ongoing communications with these teams during incidents, the CISO monitors the triage, mitigation and remediation of cybersecurity incidents, and reports such incidents to executive management, the Audit Committee and other Pfizer colleagues in accordance with our cybersecurity policies and procedures, as is appropriate.</span></div></ix:continuation></ix:nonnumeric><div><span style="background-color:#ffffff;color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="c-1" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false" id="f-53" continuedat="f-53-1">For the fiscal year ended December 31, 2024</ix:nonnumeric></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="f-53-1">, we are not aware of any cybersecurity incidents that have materially affected or are reasonably likely to materially affect the Company, including our business strategy, results of operations, or financial condition.</ix:continuation> For further discussion of the risks associated with cybersecurity incidents, see the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67">Item 1A. Risk FactorsInformation Technology and Security</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section in this Form 10-K.</span></div><div id="i8531e747ebb543f3bf818166f157d26a_73"></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tbody><tr><td style="width:1.0%"></td><td style="width:10.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&nbsp;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROPERTIES</span></td></tr></tbody></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our global headquarters are located in New York City. We own and lease space globally for sales and marketing, customer service, regulatory compliance, R&amp;D, manufacturing and distribution and corporate enabling functions. In many locations, our business and operations are co-located to achieve synergy and operational efficiencies. We continue to advance our global workplace strategy to provide workplaces that promote our forward-thinking and highly inclusive culture. As of December 31, 2024, we had 251 owned and leased properties worldwide, amounting to approximately 37 million square feet. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of December 31, 2024, PGS had responsibility for 37 plants around the world, which manufacture products for our commercial divisions, including in Belgium, Germany, India, Ireland, Italy, Japan, Singapore and the U.S. The leadership team for PGS is primarily located in New York City. PGS also operates multiple distribution facilities around the world. PGS continuously evaluates it network and capacity to meet Pfizer's ever changing needs and help inform future decisions.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">In the U.S., our R&amp;D facilities contain an aggregate of approximately 9 million square feet, with the majority of that area owned by Pfizer. Outside of the U.S., we lease R&amp;D labs in the U.K., India and Belgium.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">In general, we believe that our properties, including the principal properties described above, are well-maintained, adequate and suitable for their current requirements and for our operations in the foreseeable future. See </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_238">Note 9</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">for amounts invested in land, buildings and equipment. </span></div><div id="i8531e747ebb543f3bf818166f157d26a_76"></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tbody><tr><td style="width:1.0%"></td><td style="width:10.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&nbsp;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:10pt;font-weight:700;line-height:120%">LEGAL PROCEEDINGS</span></td></tr></tbody></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain legal proceedings in which we are involved are discussed in </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_268">Note 16A</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">25</span></div></td></tr></tbody></table></div></div></div><div id="i8531e747ebb543f3bf818166f157d26a_79"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">INFORMATION ABOUT OUR EXECUTIVE OFFICERS</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The executive officers of the Company are set forth in this table. Each holds the office or offices indicated until his or her successor is chosen and qualified at the regular meeting of the BOD to be held on the date of the 2025 Annual Meeting of Shareholders, or until his or her earlier death, resignation or removal. Each of the executive officers is a member of the Pfizer Executive Leadership Team.</span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tbody><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.029%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Age</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Position</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Albert Bourla, DVM, Ph.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">63</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Chairman of the Board since January 2020 and Chief Executive Officer since January 2019. Chief Operating Officer from January 2018 until December 2018. Group President, Pfizer Innovative Health from June 2016 until December 2017. Group President, Global Innovative Pharma Business (responsible for Vaccines, Oncology and Consumer Healthcare since 2014) from February 2016 until June 2016. President and General Manager of Established Products Business Unit from December 2010 until December 2013. Our Director since February 2018.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Andrew Baum, MA, BM ChB</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">55</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Chief Strategy and Innovation Officer and Executive Vice President since 2024. Prior to joining Pfizer, he was Head of Global Healthcare - Managing Director Equity Research at Citigroup from 2011 until 2024.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Chris Boshoff, MD, FRCP, FMedSci, Ph.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">61</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Chief Scientific Officer and President, Research &amp; Development, since January 2025. Chief Oncology Officer, Executive Vice President from December 2023 until December 2024. Chief Oncology Research and Development Officer and Executive Vice President from July 2023 until December 2023. Senior Vice President, Oncology, from 2017 until 2023.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">David M. Denton</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">59</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Chief Financial Officer, Executive Vice President since May 2022. Executive Vice President, Chief Financial Officer, Lowes Companies, Inc., from November 2018 until April 2022; Executive Vice President and Chief Financial Officer, CVS Health Corporation (a diversified health solutions company), from January 2010 until November 2018. Served as Director of Haleon plc from March 2023 to December 2024.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Alexandre de Germay</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">57</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Chief International Commercial Officer, Executive Vice President since December 2023. Chief Executive Officer, Laboratoires Majorelle (a specialty pharma company based in France dedicated to womens health and urology) from 2021 until January 2024 (assisting with transition matters after December 15, 2023). From 2020 until 2021 was Senior Vice President; Global Franchise Head of Cardiology, Transplant and Established Products, and from 2016 until 2020 was Head of Mature Markets General Medicines of Sanofi. Regional President of Asia-Pacific of Pfizer Inc. from 2013 until 2016.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lidia Fonseca</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">56</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Chief Digital and Technology Officer, Executive Vice President since January 2019. Chief Information Officer and Senior Vice President of Quest Diagnostics Incorporated from 2014 to 2018. Senior Vice President of Laboratory Corporation of America Holdings from 2008 until March 2013. Director of Medtronic plc.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Douglas M. Lankler</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">59</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Chief Legal Officer, Executive Vice President since January 2025. General Counsel, Executive Vice President from December 2013 until December 2024. Corporate Secretary from January 2014 until February 2014. Executive Vice President, Chief Compliance and Risk Officer from February 2011 until December 2013. </span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Aamir Malik</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">49</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Chief U.S. Commercial Officer, Executive Vice President since December 2023. Chief Business Innovation Officer, Executive Vice President from August 2021 until December 2023. Various U.S. geographic leadership roles with McKinsey &amp; Company from 2019 to 2021; previously co-led McKinsey &amp; Companys Global Pharmaceuticals &amp; Medical Products practice from 2015 to 2018. </span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Michael McDermott</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">59</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Chief Global Supply and Quality Officer, Executive Vice President since January 2025. Chief Global Supply Officer, Executive Vice President from 2022 until December 2024. President of Pfizer Global Supply from 2018 until 2021. Vice President of Pfizer Global Supply from 2014 until 2018. Vice President of the Biotechnology Unit from 2012 until 2014. </span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Payal Sahni</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">50</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Chief People Experience Officer, Executive Vice President since January 2022. Chief Human Resources Officer, Executive Vice President from June 2020 to December 2021. From May 2016 until June 2020 served as Senior Vice President of Human Resources for multiple operating units. Vice President of Human Resources, Vaccines, Oncology &amp; Consumer from 2015 until 2016. Ms. Sahni has served in a number of positions in the Human Resources organization with increasing responsibility since joining Pfizer in 1997.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sally Susman</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">63</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Chief Corporate Affairs Officer, Executive Vice President since January 2019. Executive Vice President, Corporate Affairs (formerly Policy, External Affairs and Communications) from December 2010 until December 2018. Senior Vice President, Policy, External Affairs and Communications from December 2009 until December 2010. Director of UL Solutions Inc.</span></div></td></tr></tbody></table></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">26</span></div></td></tr></tbody></table></div></div></div><div id="i8531e747ebb543f3bf818166f157d26a_82"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:36.111%"><tbody><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #006ebf;border-top:1pt dotted #006ebf;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:11pt;font-weight:700;line-height:120%">PART II</span></td></tr></tbody></table></div><div id="i8531e747ebb543f3bf818166f157d26a_85"></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tbody><tr><td style="width:1.0%"></td><td style="width:10.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&nbsp;5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:10pt;font-weight:700;line-height:120%">MARKET FOR THE COMPANYS COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES </span></td></tr></tbody></table></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The principal market for our common stock is the NYSE. Our common stock currently trades on the NYSE under the symbol PFE. As of February&nbsp;20, 2025, there were 113,116 holders of record of our common stock.</span></div><div><span><br></span></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following summarizes purchases of our common stock during the fourth quarter of 2024:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:35.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">Period</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total&nbsp;Number</span></div><div style="text-align:right"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">of Shares</span></div><div style="text-align:right"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Purchased</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average Price</span></div><div style="text-align:right"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Paid&nbsp;per</span></div><div style="text-align:right"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">&nbsp;&nbsp;&nbsp;&nbsp;Share</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total&nbsp;Number&nbsp;of<br>Shares&nbsp;Purchased&nbsp;as<br>Part of Publicly<br>&nbsp;&nbsp;&nbsp;&nbsp;Announced&nbsp;Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Approximate Value of Shares</span></div><div style="text-align:right"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">that May Yet Be Purchased</span></div><div style="text-align:right"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">&nbsp;&nbsp;&nbsp;&nbsp;Under&nbsp;the&nbsp;Plan</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30 through October 27, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">33,110</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">29.04</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,292,882,444</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">October 28 through November 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">34,233</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">27.85</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,292,882,444</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 1 through December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">63,672</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">26.21</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,292,882,444</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">131,015</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">27.36</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Represents (i) 127,726 shares of common stock surrendered to the Company to satisfy tax withholding obligations in connection with the vesting of awards under our long-term incentive programs and (ii) the open market purchase by the trustee of 3,289 shares of common stock in connection with the reinvestment of dividends paid on common stock held in trust for employees who deferred receipt of performance share awards.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">See </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_250">Note 12</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div id="i8531e747ebb543f3bf818166f157d26a_88"></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">PEER GROUP PERFORMANCE GRAPH </span></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following graph assumes a $100 investment on December 31, 2019, and reinvestment of all dividends, in each of the Companys Common Stock, a composite peer group of the major U.S. and European-based pharmaceutical companies, which are: AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company, GSK plc, Johnson &amp; Johnson, Merck &amp; Co., Inc., Novartis AG, Novo Nordisk, Roche Holding AG and Sanofi, the S&amp;P 500 Index and the NYSE Arca Pharmaceutical Index (DRG index).</span></div><div style="text-align:center"><img src="./PFIZER_files/pfe-20241231_g3.jpg" alt="543" style="height:300px;margin-bottom:5pt;vertical-align:text-bottom;width:609px"></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Five Year Performance</span></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></div><div style="margin-top:5pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.795%"><tbody><tr><td style="width:1.0%"></td><td style="width:14.072%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.175%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.175%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.175%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.175%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.175%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.181%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">PFIZER&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$100.0</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$103.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$172.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$154.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$90.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$88.8</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">PEER GROUP</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$100.0</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$105.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$126.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$147.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$170.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$177.4</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">S&amp;P&nbsp;500&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$100.0</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$118.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$152.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$124.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$157.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$196.8</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">DRG Index</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$100.0</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$108.7</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$134.2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$144.5</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$155.7</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$163.6</span></td></tr></tbody></table></div><div><span><br></span></div><div id="i8531e747ebb543f3bf818166f157d26a_91"></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tbody><tr><td style="width:1.0%"></td><td style="width:10.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&nbsp;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:10pt;font-weight:700;line-height:120%">[RESERVED]</span></td></tr></tbody></table></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">27</span></div></td></tr></tbody></table></div></div></div><div id="i8531e747ebb543f3bf818166f157d26a_94"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tbody><tr><td style="width:1.0%"></td><td style="width:10.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&nbsp;7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></td></tr></tbody></table></div><div id="i8531e747ebb543f3bf818166f157d26a_97"></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">GENERAL</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following MD&amp;A is intended to assist the reader in understanding our financial condition and results of operations, including an evaluation of the amounts and certainty of cash flows from operations and from outside sources, and is provided as a supplement to and should be read in conjunction with the consolidated financial statements and related notes in </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_154">Item 8. Financial Statements and Supplementary Data</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in this Form 10-K. Discussions of 2022 items and year-to-year comparisons between 2023 and 2022 that are not included in this Form 10-K can be found within MD&amp;A in our 2023 Form 10-K.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">References to operational variances pertain to period-over-period changes that exclude the impact of foreign exchange rates. Although foreign exchange rate changes are part of our business, they are not within our control and because they can mask positive or negative trends in the business, we believe presenting operational variances excluding these foreign exchange changes provides useful information to evaluate our results.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">In the first quarter of 2024, we reclassified royalty income (substantially all of which is related to our Biopharma segment) from </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductionsnet</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and began presenting </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Royalty revenues</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> as a separate line item within </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Total revenues</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in our consolidated statements of operations. Prior-period amounts have been recast to conform to the current presentation.</span></div><div id="i8531e747ebb543f3bf818166f157d26a_100"></div><div style="margin-bottom:5pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">OVERVIEW OF OUR PERFORMANCE, OPERATING ENVIRONMENT, STRATEGY AND OUTLOOK</span></div><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial Highlights</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following is a summary of certain financial performance metrics (in billions, except per share data):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:504.00pt"><tbody><tr><td style="width:1.0pt"></td><td style="width:250.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:250.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024 Total Revenues$63.6 billion</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024 Net Cash Flow from Operations$12.7 billion</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">An increase of 7% compared to 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">An increase of 46% compared to 2023</span></td></tr></tbody></table></div><div style="text-align:center"><img src="./PFIZER_files/pfe-20241231_g4.jpg" alt="209" style="height:138px;margin-bottom:5pt;vertical-align:text-bottom;width:336px"><img src="./PFIZER_files/pfe-20241231_g5.jpg" alt="210" style="height:138px;margin-bottom:5pt;vertical-align:text-bottom;width:336px"></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:504.00pt"><tbody><tr><td style="width:1.0pt"></td><td style="width:250.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:250.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024 Reported Diluted EPS$1.41</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024 Adjusted Diluted EPS (Non-GAAP)$3.11**</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">An increase of over 100% compared to 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">An increase of 69% compared to 2023</span></td></tr></tbody></table></div><div style="text-align:center"><img src="./PFIZER_files/pfe-20241231_g6.jpg" alt="214" style="height:138px;margin-bottom:5pt;vertical-align:text-bottom;width:336px"><img src="./PFIZER_files/pfe-20241231_g7.jpg" alt="215" style="height:138px;margin-bottom:5pt;vertical-align:text-bottom;width:336px"></div><div style="margin-bottom:5pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">**  For additional information regarding Adjusted diluted EPS (which is a non-GAAP financial measure), including reconciliations of certain GAAP Reported to non- GAAP Adjusted information, see the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_136">Non-GAAP Financial Measure: Adjusted Income</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%"> section within MD&amp;A.</span></div><div style="margin-bottom:3pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Our Business and Strategy</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. is a research-based, global biopharmaceutical company. We apply science and our global resources to bring therapies to people that extend and significantly improve their lives. See the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_28">Item 1. Business</a><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_28">About Pfizer</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">section. As a science-driven global biopharmaceutical company, we remain focused on advancing our pipeline, supporting our marketed brands and deploying capital responsibly, with a focus on initiatives that can help contribute to our long-term revenue and future growth. Most of our revenues come from the manufacture and sale of biopharmaceutical products. We believe that our medicines and vaccines provide significant value for healthcare providers and patients, and we continuously evaluate how we can best collaborate with patients, physicians and payors to support and expand patient access to reliable, affordable healthcare around the world. In addition, we continually seek to expand and broaden our product portfolio offerings through prioritized development of our pipeline and business development opportunities targeted at critical unmet patient needs. As a result, our commercial organizational structure and R&amp;D operations are critical to the successful execution of our business strategy. Our ability to fulfill our purpose, </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Breakthroughs that change patients lives</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">, remains a core focus and underscores our commitment to addressing the needs of society to help sustain long-term value creation for all stakeholders.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our 2025 key priorities are:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.34pt">Improve R&amp;D productivity with sharpened focus</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.34pt">Expand margins and maximize operational efficiency</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.34pt">Achieve commercial excellence in our key categories</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.34pt">Optimize capital allocation.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">28</span></div></td></tr></tbody></table></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:5pt;margin-top:3pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">One way we believe we will be more efficient, effective and able to execute on these strategic priorities is through technology, including AI.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">In 2024, we managed our commercial operations through a global structure consisting of three operating segments: Biopharma, PC1 and Pfizer Ignite. Biopharma was the only reportable segment. See </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_271">Note 1</a><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_271">7</a><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_271">A</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">and the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_31">Item 1. BusinessCommercial Operations</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">section. At the beginning of 2025, we made the following changes within our Biopharma reportable segment that went into effect on January 1, 2025 to support our continued focus on commercial execution and to further strengthen Pfizers capabilities and leadership in discovering and developing breakthrough medicines and vaccines:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">transitioned the Pfizer U.S. Oncology commercial organization and the global Oncology marketing organization, which were part of the former Pfizer Oncology Division, into the Pfizer U.S. Commercial Division, which now focuses on the commercialization of Pfizers entire product portfolio in the U.S. and is led by the Chief U.S. Commercial Officer, Executive Vice President; and</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:112%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:112%;padding-left:6.2pt">combined our global ORD and PRD organizations to form a single Pfizer R&amp;D organization that is responsible for all R&amp;D activities across all therapeutic areas.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">In the fourth quarter of 2023, we announced that we launched a multi-year, enterprise-wide cost realignment program (Realigning Our Cost Base Program) that aims to realign our costs with our longer-term revenue expectations. In the second quarter of 2024, we announced that we launched a multi-year, multi-phased program to reduce our costs of goods sold (Manufacturing Optimization Program), which is expected to include operational efficiencies, network structure changes, and product portfolio enhancements. See </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_199">Note 3</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">. For a description of anticipated savings related to these programs, see the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_124">Costs and ExpensesRestructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">section within MD&amp;A</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">R&amp;D:</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> We believe we have a strong pipeline and are well-positioned for future growth. R&amp;D is at the heart of fulfilling our purpose to deliver breakthroughs that change patients lives as we work to translate advanced science and technologies into the medicines and vaccines that may be the most impactful for patients. Innovation, drug discovery and development are critical to our success. In addition to discovering and developing new products, our R&amp;D efforts seek to add value to our existing products by improving their effectiveness and ease of dosing and by discovering potential new indications. See the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_34">Item 1. Business</a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_34"></a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_34">Research and Development</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">section for our R&amp;D priorities and strategy.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We seek to leverage a strong pipeline, organize around expected operational growth drivers and capitalize on trends creating long-term growth opportunities, including:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">an aging global population that is generating increased demand for innovative medicines and vaccines that address patients unmet needs; and</span></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">advances in both biological science and platform technologies that are enhancing the delivery of potential breakthrough new medicines and vaccines.</span></div><div style="margin-bottom:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Our Business Development Initiatives</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We are committed to strategically capitalizing on growth opportunities, primarily by advancing our own product pipeline and maximizing the value of our existing products, but also through various business development activities. We view our business development activity as an enabler of our strategies and seek to generate growth by pursuing opportunities and transactions that have the potential to strengthen our business and our capabilities. We assess our business, assets and scientific capabilities/portfolio as part of our regular, ongoing portfolio review process and also continue to consider business development activities that will help advance our business strategy. See </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_181">Note 2</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">for significant recent activities.</span></div><div style="margin-bottom:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Our 2024 Performance</span></div><div style="margin-bottom:3pt"><span style="color:#006ebf;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Total Revenues</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Total revenues</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> increased $4.1 billion, or 7%, to $63.6 billion in 2024 from $59.6 billion in 2023, reflecting an operational increase of $4.4 billion, or 7%, partially offset by an unfavorable impact of foreign exchange of $349 million, or approximately 1%. The operational increase was primarily driven by Paxlovid, the addition of legacy Seagen revenues in full-year 2024 following the acquisition in December 2023, and growth from the Vyndaqel family and Eliquis, partially offset by declines in Comirnaty. The operational increase for Paxlovid was primarily due to: (i) a non-cash revenue reversal of $3.5 billion recorded in the fourth quarter of 2023 related to the expected return of an estimated 6.5 million treatment courses of EUA labeled U.S. government inventory and (ii) revenue in 2024 of $1.2 billion from two one-time items: a $771 million favorable final adjustment recorded in the first quarter of 2024 to the aforementioned $3.5 billion revenue reversal; and $442 million from the one-time contractual delivery of treatment courses to the U.S. SNS. See </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_280">Note 17C</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Excluding contributions from Comirnaty and Paxlovid, </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Total revenues</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> increased 12% operationally.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following chart outlines the components of the net change in </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Total revenues</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:3pt;text-align:center"><img src="./PFIZER_files/pfe-20241231_g8.jpg" alt="7491" style="height:200px;margin-bottom:5pt;vertical-align:text-bottom;width:720px"></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">See the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_115">Total Revenues by Geography</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">and </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_121">Total RevenuesSelected Product Discussion</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> sections within MD&amp;A for more information, including a discussion of key drivers of our revenue performance. Certain of our vaccines, including Comirnaty, are subject to seasonality of demand, with a greater portion of revenues anticipated in the fall and winter seasons, and Paxlovid revenues trend with infection rates. See also </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The Global </span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">29</span></div></td></tr></tbody></table></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Economic EnvironmentCOVID-19</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section below for information about our COVID-19 products. For information regarding the primary indications or class of certain products, see </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_280">Note 17C</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt"><span style="color:#006ebf;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Income from Continuing Operations Before Provision/(Benefit) for Taxes on Income</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The increase in </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Income from continuing operations before provision/(benefit) for taxes on income</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> of $7.0 billion, to $8.0 billion in 2024 from $1.1 billion in 2023, was primarily attributable to (i) a decrease in </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of Sales, </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(ii) higher revenues and (iii) a decrease in </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs, </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">partially offset by (iv) higher net interest expense, (v) net periodic benefit costs associated with pension and other postretirement plans incurred in 2024 versus net periodic benefit credits in 2023, (vi) lower net gains on equity securities and (vii) an increase in </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Amortization of intangible assets.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">See</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">the</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_112">Analysis of the Consolidated Statements of Operations</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section within MD&amp;A and </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_202">Note 4</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">. For information on our tax provision and effective tax rate, see the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_127">Provision/(Benefit) for Taxes on Income</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section within MD&amp;A and </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_208">Note 5</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Our Operating Environment</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We, like other businesses in our industry, are subject to certain industry-specific challenges. These include, among others, the topics listed below. See also the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_58">Item 1. BusinessGovernment Regulation and Price Constraints</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67">Item 1A. Risk Factors</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">sections.</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:5pt"><span style="color:#006ebf;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Regulatory EnvironmentPipeline Productivity</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our product lines must be replenished over time to offset revenue losses when products lose exclusivity or market share or to respond to healthcare and innovation trends, as well as to provide for earnings growth, primarily through internal R&amp;D or through collaborations, acquisitions, JVs, licensing or other arrangements. As a result, we devote considerable resources to our R&amp;D activities which, while essential to our growth, incorporate a high degree of risk and cost, including whether a particular product candidate or new indication for an in-line product will achieve the desired clinical endpoint or safety profile, will be approved by regulators or will be successful commercially. Clinical trials are conducted to determine, among other things, whether an investigational drug, vaccine or device is safe and effective for a particular patient population. After a product has been approved or authorized and launched, we continue to monitor its safety as long as it is available to patients, including conducting postmarketing trials, voluntarily or pursuant to a regulatory request. For the entire life of the product, we collect safety data and report safety information to the FDA and other regulators. Regulatory authorities evaluate potential safety concerns and take any regulatory action deemed necessary and appropriate. Such action(s) may include: updating a products labeling, restricting its use, communicating new safety information or, in rare cases, seeking to suspend or remove a product from the market.</span></div><div style="margin-bottom:5pt"><span style="color:#006ebf;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Intellectual Property Rights and Collaboration/Licensing Rights</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The loss, expiration or invalidation of intellectual property rights, patent litigation settlements and judgments, and the expiration of co-promotion and licensing rights can have a material adverse effect on our revenues. Certain of our products have experienced patent-based expirations or loss of regulatory exclusivity in certain markets in the last few years, and we expect certain products to face increased generic competition over the next few years. While additional patent-based or regulatory exclusivity expiries will continue, we expect a moderate impact of reduced revenues due to patent expiries in 2025 and anticipate a more significant impact of reduced revenues from patent-based or regulatory exclusivity expiries in 2026 through 2030 as several of our in-line products experience these expirations. We continue to vigorously defend our patent rights against infringement, and we will continue to support efforts that strengthen worldwide recognition of patent rights while taking necessary steps to help ensure appropriate patient access.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">For additional information on patent rights we consider most significant to our business as a whole, see the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_46">Item 1. BusinessPatents and Other Intellectual Property Rights</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section. For a discussion of recent developments with respect to patent litigation involving certain of our products, see </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_268">Note 16A1</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt"><span style="color:#006ebf;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Regulatory Environment/Pricing and AccessGovernment and Other Payor Group Pressures</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The pricing of medicines and vaccines by pharmaceutical manufacturers and the cost of healthcare, which includes medicines, vaccines, medical services and hospital services, continues to be important to payors, governments, patients, and other stakeholders. Federal and state governments and private third-party payors in the U.S. continue to take action to manage the utilization and cost of drugs, including increasingly employing formularies to control costs and encourage utilization of certain drugs, including through the use of deductibles, utilization management tools, cost sharing or formulary placement. We consider a number of factors impacting the pricing of our medicines and vaccines. Within the U.S., we often engage with patients, doctors and healthcare plans. We also often provide significant discounts from the list price to insurers, including PBMs and MCOs. The price that patients pay in the U.S. for prescribed medicines and vaccines is ultimately set by healthcare providers and insurers, including government healthcare programs. Governments globally, as well as private third-party payors in the U.S., may use a variety of measures to control costs, including, among others, legislative or regulatory pricing reforms, drug formularies (including tiering and utilization management tools), cross country collaboration and procurement, price cuts, mandatory rebates, health technology assessments, forced localization as a condition of market access, international reference pricing (i.e., the practice of a country linking its regulated medicine prices to those of other countries), quality consistency evaluation processes and volume-based procurement. We anticipate that these and similar initiatives will continue to increase pricing and access pressures globally. In the U.S., we expect to see continued focus by the U.S. government on regulating drug pricing and access to medicine. The drug pricing provisions of the IRA are being implemented over the next several years. In August 2023, CMS published the first ten medicines subject to the MDPNP, which requires manufacturers of select drugs to engage in a process with the federal government to set new Medicare prices which would go into effect in 2026. Eliquis was among the first ten medicines subject to MDPNP. In August 2024, the government released the new Medicare price for Eliquis, which, effective January 1, 2026, will be required to be offered to all Medicare beneficiaries and to covered entities participating in the 340B Program that dispense Eliquis to a Medicare beneficiary if that maximum fair price is lower than the discounted price such entities are offered under the 340B Program ceiling price calculation. The Eliquis Medicare price is factored into our long-term financial planning, in accordance with our standard financial reporting and forecasting protocols. On January 17, 2025, CMS announced the selection of another 15 drugs from Medicare Part D for the maximum fair price, with prices to be set and effective on January 1, 2027. Ibrance and Xtandi were included in the list of 15 drugs selected. Another 15 drugs from Medicare Part B or Medicare Part D will be selected by February 1, 2026, for the maximum price to be set and in effect by January 1, 2028. It is possible that more of our products could be selected in future years, which could, among other things, lead to lower revenues prior to expiry of intellectual property protections. We continue to evaluate the impact of the IRA on our business, operations and financial condition and results as the full effect of the IRA on our business and the pharmaceutical industry remains uncertain. The IRA made significant changes to the Medicare Part D benefit design, which will impact Pfizer revenues in 2025, including: an expected favorable impact from the $2,000 annual out-of-pocket cap and new Prescription Payment Plan, more than offset by an expected unfavorable impact from the sunsetting of the Coverage Gap Discount Program and the addition of new manufacturer discounts in the initial and catastrophic coverage phases. We anticipate a net unfavorable impact to revenue in 2025 of approximately $1 billion, year-over-year, related to the Medicare Part D Redesign changes that take effect in 2025. We expect these changes will more acutely impact our higher-priced medicines as they are expected to reach catastrophic coverage earlier in the year. In addition, changes to the MDRP or the 340B Program, including legal or legislative developments at the federal or state level with respect to the 340B Program, could </span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">30</span></div></td></tr></tbody></table></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">have a material impact on our business. See the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_52">Item 1. Business</a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_52"></a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_52">Pricing Pressures and Managed Care Organizations</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">and </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_58">Government Regulation and Price Constraints</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67">Item 1A. Risk Factors</a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67"></a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67">Pricing and Reimbursement</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">sections.</span></div><div style="margin-bottom:5pt"><span style="color:#006ebf;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Impact of the July 2023 Tornado in Rocky Mount, North Carolina (NC)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our manufacturing facility in Rocky Mount, NC was damaged by a tornado in July 2023. The facility is a key producer of sterile injectables and is responsible for manufacturing nearly 25 percent of all our sterile injectablesincluding anesthesia, analgesia, and micronutrients. Supply of medicines has recovered from the impact of the tornado. We incurred losses in 2023 and 2024 that were partially offset by insurance recoveries received.</span></div><div style="margin-bottom:5pt"><span style="color:#006ebf;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Product Supply</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We periodically encounter supply delays, disruptions and shortages, including due to voluntary product recalls and natural or man-made disasters. In response to requests from various regulatory authorities, manufacturers across the pharmaceutical industry, including Pfizer, are evaluating their product portfolios for the potential presence or formation of nitrosamines and we are actively engaging with regulatory authorities on this topic. If nitrosamines are detected above certain levels in our products, this may lead to market action for such products. For example, in 2021, Pfizer recalled all lots of Chantix due to the presence of a nitrosamine, N-nitroso-varenicline, at or above acceptable intake limits communicated by various regulatory authorities. Regulatory authorities have since issued updated guidance on nitrosamine acceptable intake levels. With this guidance, which included an updated intake level for N-nitroso-varenicline, we have started making regulatory submissions to potentially enable Chantix to return to market in the U.S. and in certain international markets. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Except for the impact of the tornado in Rocky Mount, NC discussed above, we have not seen a significant disruption of our supply chain in 2024 and through the date of filing of this Form 10-K, and all of our manufacturing sites globally have continued to operate at or near normal levels. We do not anticipate the availability of raw materials to have a significant impact on our operations in 2025, but are monitoring potential supply chain disruptions as a result of ongoing geopolitical and trade negotiations, which could, among other things, impact costs. We are continuing to monitor and implement mitigation strategies to reduce any potential risk or impact including active supplier management, qualification of additional suppliers and advanced purchasing to the extent possible. For information on risks related to product manufacturing, see the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67">Item 1A. Risk FactorsProduct Manufacturing, Sales and Marketing Risks</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section.</span></div><div style="margin-bottom:8pt"><span style="color:#05497c;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Voluntary Withdrawal of Oxbryta</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">See the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_133">Product Developments</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section within MD&amp;A.</span></div><div style="margin-bottom:5pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">The Global Economic Environment</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">In addition to the industry-specific factors discussed above, we, like other businesses of our size and global extent of activities, are exposed to economic cycles. Certain factors in the global economic environment that may impact our global operations include, among other things, currency and interest rate fluctuations, capital and exchange controls, local and global economic conditions including inflation, recession, volatility and/or lack of liquidity in capital markets, expropriation and other restrictive government actions, changes in intellectual property, legal protections and remedies, trade regulations, tariffs, tax laws and regulations and procedures and actions affecting approval, production, pricing, and marketing of, reimbursement for and access to our products, as well as impacts of political or civil unrest or military action, including the ongoing conflicts between Russia and Ukraine and in the Middle East and their economic consequences, geopolitical instability, terrorist activity, unstable governments and legal systems, inter-governmental disputes, public health outbreaks, epidemics, pandemics, natural disasters or disruptions related to climate change. Government pressures can lead to negative pricing pressure in various markets where governments take an active role in setting prices, access criteria or other means of cost control. In addition, issued or future executive orders or other new or changes in laws, regulations or policy regarding tariffs, could have a material adverse effect on our business, earnings and financial guidance. The actual impact of the new tariffs on our business is subject to a number of factors including, but not limited to, restrictions on trade, the effective date and duration of such tariffs, countries included in the scope of tariffs, changes to amounts of tariffs, and potential retaliatory tariffs imposed by other countries. We are evaluating opportunities and developing plans which may help mitigate the potential impact of tariffs on our business and operations. For additional information on risks related to our global operations and changes in laws, see the</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67">Item 1A. Risk FactorsGlobal Operations</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">and </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67">Changes in Laws and Accounting Standar</a><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67">ds</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">sections.</span></div><div style="margin-bottom:5pt"><span style="color:#006ebf;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">COVID-19</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">In response to COVID-19, we developed Paxlovid and collaborated with BioNTech to jointly develop Comirnaty. As part of our strategy for COVID-19, we are continuing to make significant investments in breakthrough science. This includes continuing to evaluate Comirnaty and Paxlovid, including against new variants of concern, developing variant adapted vaccine candidates and developing potential combination respiratory vaccines and potential next generation vaccines and therapies. We are also evaluating Paxlovid for certain pediatric patients. See the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_133">Product Developments</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section within MD&amp;A.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">In 2023, we principally sold Comirnaty globally under government contracts. In September 2023, Comirnaty transitioned to traditional commercial market sales in the U.S., triggered by the expiration of contracts and the COVID-19 vaccines from Pfizer and BioNTech purchased through them becoming either depleted or not used following the introduction of a new variant vaccine. Internationally, sales of Comirnaty in international developed markets were generally under government contracts in 2023 and 2024, and in emerging markets, under a combination of private channels and government contracts; in both cases, we started transitioning to commercial markets in 2024. Due to the commercial market transition as well as the seasonality of demand for COVID-19 vaccinations, the majority of our global revenues for Comirnaty were recorded in the fourth quarter of 2024. In 2025, for Comirnaty we expect vaccination rates and market share in commercial markets and revenue phasing similar to 2024, primarily concentrated in the second-half of the year. We have assumed no material U.S. policy changes for our vaccines portfolio in 2025 for purposes of our financial guidance, but see </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67">Item 1A. Risk FactorsU.S.</a><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67"> Healthcare Regulati</a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67">on</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> for a description of risks and uncertainties that could impact revenue from our portfolio of vaccines.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">In 2023, we principally sold Paxlovid globally to government agencies. On October 13, 2023, we announced an amended agreement with the U.S. government, which facilitated the transition of Paxlovid to traditional commercial markets in the U.S. in November 2023, with minimal uptake of NDA-labeled commercial product before January 1, 2024 (see </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_280">Note 17C</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">). Internationally, for Paxlovid, most markets have now transitioned to commercial markets, and we are expecting most revenue for Paxlovid to be generated through commercial channels. In 2025, we expect utilization for Paxlovid to follow infection rates and stable market share, and revenues may fluctuate based on the timing, duration and severity of COVID-19 cases.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">For information on risks associated with our COVID-19 products, as well as COVID-19 intellectual property disputes, see the</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67">Item 1A. Risk Factors</a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67"></a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67">COVID-19</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67"></a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67">Intellectual Property Protectio</a><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67">n</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">and </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67"></a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67">Third-Party Intellectual Property Claims</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> sections as well as </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_268">Notes 16A1</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> and </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_280">17C</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt"><span style="color:#006ebf;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Israel/Hamas Conflict</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our local operations have been impacted by the armed conflict between Israel and Hamas that began on October 7, 2023. For the years ended December 31, 2024 and 2023, the business of our Israeli subsidiary represented less than 1% of our consolidated revenues and assets. We are closely monitoring developments in this conflict, including evaluating potential impacts to our business, customers, suppliers, employees, and operations in Israel and elsewhere in the Middle East that may impact global operations. At this time, longer term impacts from these events to the Company are uncertain and subject to change.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">31</span></div></td></tr></tbody></table></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:5pt"><span style="color:#006ebf;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Russia/Ukraine Conflict</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our local operations have been impacted by the armed conflict between Russia and Ukraine. For the years ended December 31, 2024 and 2023, the business of our Russia and Ukraine subsidiaries represented less than 1% of our consolidated revenues and assets. While we are monitoring the effects of the conflict between Russia and Ukraine, the situation continues to evolve and the long-term implications, including the broader economic consequences of the conflict, potential additional sanctions, and actions by our customers or suppliers (including financial institutions) are difficult to predict at this time.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">For information on risks associated with these conflicts, see the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67">Item 1A. Risk FactorsGlobal Operations</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section.</span></div><div id="i8531e747ebb543f3bf818166f157d26a_109"></div><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">SIGNIFICANT ACCOUNTING POLICIES AND APPLICATION OF CRITICAL ACCOUNTING ESTIMATES AND ASSUMPTIONS</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Following is a discussion about the critical accounting estimates and assumptions impacting our consolidated financial statements. Also, see </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_178">Note 1C</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">For a description of our significant accounting policies, see </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_178">Note 1</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Of these policies, the following are considered critical to an understanding of our consolidated financial statements as they require the application of the most subjective and the most complex judgments: Acquisitions <br>(</span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_178">Note 1D</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">);&nbsp;Fair Value (</span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_178">Note 1E</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">); Revenues (</span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_178">Note 1G</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">);&nbsp;Asset Impairments (</span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_178">Note 1M</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">);&nbsp;Tax Assets and Liabilities and</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Income Tax Contingencies (</span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_178">Note 1Q</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">);&nbsp;Pension and Postretirement Benefit Plans (</span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_178">Note 1R</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">); and Legal and Environmental Contingencies (</span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_178">Note 1S</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">For a discussion of recently adopted accounting standards, see </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_178">Note 1B</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Acquisitions</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We account for acquired businesses using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair value as of the acquisition date. To estimate fair value, we utilize an exit price approach from the perspective of a market participant. For further detail on acquisition accounting, see </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_178">Note 1D</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">. For further detail on the techniques and methodologies that we use to estimate fair value, see </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_178">Note 1E</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Historically, intangible assets have been the most significant fair values within our business combinations. We utilize an income approach to estimate the acquisition date fair value of each identifiable intangible asset. Some of the more significant estimates and assumptions inherent in this approach include the amount and timing of projected net cash flows, the discount rate, the tax rate, and, for IPR&amp;D assets, the probability of technical and regulatory success (PTRS). All of these judgments and estimates can materially impact our results of operations. For further information on our process to estimate the fair value of intangible assets, see </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Asset Impairments</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> below. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We estimate the fair value of acquired inventory, including finished goods and work in process, by determining the estimated selling price when completed, less an estimate of costs to be incurred to complete and sell the inventory, and an estimate of a reasonable profit allowance for those manufacturing and selling efforts. The fair value of inventory is recognized in our results of operations as the inventory is sold. Some of the more significant estimates and assumptions inherent in the estimate of the fair value of inventory include stage of completion, costs to complete, costs to dispose and selling price.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We estimate the fair value of acquired PP&amp;E using a combination of the cost and market approaches. Some of the more significant estimates and assumptions inherent in these approaches are the values of asset replacement costs, comparable assets and estimated remaining economic lives of the assets.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Revenues</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our gross product revenues are subject to a variety of deductions, which generally are estimated and recorded in the same period that the revenues are recognized. Such variable consideration represents chargebacks, rebates, sales allowances and sales returns. These deductions represent estimates of the related obligations and, as such, knowledge and judgment are required when estimating the impact of these revenue deductions on gross sales for a reporting period. Historically, adjustments to these estimates to reflect actual results or updated expectations, have not been material to our overall business and generally have been less than 1% of revenues. Product-specific rebates, however, can have a significant impact on year-over-year individual product revenue growth trends. If any of our ratios, factors, assessments, experiences or judgments are not indicative or accurate estimates of our future experience, our results could be materially affected. The potential of our estimates to vary (sensitivity) differs by program, product, type of customer and geographic location. However, estimates associated with U.S. Medicare, Medicaid and performance-based contract rebates are most at risk for material adjustment because of the extensive time delay between the recording of the accrual and its ultimate settlement, an interval that can generally range up to one year. Because of this lag, our recording of adjustments to reflect actual amounts can incorporate revisions of several prior quarters. Rebate accruals are product specific and, therefore for any period, are impacted by the mix of products sold as well as the forecasted channel mix for each individual product. For further information, see the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_118">Product Revenue Deductions</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section within MD&amp;A and </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_178">Note 1G</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Asset Impairments</span></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We review all of our long-lived assets for impairment indicators throughout the year. We perform impairment testing for indefinite-lived intangible assets and goodwill at least annually and for all other long-lived assets whenever impairment indicators are present. When necessary, we record charges for impairments of long-lived assets for the amount by which the fair value is less than the carrying value of these assets. Our impairment review processes are described in </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_178">Note 1M</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Examples of events or circumstances that may be indicative of impairment include:</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">A significant adverse change in legal factors or in the business climate that could affect the value of the asset. For example, a successful challenge of our patent rights would likely result in generic competition earlier than expected.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">A significant adverse change in the extent or manner in which an asset is used such as a restriction imposed by the FDA or other regulatory authorities, withdrawals or other unusual items that could affect our ability to manufacture or sell a product.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">An expectation of losses or reduced profits associated with an asset. This could result, for example, from a change in development plans or a change in a government reimbursement program that results in an inability to sustain projected product revenues and profitability. This also could result from the introduction of a competitors product that impacts projected revenue growth, as well as the lack of acceptance of a product by patients, physicians and payors. For IPR&amp;D projects, this could result from, among other things, a change in outlook based on clinical trial data, a delay in the projected launch date or additional expenditures to commercialize the product.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">32</span></div></td></tr></tbody></table></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Changes in development plans and/or de-prioritization of certain assets.</span></div><div style="margin-bottom:8pt;margin-top:3pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Identifiable Intangible Assets</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We use an income approach, specifically the discounted cash flow method to determine the fair value of intangible assets, other than goodwill. We start with a forecast of all the expected net cash flows associated with the asset, which incorporates the consideration of a terminal value for indefinite-lived assets, and then we apply an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions that impact our fair value estimates include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the projections and the impact of technological advancements and risk associated with IPR&amp;D assets, as well as the selection of a long-term growth rate; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the jurisdictional mix of the projected cash flows.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">While all intangible assets other than goodwill can face events and circumstances that can lead to impairment, those that are most at risk of impairment include IPR&amp;D assets (approximately $18.9 billion as of December 31, 2024) and newly acquired or recently impaired indefinite-lived brand assets. IPR&amp;D assets are high-risk assets, given the uncertain nature of R&amp;D. Newly acquired and recently impaired indefinite-lived assets are more vulnerable to impairment as the assets are recorded at fair value and are then subsequently measured at the lower of fair value or carrying value at the end of each reporting period. As such, immediately after acquisition or impairment, even small declines in the outlook for these assets can negatively impact our ability to recover the carrying value and can result in an impairment charge.</span></div><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our goodwill impairment review work as of December 31, 2024 concluded that none of our goodwill was impaired and we do not believe the risk of impairment is significant at this time, as the fair value of each of our reporting units is significantly higher than their respective net book values.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">In our review, we first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. Qualitative factors that we consider include, for example, macroeconomic and industry conditions, overall financial performance and other relevant entity-specific events. If we conclude that it is more likely than not that the fair value of a reporting unit is less than its carrying value, we then perform a quantitative fair value test.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">When we are required to determine the fair value of a reporting unit, we typically use the income approach. The income approach is a forward-looking approach to estimating fair value and relies primarily on internal forecasts. Within the income approach, we use the discounted cash flow method. We start with a forecast of all the expected net cash flows for the reporting unit, which includes the application of a terminal value, and then we apply a reporting unit-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of technological risk and competitive, legal and/or regulatory forces on the projections, as well as the selection of a long-term growth rate; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.</span></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">For all of our reporting units, there are a number of future events and factors that may impact future results and that could potentially have an impact on the outcome of subsequent goodwill impairment testing. For a list of these factors, see the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_19">Forward-Looking Information and Factors That May Affect Future Result</a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_19">s</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67">Item 1A. Risk Factors</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> sections.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Benefit Plans</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">For a description of our different benefit plans, see</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_244">Note 11</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our assumptions reflect our historical experiences and our judgment regarding future expectations that have been deemed reasonable by management. The judgments made in determining the costs of our benefit plans can materially impact our results of operations.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tbody><tr><td style="width:1.0%"></td><td style="width:57.469%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.014%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.865%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.017%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following provides (i) at the end of each year, the expected annual rate of return on plan assets for the following year, (ii) the actual annual rate of return on plan assets achieved in each year, and (iii) the weighted-average discount rate used to measure the benefit obligations at the end of each year for our U.S. pension plans and our international pension plans</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">U.S. Pension Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Expected annual rate of return on plan assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">7.7</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">8.0&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">7.5&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Actual annual rate of return on plan assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">1.3</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.4&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(22.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Discount rate used to measure the plan obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">5.7</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.4&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.4&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">International Pension Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Expected annual rate of return on plan assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">4.9</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.1&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.5&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Actual annual rate of return on plan assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">6.4</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(26.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Discount rate used to measure the plan obligations</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">4.1</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.4&nbsp;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.8&nbsp;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">For detailed assumptions associated with our benefit plans, see </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_244">Note 11B</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Expected Annual Rate of Return on Plan Assets</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The assumptions for the expected annual rate of return on all of our plan assets reflect our actual historical return experience and our long-term assessment of forward-looking return expectations by asset classes, which is used to develop a weighted-average expected return based on the implementation of our targeted asset allocation in our respective plans. </span></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The expected annual rate of return on plan assets for our U.S. plans and international plans is applied to the fair value of plan assets at each year-end and the resulting amount is reflected in our net periodic benefit costs in the following year. Differences between the actual rate of return on plan assets and the expected annual rate of return on plan assets are immediately recognized through earnings upon remeasurement.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">33</span></div></td></tr></tbody></table></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tbody><tr><td style="width:1.0%"></td><td style="width:61.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.608%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.758%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following illustrates the sensitivity of net periodic benefit costs to a 50 basis point decline in our assumption for the expected annual rate of return on plan assets, holding all other assumptions constant (in millions, pre-tax):</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">Assumption</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Increase in 2025 </span></div><div style="text-align:right"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net Periodic</span></div><div style="text-align:right"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Benefit Costs</span></div></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Expected annual rate of return on plan assets</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">50 basis point decline</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$86</span></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The estimate excludes any potential mark-to-market adjustments.</span></div><div><span><br></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The actual return on plan assets was $652 million during 2024</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Discount Rate Used to Measure Plan Obligations</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The weighted-average discount rate used to measure the plan obligations for our U.S. defined benefit plans is determined at least annually and evaluated and modified, as required, to reflect the prevailing market rate of a portfolio of high-quality fixed income investments, rated AA/Aa or better, that reflect the rates at which the pension benefits could be effectively settled. The discount rate used to measure the plan obligations for our significant international plans is determined at least annually by reference to investment grade corporate bonds, rated AA/Aa or better, including, when there is sufficient data, a yield-curve approach. These discount rate determinations are made in consideration of local requirements. The measurement of plan obligations at the end of the year will affect (i) the actuarial (gains)/losses recognized in our net periodic benefit cost for that year and (ii) the amount of service cost and interest cost reflected in our net periodic benefit costs in the following year.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tbody><tr><td style="width:1.0%"></td><td style="width:49.941%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.798%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.997%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following illustrates the sensitivity of net periodic benefit costs and benefit obligations to a 10 basis point decline in our assumption for the discount rate, holding all other assumptions constant (in millions, pre-tax):</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">Assumption</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Decrease in 2025 Net Periodic Benefit Costs</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Increase to 2024 Benefit Obligations</span></div></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Discount rate</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">10 basis point decline</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$5</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$208</span></td></tr></tbody></table></div><div><span><br></span></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The change in the discount rates used in measuring our plan obligations as of December 31, 2024 resulted in an increase in the measurement of our aggregate plan obligations by approximately $25 million.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Income Tax Assets and Liabilities</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Income tax assets and liabilities include income tax valuation allowances and accruals for uncertain tax positions. See </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_178">Notes 1Q</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">and </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_208">5</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">as well as the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_145">Analysis of Financial Condition, Liquidity, Capital Resources and Market Risk</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section within MD&amp;A</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Contingencies</span></div><div><span><br></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, including tax and legal contingencies, guarantees and indemnifications. See </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_178">Notes 1Q</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_178">,</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_178"> </a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_178">1S</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_208">5D</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_268">16</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div id="i8531e747ebb543f3bf818166f157d26a_112"></div><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">ANALYSIS OF THE CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div id="i8531e747ebb543f3bf818166f157d26a_115"></div><div style="margin-top:5pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total Revenues by Geography</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tbody><tr><td style="width:1.0%"></td><td style="width:14.751%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.085%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.085%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.048%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.048%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.048%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.048%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.048%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.064%"></td><td style="width:0.1%"></td></tr><tr><td colspan="93" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following presents worldwide </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Total revenues</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> by geography:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="51" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="33" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">International</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">24/23</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">23/22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">24/23</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">23/22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">24/23</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">23/22</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">Operating segments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">Biopharma</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">62,400</span><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">58,237&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">99,826&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">38,332</span><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">27,749&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">42,920&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">24,068</span><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">30,488&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">56,905&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">7</span><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">(42)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">38</span><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">(35)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">(46)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">Pfizer CentreOne</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">1,146</span><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,272&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,342&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">278</span><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">352&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">390&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">868</span><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">920&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">952&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">(10)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">Pfizer Ignite</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">82</span><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">44&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">7&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">82</span><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">44&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">7&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">85</span><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">85</span><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%"></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%"></span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Total revenues</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">63,627</span><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">59,553&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">101,175&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">38,691</span><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">28,145&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">43,317&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">24,936</span><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">31,408&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">57,858&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">7</span><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">(41)</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">37</span><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">(35)</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(21)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial Narrow&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">(46)</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2024 v. 2023</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tbody><tr><td style="width:1.0%"></td><td style="width:64.920%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.481%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.587%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.377%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following provides an analysis of the worldwide change in </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Total revenues</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> by geographic areas from 2023 to 2024:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Worldwide</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">International</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Operational growth/(decline):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Worldwide growth from Paxlovid</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">4,452</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">5,905</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,453)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Increase in revenues from legacy Seagen, which was acquired in December 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,223</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,071</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">153</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Worldwide growth from the Vyndaqel family, Eliquis, Xtandi and Nurtec ODT/Vydura, partially offset by declines from Xeljanz, Ibrance, Abrysvo, Inlyta and the Prevnar family</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,403</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,770</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">633</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Worldwide declines from Comirnaty</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">(5,907)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">(400)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">(5,507)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Decline in oncology biosimilars, largely due to lower net price in the U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">(362)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">(338)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other operational factors, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">614</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">538</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">76</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Operational growth/(decline), net</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">4,423</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">10,546</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">(6,123)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unfavorable impact of foreign exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">(349)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">(349)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Total revenues</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> increase/(decrease)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">4,074</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">10,546</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">(6,472)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">34</span></div></td></tr></tbody></table></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2023 v. </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">2022</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tbody><tr><td style="width:1.0%"></td><td style="width:64.920%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.481%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.587%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.377%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following provides an analysis of the worldwide change in </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Total revenues</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> by geographic areas from 2022 to 2023:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">International</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Operational growth/(decline):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Worldwide declines from Comirnaty</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(26,427)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6,374)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(20,053)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Worldwide declines from Paxlovid</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(17,506)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(11,803)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5,703)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Worldwide growth from the Vyndaqel family, Eliquis, the Prevnar family and Inlyta, partially offset by worldwide declines from Ibrance and Xeljanz</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,079&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,081&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Increase in revenues from Nurtec ODT/Vydura and Oxbryta, which were acquired in the fourth quarter of 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">972&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">949&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">23&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revenues from Abrysvo, primarily driven by launch of the older adult indication in the U.S. in July 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">890&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">888&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revenues from legacy Seagen products subsequent to the acquisition on December 14, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">132&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">132&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other operational factors, net</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">260&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(45)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">305&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Operational growth/(decline), net</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(40,600)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(15,172)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(25,428)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unfavorable impact of foreign exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,022)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Calibri&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,022)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Total revenues</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> increase/(decrease)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(41,621)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(15,172)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(26,450)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">See the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_121">Total RevenuesSelected Product Discussion</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section within MD&amp;A for additional analysis and </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_280">Note </a><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_280">17C</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div id="i8531e747ebb543f3bf818166f157d26a_118"></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Product Revenue Deductions</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our gross product revenues are subject to a variety of deductions, which generally are estimated and recorded in the same period that the revenues are recognized. These deductions represent estimates of the related obligations and, as such, knowledge and judgment are required when estimating the impact of these product revenue deductions on gross sales for a reporting period. Historically, adjustments to these estimates to reflect actual results or updated expectations, have not been material to our overall business and generally have been less than 1% of revenues. Product-specific rebates, however, can have a significant impact on year-over-year individual product revenue growth trends.</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tbody><tr><td style="width:1.0%"></td><td style="width:55.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.631%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.183%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.783%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following presents information about product revenue deductions:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year&nbsp;Ended&nbsp;December&nbsp;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Medicare rebates</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">4,145</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">997&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">838&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Medicaid and related state program rebates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,252</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,655&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">973&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Performance-based contract rebates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,497</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,159&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,575&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Chargebacks</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">12,698</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">9,828&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">7,560&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sales allowances</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,444</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,790&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,460&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sales returns and cash discounts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,852</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,619&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,290&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">33,888</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">30,048&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">19,697&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The increase in revenue deductions in 2024 was primarily driven by the transition of Paxlovid and Comirnaty to commercial markets, an increase in sales from legacy Seagen products acquired in December 2023, sales growth from the Vyndaqel family, and higher sales of acquired products, partially offset by a $771 million favorable final adjustment recorded in the first quarter of 2024 to the estimated non-cash Paxlovid revenue reversal of $3.5 billion recorded in the fourth quarter of 2023 (see </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_280">Note 17C</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">).</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Product revenue deductions are primarily a function of product sales volume, mix of products sold, contractual or legislative discounts and rebates.</span></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">For information on our accruals for product revenue deductions, including the balance sheet classification of these accruals, see </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_178">Note 1G</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div id="i8531e747ebb543f3bf818166f157d26a_121"></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total RevenuesSelected Product Discussion</span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Biopharma</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.360%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Year Ended Dec. 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Product</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Global<br>Revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Region</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Oper.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Operational Results Commentary</span></td></tr><tr style="height:24pt"><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Eliquis</span></td><td colspan="3" rowspan="3" style="border-right:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$7,366</span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Up 10%</span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(operationally)</span></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">4,803</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">4,228&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">14</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">Growth driven primarily by continued oral anti-coagulant adoption and market share gains in the non-valvular atrial fibrillation indication in the U.S. and certain markets in Europe, partially offset by declines due to loss of patent-based exclusivity and generic competition in certain international markets.</span></div></td></tr><tr style="height:18pt"><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">Intl.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">2,563</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">2,519&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">2</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">3</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">Worldwide</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">7,366</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">6,747&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">9</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">10</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:39pt"><td colspan="3" rowspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Prevnar family</span></td><td colspan="3" rowspan="3" style="border-right:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$6,411</span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Down 1% </span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(operationally)</span></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">4,233</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">4,265&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(1)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">Declines driven by fewer adult vaccinations in the U.S. and lower pediatric indication sales in most international developed markets and certain emerging markets, partially offset by growth in the pediatric indication in the U.S. reflecting recovered market share as a result of the Prevnar 20 launch in 2023, as well as strong uptake of the adult indication in certain international markets.</span></div></td></tr><tr style="height:11pt"><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">Intl.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">2,178</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">2,236&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">6,411</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">6,501&nbsp;</span></td><td style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(1)</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(1)</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></tbody></table></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">35</span></div></td></tr></tbody></table></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.360%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Year Ended Dec. 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Product</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Global<br>Revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Region</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Oper.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Operational Results Commentary</span></td></tr><tr style="height:51pt"><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Paxlovid</span></td><td colspan="3" rowspan="3" style="border-right:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$5,716</span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Up *</span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(operationally)</span></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">4,616</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1,289)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">Growth primarily driven by:</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%"> a non-cash revenue reversal of $3.5 billion recorded in the fourth quarter of 2023 (see </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_280">Note </a><a style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_280">17C</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">);</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%"> a $771 million favorable final adjustment recorded in the first quarter of 2024 to the estimated non-cash revenue reversal of $3.5 billion recorded in the fourth quarter of 2023; and</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%"> $442 million from the one-time contractual delivery of treatment courses to the U.S. SNS in the third quarter of 2024,</span></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">partially offset by:</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%"> lower contractual deliveries in most international markets as a result of the transition to traditional commercial market sales; and</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%"> lower demand globally, largely in China due to the non-recurrent surge in COVID-19 infection during the first quarter of 2023 and transition to the out-of-pocket market in the second quarter of 2023.</span></div></td></tr><tr style="height:51pt"><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">Intl.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">1,100</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">2,568&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(57)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(57)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:51pt"><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">5,716</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,279&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">*</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Vyndaqel family</span></td><td colspan="3" rowspan="3" style="border-right:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$5,451</span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Up 65%</span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(operationally)</span></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">3,547</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,863&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">90</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">Growth largely driven by strong demand with continuing uptake in patient diagnosis, primarily in the U.S. and international developed markets, as well as increased affordability in the U.S.</span></div></td></tr><tr style="height:17pt"><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">Intl.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">1,904</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,458&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">31</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">32</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">Worldwide</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">5,451</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">3,321&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">64</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">65</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:18pt"><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Comirnaty</span></div></td><td colspan="3" rowspan="3" style="border-right:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$5,353</span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Down 53% </span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(operationally)</span></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">2,004</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">2,404&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(17)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">Declines largely driven by lower contractual deliveries in international markets as well as a decrease in vaccinations globally. </span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">Intl.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">3,349</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">8,816&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(62)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(62)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">5,353</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">11,220&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(52)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Ibrance</span></td><td colspan="3" rowspan="3" style="border-right:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$4,367</span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Down 8%</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">&nbsp;</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(operationally)</span></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">2,849</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">3,151&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(10)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">Declines primarily driven by lower demand due to competitive pressures mainly in the U.S., price decreases in certain international developed markets and generic penetration in certain emerging markets.</span></div></td></tr><tr style="height:17pt"><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">Intl.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">1,518</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,602&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">4,367</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">4,753&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Xtandi</span></td><td colspan="3" rowspan="3" style="border-right:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$2,039</span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Up 23% </span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(operationally)</span></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">2,039</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,659&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">23</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">Growth largely driven by strong demand due to uptake of the nmCSPC indication following approval in the fourth quarter of 2023 and increased affordability in the U.S.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">Intl.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%"></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%"></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:18pt"><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">Worldwide</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">2,039</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,659&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">23</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">23</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Padcev</span></div></td><td colspan="3" rowspan="3" style="border-right:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$1,588</span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Up *</span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(operationally)</span></div></td><td colspan="3" rowspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">1,561</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">53&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">*</span></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">Growth driven by the acquisition of Seagen in the fourth quarter of 2023 as well as strong demand.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">Intl.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">27</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">*</span></td></tr><tr style="height:21pt"><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">Worldwide</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">1,588</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">53&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">*</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nurtec ODT/Vydura</span></td><td colspan="3" rowspan="3" style="border-right:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$1,263</span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Up 36%</span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(operationally)</span></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">1,193</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">908&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">31</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">Growth primarily driven by strong demand in the U.S. and, to a much lesser extent, recent launches in international markets, partially offset by lower net price in the U.S. due to unfavorable changes in channel mix.</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">Intl.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">69</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">20&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">*</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:20pt"><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">Worldwide</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">1,263</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">928&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">36</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">36</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Xeljanz</span></td><td colspan="3" rowspan="3" style="border-right:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$1,168</span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Down 31% </span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(operationally)</span></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">680</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,154&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(41)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">Declines primarily driven by lower demand globally resulting from ongoing shifts in prescribing patterns related to label changes, as well as lower net price in the U.S. and the impact of regulatory exclusivity expiry in Canada.</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">Intl.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">488</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">549&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:21pt"><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">1,168</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,703&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-bottom:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adcetris</span></td><td colspan="3" rowspan="3" style="border-right:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$1,089</span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Up *</span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(operationally)</span></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">1,059</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">56&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">*</span></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">Growth driven by the acquisition of Seagen in the fourth quarter of 2023.</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">Intl.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">30</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">*</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:20pt"><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">Worldwide</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">1,089</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">56&nbsp;</span></td><td style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">*</span></td><td colspan="3" style="padding:0 1pt"></td></tr></tbody></table></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">36</span></div></td></tr></tbody></table></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.360%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Year Ended Dec. 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Product</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Global<br>Revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Region</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Oper.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Operational Results Commentary</span></td></tr><tr style="height:18pt"><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Inlyta</span></td><td colspan="3" rowspan="3" style="border-right:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$978</span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Down 5% </span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(operationally)</span></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">588</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">642&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(8)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">Declines primarily driven by lower demand in the U.S. as well as lower volumes and lower net price in international markets, partially offset by strong growth in China.</span></div></td></tr><tr style="height:18pt"><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">Intl.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">391</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">394&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">1</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:18pt"><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">Worldwide</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">978</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,036&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Abrysvo</span></div></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;border-right:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$755</span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Down 15%</span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(operationally)</span></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">594</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">888&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(33)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">Decline primarily driven by a significant reduction in vaccination rates in the U.S. for the older adult indication, partially offset by strong demand for the maternal indication in the U.S. (launched in December 2023), and launch uptake for both indications in certain international markets.</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">Intl.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">160</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">2&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">*</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="border-bottom:3pt double #000;border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">Worldwide</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">755</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">890&nbsp;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(15)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(15)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Pfizer CentreOne</span></div><div style="margin-bottom:5pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.360%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Year Ended Dec. 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Operating Segment</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Global<br>Revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Region</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Oper.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Operational Results Commentary</span></td></tr><tr style="height:17pt"><td colspan="3" rowspan="3" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">PC1</span></div></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;border-right:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-left:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$1,146</span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Down 10%</span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(operationally)</span></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">278</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">352&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(21)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">Declines primarily driven by lower manufacturing of divested and other third-party products under manufacturing and supply agreements, partially offset by growth in manufacturing-related services.</span></td></tr><tr style="height:17pt"><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">Intl.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">868</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">920&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="border-bottom:3pt double #000;border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">Worldwide</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">1,146</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,272&nbsp;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(10)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">(10)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></tbody></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">See the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_46">Item 1. Business</a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_46"></a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_46">Patents and Other Intellectual Property Rights</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section for information regarding the expiration of various patent rights, </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_268">Note 16</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">for a discussion of recent developments concerning patent and product litigation relating to certain of the products discussed above and </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_280">Note 17C</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">for the primary indications or class of the selected products discussed above.</span></div><div id="i8531e747ebb543f3bf818166f157d26a_124"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Costs and Expenses</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.166%"></td><td style="width:0.1%"></td></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Costs and expenses follow:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year&nbsp;Ended&nbsp;December&nbsp;31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">24/23</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">23/22</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">17,851</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">24,954&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">34,344&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">(28)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(27)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Percentage of </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Total revenues</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">28.1</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">41.9&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">33.9&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">14,730</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">14,771&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">13,677&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">8&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">10,822</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,679&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">11,428&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">1</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Acquired in-process research and development expenses</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">108</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">194&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">953&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(80)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Amortization of intangible assets</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">5,286</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,733&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,609&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">12</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">31&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related </span></div><div style="padding-left:4.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">costs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,419</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,943&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,375&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductionsnet</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">4,388</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">222&nbsp;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,062&nbsp;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">*</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(79)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2024 v. 2023</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Cost of Sales</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> decreased $7.1&nbsp;billion, primarily due to:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Times New Roman&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the non-recurrence of a non-cash charge of $6.2&nbsp;billion in 2023 related to Paxlovid and Comirnaty recorded for inventory write-offs and related charges ($5.0&nbsp;billion for Paxlovid and $1.2&nbsp;billion for Comirnaty); and</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">a favorable change in sales mix of $2.6&nbsp;billion, primarily driven by lower sales of Comirnaty,</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> partially offset by:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">an impact of $1.9 billion from our Seagen acquisition, inclusive of the amortization of the fair value step-up of inventory.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The decrease in </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> as a percentage of revenues reflects the non-recurrence of the aforementioned non-cash charge of $6.2 billion, as well as significantly lower sales of Comirnaty.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain of our vaccines, including Comirnaty, are subject to seasonality of demand, with a greater portion of revenues and related cost of sales anticipated in the fall and winter seasons. See also </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_100">Overview of Our Performance, Operating Environment, Strategy and Outlook</a><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_100">The Global Economic EnvironmentCOVID-19</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section for information about our COVID-19 products.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">37</span></div></td></tr></tbody></table></div></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:5pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Selling, Informational and Administrative Expenses</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">decreased $41&nbsp;million, mostly due to:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">a decrease of $790&nbsp;million due to lower promotional and marketing spend for various products, including Comirnaty and Paxlovid, </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">partially offset by:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">higher compensation-related expenses of $630&nbsp;million; and</span></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">an increase of $140&nbsp;million for corporate enabling functions primarily driven by our acquisition of Seagen.</span></div><div style="margin-bottom:5pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Research and Development Expenses</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> increased $143 million, primarily due to:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">a net increase in spending of $1.1&nbsp;billion mainly to develop certain product candidates acquired from Seagen; and</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">an increase of $680&nbsp;million in compensation-related expenses,</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">partially offset by:</span></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">lower spending of $1.6&nbsp;billion as a result of our cost realignment program and on various product candidates, primarily ongoing vaccine programs.</span></div><div style="margin-bottom:5pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Amortization of Intangible Assets</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Amortization of intangible assets</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> increased $553 million, primarily due to:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#05497c;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">an increase of $570 million from our December 2023 acquisition of Seagen; and</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#05497c;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">an increase of $470 million related to assets reclassified in 2023 from IPR&amp;D to developed technology rights and from indefinite-lived to finite-lived brands,</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">partially offset by:</span></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">a decrease of $570 million related to changes in asset lives and fully amortized assets.</span></div><div style="margin-bottom:5pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span></div><div style="margin-bottom:5pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Realigning our Cost Base Program</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">This program is expected to deliver total net cost savings of approximately $4.5&nbsp;billion by the end of 2025, most of which was achieved by year-end 2024.</span></div><div style="margin-bottom:5pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Manufacturing Optimization Program</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We expect to begin to achieve initial savings from Phase 1 of this multi-phased program in the latter part of 2025 and continue to expect approximately $1.5&nbsp;billion in savings from this first phase by the end of 2027.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain qualifying costs for these programs in all periods since inception were recorded and reflected as Certain Significant Items and excluded from our non-GAAP measure of Adjusted Income. See the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_136">Non-GAAP Financial Measure: Adjusted Income</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section within MD&amp;A.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">For a description of our programs, as well as the anticipated and actual costs, see </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_199">Note 3A</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The program savings discussed above may be rounded and represent approximations. In addition to these programs, we continuously monitor our operations for cost reduction and/or productivity opportunities in light of patent-based and regulatory exclusivity expiries as well as the expiration of collaborative arrangements for various products. Long-term improvement in gross margin will remain a key focus for the Company over the next few years.</span></div><div style="margin-bottom:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Seagen acquisition</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">In connection with our acquisition of Seagen, we are focusing our efforts on achieving an appropriate cost structure for the combined company. We expect to generate approximately $1 billion of annual cost synergies, to be achieved by 2026. The one-time costs to generate these synergies are expected to be approximately $1.7&nbsp;billion, incurred primarily from 2023 through 2025.</span></div><div style="margin-bottom:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Other (Income)/DeductionsNet</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2024 v. 2023</span></div><div style="margin-bottom:8pt;margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The unfavorable period-over-period change of $4.2 billion was primarily driven by (i) higher net interest expense of $2.0 billion, (ii) an unfavorable impact of $760 million due to net periodic benefit costs associated with pension and postretirement plans in 2024 versus net periodic benefit credits in 2023, (iii) lower net gains on equity securities of $580 million, (iv) a charge of $420 million in 2024 related to the expected sale of one of our facilities resulting from the discontinuation of our DMD program and (v) lower Haleon equity method income of $400 million, partially offset by (vi) gains of $945&nbsp;million in 2024 on the partial sales of our investment in Haleon.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2023 v. 2022</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The favorable period-over period change of $840 million was mainly driven by a favorable impact of $2.9 billion due to net gains on equity securities in 2023 versus net losses recognized on equity securities in 2022 and lower net interest expense of $400 million, partially offset by higher intangible asset impairment charges of $2.6 billion.</span></div><div style="margin-bottom:8pt;margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">See </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_202">Note 4</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div id="i8531e747ebb543f3bf818166f157d26a_127"></div><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Provision/(Benefit) for Taxes on Income</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.376%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.064%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year&nbsp;Ended&nbsp;December&nbsp;31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">24/23</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">23/22</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Provision/(benefit) for taxes on income</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">(28)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,115)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,328&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">(97)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Effective tax rate on continuing operations</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">(0.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">9.6&nbsp;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></tbody></table></div><div><span><br></span></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">For information about our effective tax rate and the events and circumstances contributing to the changes between periods, as well as details about discrete elements that impacted our tax provisions, and cash paid for income taxes, net of refunds, see </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_208">Note 5</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">38</span></div></td></tr></tbody></table></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Changes in Tax Laws</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Many countries outside the U.S. have enacted legislation for global minimum taxation resulting from the Organization for Economic Co-operation and Developments (OECD) Base Erosion and Profit Shifting Pillar 2 project. The EU has approved a directive requiring member states to incorporate the OECD provisions into their respective domestic laws, and countries outside the EU are also enacting the provisions into their domestic law. The provisions are generally effective for Pfizer in 2024, though significant details and guidance around the provisions are still pending. Income tax expense could be adversely affected as the legislation becomes effective in countries in which we do business, and such impact could be material to our results of operations. We continue to monitor pending OECD guidance and legislation enactment and implementation by individual countries.</span></div><div id="i8531e747ebb543f3bf818166f157d26a_133"></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">PRODUCT DEVELOPMENTS </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">A comprehensive update of Pfizers development pipeline was published as of February&nbsp;4, 2025 and is available at www.pfizer.com/science/drug-product-pipeline. It includes an overview of our research and a list of compounds in development with targeted indication and phase of development, as well as mechanism of action for some candidates in Phase 1 and all candidates from Phase 2 through registration.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">This section provides information as of the date of this filing about significant marketing application-related regulatory actions by, and filings pending with, the FDA and regulatory authorities in the EU and Japan.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The table below includes filing and approval milestones for products that have occurred in the last twelve months and generally do not include approvals that may have occurred prior to that time. The table includes filings with regulatory decisions pending (even if the filing occurred outside of the last twelve-month period).</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">39</span></div></td></tr></tbody></table></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:3pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Products</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:17.787%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.099%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.099%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.247%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">PRODUCT</span></td><td colspan="3" rowspan="2" style="border-bottom:0.5pt solid #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">INDICATION OR PROPOSED INDICATION</span></td><td colspan="9" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">APPROVED/FILED^</span></td></tr><tr style="height:11pt"><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">EU</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">JAPAN</span></td></tr><tr style="height:29pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Prevnar 20/Prevenar 20</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(Vaccine)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Active immunization to prevent invasive disease and pneumonia caused by the 20 </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Streptococcus pneumoniae</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> (pneumococcus) serotypes in the vaccine in adults ages 18 years and older.</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">June</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">February</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2022</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">August</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2024</span></div></td></tr><tr style="height:47pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Active immunization to prevent invasive pneumococcal disease caused by the 20 </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Streptococcus pneumoniae</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> (pneumococcal) serotypes contained in the vaccine in infants and children six weeks through 17 years of age, and for the prevention of otitis media in infants six weeks through five years of age caused by the original seven serotypes contained in Prevnar</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">.</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">April</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">March</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2024</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">March</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">TicoVac<br>(Vaccine)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Active immunization to prevent tick-borne encephalitis in individuals 1 year of age and older</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">August </span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">March</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2024</span></div></td></tr><tr style="height:29pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Nurtec ODT/Vydura</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(rimegepant)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Acute treatment of migraine with or without aura in adults</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">February</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2020</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Approved</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">April </span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2022</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Filed</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> November 2024</span></div></td></tr><tr style="height:29pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Prevention of episodic migraine in adults</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">May</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Approved</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">April </span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2022</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Filed</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> November 2024</span></div></td></tr><tr style="height:29pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Abrysvo<br>(Vaccine)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Active immunization for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years and older</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">May</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">August</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">March</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2024</span></div></td></tr><tr style="height:29pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Active immunization for the prevention of lower respiratory tract disease caused by RSV in individuals 18-59 years of age who are at increased risk of lower respiratory tract disease caused by RSV</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">October</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2024</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">June</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2024</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"><div style="text-align:center"><span><br></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Velsipity (etrasimod)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Moderately to severely active ulcerative colitis in adults</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">October</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">February</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2024</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Filed</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">June </span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Braftovi (encorafenib) and Mektovi (binimetinib)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">BRAF</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">V600E</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">-mutant metastatic non-small cell lung cancer in adult patients</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">October</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">August</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2024</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Braftovi (encorafenib),</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Erbitux (cetuximab)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">and mFOLFOX6</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">First-line BRAF</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">V600E</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">-mutant mCRC</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">December 2024</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Elrexfio (elranatamab)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Triple-class relapsed/refractory multiple myeloma in adult patients</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">August</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">December</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">March</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Xtandi (enzalutamide)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">nmCSPC with biochemical recurrence at high risk for metastasis (high-risk BCR)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">November</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">April</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2024</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Hympavzi<br>(marstacimab-hncq)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Hemophilia A and B without inhibitors</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">October</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2024</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">November</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2024</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">December</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Emblaveo</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(aztreonam-avibactam)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Treatment of infections in adult patients caused by Gram-negative bacteria with limited or no treatment options</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Approved</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> February 2025</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">April</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2024</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Padcev</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(enfortumab vedotin-ejfv)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">In combination with Keytruda</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(g)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> (pembrolizumab) for locally advanced or metastatic urothelial cancer in adults</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">December</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">August</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2024</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">September</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Tivdak</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(tisotumab vedotin-tftv)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(h)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Recurrent or metastatic cervical cancer with disease progression on or after chemotherapy</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">April</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2024</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">February</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2024</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">April</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Comirnaty (COVID-19 Vaccine, mRNA) 2024-2025 Formula, Omicron KP.2-adapted</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(i)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Active immunization to prevent COVID-19 caused by SARS-CoV-2 for individuals 12 years of age and older</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">August</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2024</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Approved </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">September 2024</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"><div style="text-align:center"><span><br></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Comirnaty (COVID-19 Vaccine, mRNA) 2024-2025 Formula, Omicron JN.1-adapted</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Active immunization to prevent COVID-19 caused by SARS-CoV-2 for individuals 6 months of age and older</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">July</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2024</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">August</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Adcetris</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(brentuximab vedotin)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(j)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Relapsed/refractory diffuse large B-cell lymphoma</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">February</span></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2025</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Paxlovid (nirmatrelvir; ritonavir)</span></div></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">COVID-19 infection in high-risk children (6-11 years of age: &gt;88 lbs.)</span></div></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Filed</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> February 2025</span></div></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Filed</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> January 2025</span></div></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:700;line-height:120%">^</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;&nbsp;&nbsp;&nbsp;For the U.S., the filing date is the date on which the FDA accepted our submission. For the EU, the filing date is the date on which the EMA validated our submission.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Listed indication applies to U.S. only. For the EU, approved indications are pneumococcal invasive disease pneumonia and otitis media. For Japan, approved indication is invasive pneumococcal disease.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">40</span></div></td></tr></tbody></table></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Pierre Fabre is the Marketing Authorization Holder for Braftovi (encorafenib) and Mektovi (binimetinib) in the EU. We have exclusive rights to Braftovi and Mektovi in the U.S., Canada and certain emerging markets, and Ono, Medison Pharma and Pierre Fabre have exclusive rights in all other markets.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Erbitux</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%"> is a registered trademark of ImClone LLC. We have exclusive rights to Braftovi in the U.S., Canada, and certain emerging markets, and Ono. Medison Pharma and Pierre Fabre have exclusive rights in all other markets.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Being jointly developed and commercialized with Astellas.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Being developed in collaboration with AbbVie. AbbVie has the exclusive commercialization rights in the U.S. and Canada; Pfizer leads the joint development program and has commercialization rights in all other countries.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt">Being jointly developed and commercialized with Astellas.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(g)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Keytruda</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%"> is a registered trademark of Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(h)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Being developed in collaboration with Genmab A/S. The April 2024 approval date in the U.S. refers to the conversion of a prior accelerated approval to full approval.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(i)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.39pt">In September 2024, the EC approved the Pfizer/BioNTech Omicron KP.2-adapted monovalent COVID-19 vaccine for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. U.S. approval (August 2024) is for individuals 12 years of age and older, with EUA granted for individuals 6 months through 11 years of age. </span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(j)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.39pt">Being developed in collaboration with Takeda. Takeda has ex-U.S./Canada rights.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer submitted its intent to withdraw Penbraya from the EU market. The EC has confirmed the withdrawal of the Penbraya EU Marketing Authorisation Application with an effective date of February 20, 2025.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">In February 2025, Pfizer decided to terminate development and commercialization of Beqvez (fidanacogene elaparvovec) and elected to terminate the license agreement between Pfizer and Spark Therapeutics, Inc. effective as of August 6, 2025.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">In December 2024, Pfizer submitted a withdrawal of the Ngenla (somatrogon) filing for adult human growth hormone deficiency in the EU.</span></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following provides information about additional indications and new drug candidates in late-stage development:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:12.998%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.138%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:61.983%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="17" style="background-color:#cceeff;border-right:0.25pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">PRODUCT/CANDIDATE</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">PROPOSED DISEASE AREA</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="16" style="background-color:#cceeff;border-left:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">LATE-STAGE CLINICAL PROGRAMS FOR ADDITIONAL USES AND DOSAGE FORMS<br>FOR IN-LINE AND IN-REGISTRATION PRODUCTS</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Ibrance (palbociclib)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:115%">ER+/HER2+ metastatic breast cancer</span></td></tr><tr style="height:11pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Talzenna (talazoparib)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Combination with Xtandi (enzalutamide) for DNA Damage Repair-deficient mCSPC</span></td></tr><tr style="height:11pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Litfulo (ritlecitinib)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Vitiligo</span></td></tr><tr style="height:11pt"><td colspan="3" rowspan="4" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Elrexfio (elranatamab)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Multiple myeloma double-class exposed</span></td></tr><tr style="height:11pt"><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Newly diagnosed multiple myeloma post-transplant maintenance</span></td></tr><tr style="height:11pt"><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Newly diagnosed multiple myeloma transplant-ineligible</span></td></tr><tr style="height:11pt"><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2nd line + relapsed refractory multiple myeloma </span></td></tr><tr style="height:11pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Eliquis (apixaban)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Venous thromboembolism (pediatric)</span></td></tr><tr style="height:11pt"><td colspan="3" rowspan="2" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Padcev (enfortumab vedotin)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Cisplatin-ineligible/decline muscle-invasive bladder cancer </span></td></tr><tr style="height:11pt"><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Cisplatin-eligible muscle-invasive bladder cancer</span></td></tr><tr style="height:11pt"><td colspan="3" rowspan="4" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Tukysa (tucatinib)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">HER2+ adjuvant breast cancer </span></td></tr><tr style="height:11pt"><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2nd line/3rd line HER2+ metastatic breast cancer</span></td></tr><tr style="height:11pt"><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1st line HER2+ maintenance metastatic breast cancer </span></td></tr><tr style="height:11pt"><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1st line HER2+ metastatic colorectal cancer&nbsp;</span></td></tr><tr style="height:11pt"><td colspan="3" rowspan="2" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Hympavzi</span></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(marstacimab-hncq)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Hemophilia (pediatric)</span></div></td></tr><tr style="height:11pt"><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Hemophilia (inhibitor cohort)</span></div></td></tr><tr style="height:12pt"><td colspan="3" rowspan="15" style="background-color:#cceeff;border-bottom:3pt double #000;border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;text-indent:5.65pt;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">NEW DRUG CANDIDATES IN LATE-STAGE DEVELOPMENT</span></td><td colspan="3" rowspan="15" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">PF-06425090 (vaccine)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Immunization to prevent primary </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">clostridioides difficile</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> infection</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">sasanlimab (PF-06801591)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Combination with Bacillus Calmette-Guerin for non-muscle-invasive bladder cancer</span></td></tr><tr style="height:11pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">VLA15 (PF-07307405) vaccine</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Immunization to prevent Lyme disease</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">vepdegestrant (PF-07850327)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Breast cancer metastatic - 2nd line ER+/HER2-</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">inclacumab (PF-07940370)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Sickle cell disease</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Ibrance + vepdegestrant</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ER+/HER2- metastatic breast cancer</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">dazukibart (PF-06823859)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Dermatomyositis, polymyositis</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">disitamab vedotin</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1st line HER2 (&#8805;IHC1+) metastatic urothelial cancer</span></td></tr><tr style="height:20pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">sigvotatug vedotin (PF-08046047)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2nd line+ metastatic non-small cell lung cancer</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">osivelotor (PF-07940367)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Sickle cell disease</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">atirmociclib (PF-07220060)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2nd line metastatic breast cancer</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ibuzatrelvir (PF-07817883)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">COVID-19 infection</span></div></td></tr><tr style="height:20pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">mevrometostat (PF-06821497) + enzalutamide</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1st line/2nd line metastatic castration resistant prostate cancer post-Abiraterone </span></div></td></tr><tr style="height:20pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">mevrometostat (PF-06821497) + enzalutamide</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1st line metastatic castration resistant prostate cancer neoadjuvant hormonal therapy nave </span></div></td></tr><tr style="height:11pt"><td colspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">atirmociclib (PF-07220060)</span></div></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1st line metastatic breast cancer</span></div></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Ibrance for ER+/HER2+ metastatic breast cancer is being developed in collaboration with Alliance Foundation Trials, LLC.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Eliquis is being developed in collaboration with BMS.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Padcev is being jointly developed and commercialized with Astellas.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">VLA15 is being developed in collaboration with Valneva SE.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Vepdegestrant is being developed in collaboration with Arvinas.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt">Disitamab vedotin is being developed in collaboration with RemeGen Co., Ltd</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">41</span></div></td></tr></tbody></table></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">In December 2024, Pfizer decided to terminate development of giroctocogene fitelparvovec (PF-07055480) and elected to terminate the collaboration and license agreement between Pfizer and Sangamo Therapeutics, Inc. effective as of April 21, 2025.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">In August 2024, Pfizer announced Phase 3 top-line results for Pfizer and BioNTechs combination mRNA vaccine candidate against influenza and COVID-19 in healthy individuals 18-64 years of age. The trial did not meet one of its primary immunogenicity objectives of non-inferiority against the influenza B strain despite obtaining higher influenza A responses and comparable COVID-19 responses versus the comparator vaccines. In November 2024, PF-07926307 (COVID-19/mRNA flu combo vaccine) reverted from Phase 3 to Phase 1 clinical trials and has been removed from the table above.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">I</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">n September 2024, Pfizer announced that it was voluntarily withdrawing all lots of Oxbryta (voxelotor) for the treatment of sickle cell disease in all markets where it is approved. Pfizer also discontinued all active voxelotor clinical trials and expanded access programs worldwide. Pfizers decision was based on the totality of clinical data that indicated at that time the overall benefit of Oxbryta no longer outweighs the risk in the approved sickle cell patient population. The data suggested an imbalance in vaso-occlusive crises and fatal events, which requires further assessment that remains ongoing. Pfizer has notified regulatory authorities about these findings and its decision to voluntarily withdraw Oxbryta from the market and discontinue distribution and clinical studies while further reviewing the available data and investigating the findings. We are working with the FDA, EMA and other global regulatory authorities and expect the assessment to be completed in the first half of 2025.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">In July 2024, the EMA initiated a referral procedure under Article 20 of Regulation (EC) No 726/2004 for Oxbryta (voxelotor) to review the products benefits and risks. In October 2024, the EC suspended the Oxbryta marketing authorization while the EMAs review of data is ongoing. In addition, the FDA has initiated an evaluation of newly identified safety signals. The FDA also has placed the Oxbryta (voxelotor) investigational new drug application on clinical hold following Pfizers market withdrawal. Pfizer is working with the EMA, FDA, and other regulators globally in relation to this matter.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The FDA has recently issued a partial clinical hold for osivelotor, which prohibits Pfizer from enrolling new participants into osivelotor clinical studies at this time. Study participants currently enrolled can continue on the study drug. Communication with the FDA is ongoing. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">In October 2024, Pfizer stopped two clinical trials with sisunatovir (PF-07923568) following observed drug-drug interactions. Since then Pfizer has decided to terminate development of sisunatovir.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">For additional information about our R&amp;D organization, see </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_271">Note 17</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_34">Item 1. Business</a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_34"></a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_34">Research and Development</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section. For additional information regarding certain collaboration arrangements, see </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_37">Item 1. Business</a><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_37"></a><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_37">Collaboration and Co-Promotion Agreements</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div id="i8531e747ebb543f3bf818166f157d26a_136"></div><div style="margin-bottom:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">NON-GAAP FINANCIAL MEASURE: ADJUSTED INCOME</span></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Adjusted income is an alternative measure of performance used by management to evaluate our overall performance as a supplement to our GAAP Reported performance measures. As such, we believe that investors understanding of our performance is enhanced by disclosing this measure. We use Adjusted income, certain components of Adjusted income and Adjusted diluted EPS to present the results of our major operationsthe discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwideprior to considering certain income statement elements as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:27.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.879%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Measure</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Definition</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Relevance of Metrics to Our Business Performance</span></td></tr><tr style="height:90pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Adjusted income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Net income attributable to Pfizer Inc. common shareholders</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:107%">before the impact of amortization of intangible assets, certain acquisition-related items, discontinued operations and certain significant items</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Provides investors useful information to:</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.17pt">evaluate the normal recurring operational activities, and their components, on a comparable year-over-year basis</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.17pt">assist in modeling expected future performance on a normalized basis</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Provides investors insight into the way we manage our budgeting and forecasting, how we evaluate and manage our recurring operations and how we reward and compensate our senior management</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td></tr><tr style="height:60pt"><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Adjusted cost of sales, Adjusted selling, informational and administrative expenses, Adjusted research and development expenses and Adjusted other (income)/deductions</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">net</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales, Selling, informational and administrative expenses, Research and development expenses</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Other (income)/deductionsnet</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> (a)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">, each before the impact of amortization of intangible assets, certain acquisition-related items, discontinued operations and certain significant items, which are components of the Adjusted income measure</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:42pt"><td colspan="3" style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Adjusted diluted EPS</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">EPS attributable to Pfizer Inc. common shareholdersdiluted </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> before the impact of amortization of intangible assets, certain acquisition-related items, discontinued operations and certain significant items</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Most directly comparable GAAP measure.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The short-term incentive plans for substantially all non-sales-force employees worldwide are funded from a pool based on our performance, measured in significant part versus three budgeted metrics, one of which, for the 2024 performance year, was Adjusted diluted EPS (as defined for annual incentive compensation purposes), which is derived from Adjusted income and accounted for 40% of the bonus pool funding tied to financial performance. Additionally, for the 2024 performance year, the payout for performance share awards was determined in part by Adjusted net income, which is derived from Adjusted income. Since 2022, we no longer exclude any expenses for acquired IPR&amp;D from our non-GAAP Adjusted results but we continue to exclude certain of these expenses for our financial results for annual incentive compensation purposes. The bonus pool funding is largely based on financial performance, as measured by three metrics, modified by performance against certain of our non-financial metrics, and may be further modified by our Compensation Committees assessment of other factors.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">42</span></div></td></tr></tbody></table></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Adjusted income and its components and Adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by GAAP and, therefore, are limited in their usefulness to investors. Because of their non-standardized definitions, they may not be comparable to the calculation of similar measures of other companies and are presented to permit investors to more fully understand how management assesses performance. A limitation of these measures is that they provide a view of our operations without including all events during a period, and do not provide a comparable view of our performance to peers. These measures are not, and should not be viewed as, substitutes for their most directly comparable GAAP measures of</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Net income attributable to Pfizer Inc. common shareholders</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">, components of </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Net income attributable to Pfizer Inc. common shareholders</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">EPS attributable to Pfizer Inc. common shareholdersdiluted</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">, respectively.  </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We also recognize that, as internal measures of performance, these measures have limitations, and we do not restrict our performance-management process solely to these measures. We also use other tools designed to achieve the highest levels of performance. For example, our R&amp;D organization has productivity targets, upon which its effectiveness is measured. In addition, total shareholder return, both on an absolute basis and relative to a publicly traded pharmaceutical index, plays a significant role in determining payouts under certain of our incentive compensation plans.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted Income and Adjusted Diluted EPS</span></div><div style="margin-bottom:5pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Amortization of Intangible Assets</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Adjusted income excludes all amortization of intangible assets.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Acquisition-Related Items</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Adjusted income excludes certain acquisition-related items, which are composed of transaction, integration, restructuring charges and additional depreciation costs for business combinations because these costs are unique to each transaction and represent costs that were incurred to restructure and integrate businesses as a result of an acquisition. We have made no adjustments for resulting synergies.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The significant costs incurred in connection with a business combination result primarily from the need to eliminate duplicate assets, activities or employeesa natural result of acquiring a fully integrated set of activities. For this reason, we believe that such costs incurred can be viewed differently in the context of an acquisition from those costs incurred in other, more normal, business contexts. The integration and restructuring costs for a business combination may occur over several years, with the more significant impacts typically ending within three years of the relevant transaction. Because of the need for certain external approvals for some actions, the span of time needed to achieve certain restructuring and integration activities can be lengthy.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquisition-related items may include purchase accounting impacts such as the incremental charge to cost of sales from the sale of acquired inventory that was written up to fair value, depreciation related to the increase/decrease in fair value of acquired fixed assets, amortization related to the increase in fair value of acquired debt, and the fair value changes for contingent consideration. </span></div><div style="margin-top:5pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Discontinued Operations</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Adjusted income excludes the results of discontinued operations, as well as any related gains or losses on the disposal of such operations. We believe that this presentation is meaningful to investors because, while we review our product portfolio for strategic fit with our operations, we do not build or run our business with the intent to discontinue parts of our business. Restatements due to discontinued operations do not impact compensation or change the Adjusted income measure for the compensation in respect of the restated periods, but are presented for consistency across all periods.</span></div><div style="margin-top:5pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Certain Significant Items</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Adjusted income excludes certain significant items representing substantive and/or unusual items that are evaluated individually on a quantitative and qualitative basis. Certain significant items may be highly variable and difficult to predict. Furthermore, in some cases it is reasonably possible that they could reoccur in future periods. For example, although major non-acquisition-related cost-reduction programs are specific to an event or goal with a defined term, we may have subsequent programs based on reorganizations of the business, cost productivity or in response to generic or biosimilar entry or economic conditions. Legal charges to resolve litigation are also related to specific cases, which are facts and circumstances specific and, in some cases, may also be the result of litigation matters at acquired companies that were inestimable, not probable or unresolved at the date of acquisition, or legal matters related to divested products or businesses. Gains and losses on equity securities and pension and postretirement actuarial remeasurement gains and losses have a very high degree of inherent market volatility, which we do not control and cannot predict with any level of certainty, and we do not believe including these gains and losses assists investors in understanding our business or is reflective of our core operations and business. Unusual items represent items that are not part of our ongoing business; items that, either as a result of their nature or size, we would not expect to occur as part of our normal business on a regular basis; items that would be non-recurring; or items that relate to products we no longer sell. See the </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Reconciliations of GAAP Reported to Non-GAAP Adjusted InformationCertain Line Items </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">below for a non-inclusive list of certain significant items.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">43</span></div></td></tr></tbody></table></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Reconciliations of GAAP Reported to Non-GAAP Adjusted InformationCertain Line Items</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:28.182%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.996%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.996%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.474%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="36" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:39pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">Data presented will not (in all cases) aggregate to totals.</span></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">MILLIONS, EXCEPT PER SHARE DATA</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="6" style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="6" style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Other (income)/deductionsnet</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Net income attributable to Pfizer Inc. common shareholders</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(a), (b), (c)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Earnings per common share attributable to Pfizer Inc. common shareholdersdiluted</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">GAAP Reported</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">17,851</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">14,730</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">4,388</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">8,031</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">1.41</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-right:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">5,286&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Acquisition-related items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(1,341)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1,938&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Discontinued operations</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Certain significant items:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Restructuring charges/(credits) and implementation costs and additional depreciationasset restructuring</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(134)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(90)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2,213&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Certain asset impairments</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(3,295)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">3,295&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:4.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(Gains)/losses on equity securities</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1,008&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(1,008)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Actuarial valuation and other pension and postretirement plan (gains)/losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(579)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">579&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">44&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt"><span><br></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(445)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">430&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Income tax provisionnon-GAAP items</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(3,035)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Non-GAAP Adjusted</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">16,420&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">14,617&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1,031&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">17,716&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">3.11&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-right:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:28.182%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.996%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.996%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.474%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="36" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:39pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">Data presented will not (in all cases) aggregate to totals.</span></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">MILLIONS, EXCEPT PER SHARE DATA</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="6" style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="6" style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Other (income)/deductionsnet</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Net income attributable to Pfizer Inc. common shareholders</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(a), (b), (c)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Earnings per common share attributable to Pfizer Inc. common shareholdersdiluted</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">GAAP Reported</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">24,954</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">14,771</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">222</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">2,119</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">0.37</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="border-right:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">4,733&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Acquisition-related items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(629)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(28)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1,874&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Discontinued operations</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Certain significant items:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Restructuring charges/(credits) and implementation costs and additional depreciationasset restructuring</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(98)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(290)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2,227&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Certain asset impairments</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(3,024)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">3,024&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(Gains)/losses on equity securities</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1,588&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(1,588)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Actuarial valuation and other pension and postretirement plan (gains)/losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">265&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(265)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(238)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(g)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(24)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(246)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">518&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Income tax provisionnon-GAAP items</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(2,131)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Non-GAAP Adjusted</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">23,988&nbsp;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">14,446&nbsp;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(1,224)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">10,501&nbsp;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1.84&nbsp;</span></td><td style="border-bottom:3pt double #000;border-right:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">44</span></div></td></tr></tbody></table></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:28.139%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="33" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:39pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">Data presented will not (in all cases) aggregate to totals.</span></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">MILLIONS, EXCEPT PER SHARE DATA</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="6" style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="6" style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Other (income)/deductionsnet</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Net income attributable to Pfizer Inc. common shareholders</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(a), (b), (c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Earnings per common share attributable to Pfizer Inc. common shareholdersdiluted</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">GAAP Reported</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">34,344</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">13,677</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">1,062</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">31,372</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">5.47</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="border-right:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">3,609&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Acquisition-related items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(119)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(74)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">832&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Discontinued operations</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(21)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Certain significant items:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Restructuring charges/(credits) and implementation costs and additional depreciationasset restructuring</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(88)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(562)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1,396&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Certain asset impairments</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(421)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">421&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(Gains)/losses on equity securities</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(1,270)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1,270&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Actuarial valuation and other pension and postretirement plan (gains)/losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">230&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(230)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(40)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(59)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(636)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">752&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Income tax provisionnon-GAAP items</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(1,683)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Non-GAAP Adjusted</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">34,096&nbsp;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">13,049&nbsp;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(1,109)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">37,717&nbsp;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">6.58&nbsp;</span></td><td style="border-bottom:3pt double #000;border-right:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Items that reconcile GAAP Reported to non-GAAP Adjusted balances are shown pre-tax. Our effective tax rates for GAAP Reported income from continuing operations were: (0.4)% in 2024, (105.4)% in 2023 and 9.6% in 2022. See </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_208">Note 5</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">. Our effective tax rates for non-GAAP Adjusted income were: 14.5% in 2024, 9.0% in 2023 and 11.7% in 2022.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Includes reconciling amounts for </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%"> that are not material to our non-GAAP consolidated results of operations. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">For 2024, the total acquisition-related items of $1.9&nbsp;billion include reconciling amounts for </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">of $514&nbsp;million, mainly composed of $427&nbsp;million of integration costs and other charges. For 2023, the total acquisition-related items of $1.9&nbsp;billion included reconciling amounts for </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">of $1.2&nbsp;billion</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%"> mainly composed of $785&nbsp;million of integration costs and other charges, $190&nbsp;million of transaction costs and $125&nbsp;million of employee termination-related charges. For 2022, the total acquisition-related items of $832&nbsp;million included reconciling amounts for </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">of $631&nbsp;million</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%"> composed of $348&nbsp;million of integration costs and other charges, $144&nbsp;million of transaction costs and $138&nbsp;million of employee termination-related charges. See </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_199">Note 3</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Includes employee termination costs, asset impairments and other exit costs related to our cost-reduction and productivity initiatives not associated with acquisitions. See </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_199">Note 3</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">See </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_202">Note 4</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt">For 2024, the total adjustment of $445&nbsp;million includes (i) net gains of $825&nbsp;million on the partial sales of our investment in Haleon in March and October 2024, which are comprised of (a) total gains on the sales of $945&nbsp;million less (b) $120&nbsp;million recognized in our adjusted income in the fourth quarter representing our pro-rata share of Haleons third quarter 2024 adjusted income recorded on a one quarter lag and implicitly included in the gain on the sale of those shares, (ii) charges of $567 million for certain legal matters, primarily representing certain product liability expenses related to products discontinued and/or divested by Pfizer, (iii) a charge of $420 million related to the expected sale of one of our facilities resulting from the discontinuation of our DMD program and (iv) charges of $312 million mostly related to (a) our equity-method accounting pro-rata share of intangible asset amortization, impairments and restructuring costs recorded by Haleon, as well as (b) adjustments to our equity-method basis differences and (c) Pfizer's share of investee capital transactions recognized by Haleon. For 2023, the total adjustments of $246&nbsp;million included charges of (i) $474&nbsp;million for certain legal matters, primarily representing certain product liability and other legal expenses related to products discontinued and/or divested by Pfizer, and to a lesser extent, legal obligations related to pre-acquisition matters and (ii) $127&nbsp;million mostly related to our equity-method accounting pro-rata share of intangible asset amortization and impairments, costs of separating from GSK and restructuring costs recorded by Haleon, partially offset by: (i) a $222&nbsp;million gain on the divestiture of our early-stage rare disease gene therapy portfolio to Alexion and (ii) dividend income of $211&nbsp;million from our investment in Nimbus resulting from Takedas acquisition of Nimbuss oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor program subsidiary. For 2022, the total adjustments of $636&nbsp;million included charges of (i) $307&nbsp;million mostly representing our equity-method accounting pro rata share of restructuring charges and costs of separating from GSK recorded by Haleon/the Consumer Healthcare JV and adjustments to our equity-method basis differences which are also related to the separation of Haleon/the Consumer Healthcare JV from GSK and (ii) $230&nbsp;million for certain legal matters, primarily representing c</span><span style="color:#242424;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">ertain product liability and other legal expenses related to products discontinued and/or divested by Pfizer.</span></div><div style="margin-bottom:9pt;padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(g)</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">For 2023, the total adjustment of $238&nbsp;million mainly includes $286&nbsp;million in inventory losses, overhead costs related to the period in which the facility could not operate, and incremental costs resulting from tornado damage to our manufacturing facility in Rocky Mount, NC, partially offset by insurance recoveries.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">45</span></div></td></tr></tbody></table></div></div></div><div id="i8531e747ebb543f3bf818166f157d26a_142"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">ANALYSIS OF THE CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:19.221%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.831%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December&nbsp;31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Drivers of change 2024 v. 2023</span></div></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash provided by/(used in):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Operating activities</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">12,744</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,700&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">29,267&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:1pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">The change was driven primarily by an increase in net income adjusted for non-cash items partially offset by the timing of receipts and payments in the ordinary course of business, including a decrease in advance payments for Comirnaty and Paxlovid and net changes in inventory greater than one year (see </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_235">Note 8A</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">).</span></div></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Investing activities</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,652</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(32,278)</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(15,783)</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:1pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">The change was driven mainly by $43.4&nbsp;billion cash paid in 2023 for the acquisition of Seagen, net of cash acquired (see </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_181">Note 2A</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">) and $7.0&nbsp;billion of proceeds from the partial sales of our investment in Haleon in 2024, partially offset by $16.3&nbsp;billion greater net purchases of short-term investments in 2024.</span></div></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Financing activities</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">(17,140)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">26,066&nbsp;</span></td><td style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(14,834)</span></td><td style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:1pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">The change was driven mostly by $30.8&nbsp;billion of proceeds from the issuance of long-term debt in May of 2023 for the acquisition of Seagen and $12.6&nbsp;billion greater net repayments of short-term borrowings in 2024.</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div id="i8531e747ebb543f3bf818166f157d26a_145"></div><div style="margin-bottom:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">ANALYSIS OF FINANCIAL CONDITION, LIQUIDITY, CAPITAL RESOURCES AND MARKET RISK</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our historically robust operating cash flows, which we expect to continue over time, is a key strength of our liquidity and capital resources and our primary funding source. We continue to believe that with our ongoing operating cash flows, together with our financial assets, access to capital markets, revolving credit agreement, and available lines of credit, we have and will maintain the ability to meet our liquidity needs to support ongoing operations, our capital allocation objectives, and our contractual and other obligations for the foreseeable future.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We focus efforts to optimize operating cash flows through achieving working capital efficiencies that target accounts receivable, inventories, accounts payable, and other working capital. Excess cash from operating cash flows is invested in money market funds and available-for-sale debt securities which consist of primarily high-quality, highly liquid, well-diversified debt securities. We have taken, and will continue to take, a conservative approach to our financial investments and monitoring of our liquidity position in response to market changes. We typically maintain cash and cash equivalent balances and short-term investments which, together with our available revolving credit facilities, are in excess of our commercial paper and other short-term borrowings.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Additionally, we may obtain funding through short-term or long-term sources from our access to the capital markets, banking relationships and relationships with other financial intermediaries to meet our liquidity needs.</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:38.812%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:58.404%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Diverse sources of funds:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Related disclosure presented in this Form 10-K</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Internal sources:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Operating cash flows</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_172">Consolidated Statements of Cash Flows  Operating Activities</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">the</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_142">Analysis of the Consolidated Statements of Cash Flows</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">section</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">within MD&amp;A</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Cash and cash equivalents</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_166">Consolidated Balance Sheets</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Money market funds</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_214">Note 7A</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Available-for-sale debt securities</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_214">Note 7A</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_217">7B</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Equity investments</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_214">Note 7A</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_217">7B</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">External sources:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Short-term funding:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Commercial paper</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_220">Note 7C</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Revolving credit facilities</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_220">Note 7C</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Lines of credit</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_220">Note 7C</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Long-term funding:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Long-term debt</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_223">Note 7D</a></span></div></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Equity</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_169">Consolidated Statements of Equity</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_250">Note 12</a></span></div></td></tr></tbody></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">For additional information about the sources and uses of our funds and capital resources, see the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_142">Analysis of the Consolidated Statements of Cash Flows</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section within MD&amp;A.</span></div><div style="margin-bottom:5pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Credit Ratings</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The cost and availability of financing are influenced by credit ratings, and an increase or decrease in our credit rating could have a beneficial or adverse effect on financing. Our long-term debt is rated high-quality by both S&amp;P and Moodys.</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:35.942%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.668%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of the date of the filing of this Form 10-K, the following ratings have been assigned to our commercial paper and senior unsecured long-term debt:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">NAME OF RATING AGENCY</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Short-Term Rating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Long-Term Rating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Outlook/Watch</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Moodys</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">P-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">A2</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Stable Outlook</span></div></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">S&amp;P</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">A-1</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">A</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Stable Outlook</span></div></td></tr></tbody></table></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">These ratings are not a recommendation to buy, sell or hold securities and the ratings are subject to revision or withdrawal at any time by the rating organization. Each rating should be evaluated independently of any other rating.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">46</span></div></td></tr></tbody></table></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Capital Allocation Framework</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our capital allocation framework is primarily devised to enhance shareholder value and is based on three core pillars: maintaining and growing our dividend over time, reinvesting in the business and making share repurchases after de-levering our balance sheet. See the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_100">Overview of Our Performance, Operating Environment, Strategy and Outlook</a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_100"></a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_100">O</a><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_100">ur Business and Strategy</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section within MD&amp;A.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Dividends</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our current and projected dividends provide a return to shareholders while maintaining sufficient capital to invest in growing our business. Our dividends are not restricted by debt covenants. While the dividend level remains a decision of Pfizers BOD and will continue to be evaluated in the context of future business performance, we currently believe that we can support future annual dividend increases, barring significant unforeseen events. On December&nbsp;12, 2024, our BOD declared a first-quarter dividend of $0.43 per share, payable on March&nbsp;7, 2025, to shareholders of record at the close of business on January&nbsp;24, 2025. The first-quarter 2025 cash dividend will be our 345th consecutive quarterly dividend.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Common Stock Purchases</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of December 31, 2024, our remaining share-purchase authorization was $3.3 billion with no repurchases in 2024. See </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_250">Note 12</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Haleon</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">After our sales of a portion of our Haleon shares in March and October 2024, we owned approximately 15% of the outstanding voting shares of Haleon as of December 31, 2024. See </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_187">Note 2C</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">With the reduction in our Haleon ownership percentage and board representation after the October 2024 sale, we discontinued the application of the equity method to our Haleon investment, and in the fourth quarter of 2024 began to account for the investment as an equity security with a readily determinable fair value, which is carried at fair value, with changes in fair value reported in </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductionsnet. </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">In the first quarter of 2025, we sold an additional portion of our investment in Haleon for $3.0&nbsp;billion further reducing our ownership interest to approximately 7%.</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer intends to use the proceeds to support its capital allocation priorities. We intend to monetize our remaining Haleon investment in a prudent fashion during 2025.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements, Contractual, and Other Obligations</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">In the ordinary course of business, (i) we enter into off-balance sheet arrangements that may result in contractual and other obligations and (ii) in connection with the sale of assets and businesses and other transactions, we often indemnify our counterparties against certain liabilities that may arise in connection with the transaction or that are related to events and activities. For more information on guarantees and indemnifications, see </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_268">Note 16B</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Additionally, certain of our co-promotion or license agreements give our licensors or partners the rights to negotiate for, or in some cases to obtain under certain financial conditions, co-promotion or other rights in specified countries with respect to certain of our products. Furthermore, collaboration, licensing or other R&amp;D arrangements may give rise to potential milestone payments. Payments under these agreements generally become due and payable only upon the achievement of certain development, regulatory and/or commercialization milestones, which may span several years and which may never occur.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our significant contractual and other obligations as of December 31, 2024 consisted of:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Long-term debt, including current portion (see </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_223">Note 7D</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">) and related interest payments;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Estimated cash payments related to the TCJA repatriation estimated tax liability (see </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_208">Note 5</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">). Estimated future payments related to the TCJA repatriation tax liability that will occur after December 31, 2024 total $4.7 billion, of which an estimated $2.1 billion is to be paid in the next twelve months and an estimated $2.6 billion is to be paid in periods thereafter. Our obligations may vary as a result of changes in our uncertain tax positions and/or availability of attributes such as foreign tax and other credit carryforwards;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Certain commitments totaling $4.1 billion, of which an estimated $1.0 billion is to be paid in the next twelve months, and $3.1 billion in periods thereafter (see</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_268">Note 16C</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">);</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Purchases of PP&amp;E (see</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_238">Note 9</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">). In 2025, we expect to spend approximately $2.8 billion on PP&amp;E; and</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Future minimum rental commitments under non-cancelable operating leases (see </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_265">Note 15</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Global Economic Conditions</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We have operations in countries that have hyperinflationary economies. The impact to Pfizer is not considered material. See the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67">Item 1A. Risk FactorsGlobal Operations</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Market Risk</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We are subject to foreign exchange risk, interest rate risk, and equity price risk. The objective of our financial risk management program is to minimize the impact of foreign exchange rate and interest rate movements on our earnings. We address such exposures through a combination of operational means and financial instruments. For more information on how we manage our foreign exchange and interest rate risks, see </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_178">Notes 1F</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_229">7E</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">, as well as the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_67">Item 1A. Risk FactorsGlobal Operations</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">section for key currencies in which we operate. Our sensitivity analyses of such risks are discussed below.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Foreign Exchange Risk</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The fair values of our financial instrument holdings are analyzed at year-end to determine their sensitivity to foreign exchange rate changes. In this analysis, holding all other assumptions constant and assuming that a change in one currencys rate relative to the U.S. dollar would not have any effect on another currencys rates relative to the U.S. dollar, if the dollar were to move against all other currencies by 10%, as of December 31, 2024, the expected impact on our net income would not be significant.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Interest Rate Risk</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The fair values of our financial instrument holdings are analyzed at year-end to determine their sensitivity to interest rate changes. In this analysis, holding all other assumptions constant and assuming a parallel shift in the interest rate curve for all maturities and for all instruments, if there were a one hundred basis point change in interest rates as of December 31, 2024, the expected impact on our net income would not be significant.</span></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Equity Price Risk</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We hold long-term investments in equity securities with readily determinable fair values in life science companies as a result of certain business development transactions. While we are holding such securities, we are subject to equity price risk, and this may increase the volatility of our income in future periods due to changes in the fair value of equity investments. From time to time, we will sell such equity securities based on our business considerations, which may include limiting our price risk. Our equity securities with readily determinable fair values are analyzed at year-end to determine their sensitivity to equity price rate changes. In this sensitivity analysis, the expected impact on our net income would not be significant.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">47</span></div></td></tr></tbody></table></div></div></div><div id="i8531e747ebb543f3bf818166f157d26a_148"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">NEW ACCOUNTING STANDARDS</span></div><div style="margin-bottom:5pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">See </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_178">Note 1B</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards, Not Adopted as of December 31, 2024</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Standard/Description</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Effective Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">Effect on the Financial Statements</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">In December 2023, the FASB issued final guidance to improve </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">income tax disclosures</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">. The final guidance requires enhanced disclosures primarily related to existing rate reconciliation and income taxes paid information.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2025 for annual reports. Early adoption is permitted.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">This new guidance will result in increased disclosures in the notes to our financial statements.</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">In November 2024, the FASB issued final guidance which requires </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">disaggregated disclosures of certain categories of expenses that are included in expense line items on the face of the income statement</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">. The disclosures are required on an annual and interim basis. The guidance also requires the total amount of selling expenses to be disclosed and, on an annual basis, the definition of selling expenses.</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2027 for annual reports and 2028 for interim reports. Early adoption is permitted.</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">This new guidance will result in increased disclosures in the notes to our financial statements.</span></td></tr></tbody></table></div><div id="i8531e747ebb543f3bf818166f157d26a_151"></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tbody><tr><td style="width:1.0%"></td><td style="width:10.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&nbsp;7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></td></tr></tbody></table></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The information required by this Item is incorporated by reference to the discussion in the </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_145">Analysis of Financial Condition, Liquidity, Capital Resources and Market Risk</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">section within MD&amp;A.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">48</span></div></td></tr></tbody></table></div></div></div><div id="i8531e747ebb543f3bf818166f157d26a_154"></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="margin-top:5pt"><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:10.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&nbsp;8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></td></tr></tbody></table></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></tbody></table></div></div><div><span><br></span></div><div id="i8531e747ebb543f3bf818166f157d26a_157"></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">To the Board of Directors and Shareholders</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.:</span></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Opinion on the Consolidated Financial Statements</span></div><div style="margin-bottom:7pt;padding-right:9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Pfizer Inc. and Subsidiary Companies (the Company) as of December 31, 2024 and 2023, the related consolidated statements of operations, comprehensive income, equity, and cash flows for each of the years in the three-year period ended December 31, 2024, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-bottom:7pt;margin-top:8pt;padding-right:9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Companys internal control over financial reporting as of December 31, 2024, based on criteria established in </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Internal Control </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">- </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Integrated Framework (2013) </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated February&nbsp;27, 2025 expressed an unqualified opinion on the effectiveness of the Companys internal control over financial reporting.</span></div><div style="margin-bottom:7pt;padding-right:15.75pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Basis for Opinion</span></div><div style="margin-bottom:7pt;padding-right:15.75pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">These consolidated financial statements are the responsibility of the Companys management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:7pt;padding-right:15.75pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Critical Audit Matters</span></div><div style="margin-bottom:7pt;padding-right:15.75pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Evaluation of the U.S. Medicare, Medicaid, and performance-based contract rebates accrual</span></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">As discussed in </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_178">Note 1G</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> to the consolidated financial statements, the Company records estimated deductions for Medicare, Medicaid, and performance-based contract rebates (collectively, U.S. rebates) as a reduction to gross product revenues. The accrual for U.S. rebates is recorded in the same period that the corresponding revenues are recognized. The length of time between when a sale is made and when the U.S. rebate is paid by the Company can be as long as one year, which increases the need for significant management judgment and knowledge of market conditions and practices in estimating the accrual. </span></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We identified the evaluation of the U.S. rebates accrual as a critical audit matter because the evaluation of the product-specific experience ratio assumption involved especially challenging auditor judgment. The product-specific experience ratio assumption relates to estimating which of the Companys revenue transactions will ultimately be subject to a related rebate.</span></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls over the Companys U.S. rebates accrual process related to the development of the product-specific experience ratio assumptions. We estimated the U.S. rebates accrual using internal information and historical data and compared the result to the Companys estimated U.S. rebates accrual. We evaluated the Companys ability to accurately estimate the accrual for U.S. rebates by comparing historically recorded accruals to the actual amount that was ultimately paid by the Company.</span></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Evaluation of gross unrecognized tax benefits</span></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">As discussed in </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_208">Notes 5D</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_178">1Q</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">, the Companys tax positions are subject to audit by local taxing authorities in each respective tax jurisdiction, and the resolution of such audits may span multiple years. Since tax law is complex and often subject to varied interpretations and judgments, it is uncertain whether some of the Companys tax positions will be sustained upon audit. As of December 31, 2024, the Company has recorded gross unrecognized tax benefits, excluding associated interest, of $4.5 billion.</span></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We identified the evaluation of certain of the Companys gross unrecognized tax benefits as a critical audit matter because a high degree of audit effort, including specialized skills and knowledge, and complex auditor judgment was required in evaluating the Companys interpretation of tax law and its estimate of the ultimate resolution of its tax positions.</span></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of an internal control over the Companys liability for unrecognized tax position process related to (1) interpretation of tax law, (2) evaluation of which of the Companys tax positions may not be sustained upon audit, and (3) estimation and recording of the gross </span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">49</span></div></td></tr></tbody></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><span><br></span></div><div style="margin-bottom:5pt;padding-left:9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="padding-left:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></tbody></table></div></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">unrecognized tax benefits. We involved tax and valuation professionals with specialized skills and knowledge who assisted in evaluating the Companys interpretation of tax laws, including the assessment of transfer pricing practices in accordance with applicable tax laws and regulations. We inspected settlements with applicable taxing authorities, including assessing the expiration of statutes of limitations. We tested the calculation of the liability for uncertain tax positions, including an evaluation of the Companys assessment of the technical merits of tax positions and estimates of the amount of tax benefits expected to be sustained.</span></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Evaluation of product liability and other product-related litigation</span></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">As discussed in </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_178">Notes 1S</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_268">16</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> to the consolidated financial statements, the Company is involved in product liability and other product-related litigation, which can include personal injury, consumer fraud, off-label promotion, securities, antitrust and breach of contract claims, among others. Certain of these pending product and other product-related legal proceedings could result in losses that could be substantial. The accrued liability and/or disclosure for the pending product liability and other product-related legal proceedings requires a complex series of judgments by the Company about future events, which involves a number of uncertainties.</span></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We identified the evaluation of product liability and other product-related litigation as a critical audit matter. Challenging auditor judgment was required to evaluate the Companys judgments about future events and uncertainties.</span></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls over the Companys product liability and other product-related litigation processes, including controls related to (1) the evaluation of information from external and internal legal counsel, (2) forward-looking expectations, and (3) new legal proceedings, or other legal proceedings not currently reserved or disclosed. We read letters received directly from the Companys external and internal legal counsel that described the Companys probable or reasonably possible legal contingency to pending product liability and other product-related legal proceedings. We inspected the Companys minutes from meetings of the Audit Committee, which included the status of key litigation matters. We evaluated the Companys ability to estimate its monetary exposure to pending product and other product-related legal proceedings by comparing historically recorded liabilities to actual monetary amounts incurred upon resolution of prior legal matters. We analyzed relevant publicly available information about the Company, its competitors, and the industry.</span></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Evaluation of the fair value measurement of the developed technology rights and in-process research and development intangible assets acquired in the Seagen business combination</span></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">As discussed in </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_181">Note 2A</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> to the consolidated financial statements, on December 14, 2023, the Company acquired Seagen Inc. and its subsidiaries (Seagen). The total fair value of consideration transferred was $44.2&nbsp;billion. Of that, the Company recorded $7.5&nbsp;billion of developed technology rights with an estimated weighted-average life of approximately 18 years and $19.9&nbsp;billion of in-process research and development (IPR&amp;D). The preliminary estimates of the fair value of intangible assets were finalized during the measurement period in 2024.  As discussed in </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_178">Note 1</a><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_178">M</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">, the Company performs impairment testing for indefinite-lived intangible assets at least annually and for all other long-lived assets whenever impairment indicators are present. When necessary, the Company records impairments of long-lived assets for the amount by which the fair value is less than the carrying value of these assets.</span></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We identified the evaluation of the fair value measurement of Seagen acquired developed technology rights and IPR&amp;D as a critical audit matter. A high degree of subjective auditor judgment was required to evaluate certain key assumptions used to estimate the acquisition-date fair value of the acquired developed technology rights and IPR&amp;D, as well as the fair value for impairment testing purposes. Specifically, the key assumptions for certain IPR&amp;D assets, including revenue growth rates, probability of technical and regulatory success (PTRS) rates, and the discount rate, and the key assumptions for certain developed technology rights, including revenue growth rates and the discount rate, represented subjective determinations of future market and economic conditions. Changes to those assumptions could have had a significant effect on the determination of the fair value measurements.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls related to the Companys valuation process, including controls related to the development of the key assumptions for certain IPR&amp;D assets and developed technology rights. We performed sensitivity analyses over the key assumptions for certain IPR&amp;D assets and developed technology rights to assess the impact of changes in those key assumptions on the Companys determination of the fair value of the IPR&amp;D and developed technology rights, respectively. We evaluated the reasonableness of the Companys forecasted revenue growth rates by comparing them to historical results, comparable products and peer companies, analyst expectations, industry related third-party data, and the assumptions used in prior periods. Further, we evaluated the PTRS rates for certain IPR&amp;D assets by considering the phase of development of the clinical projects and the Company's history of obtaining regulatory approval and comparing them to PTRS rates derived from analyst reports and other industry related third-party data and the assumptions used in prior periods. We evaluated the data sources used by management in determining the key assumptions for certain IPR&amp;D assets and developed technology rights by comparing to industry standards and evidence obtained in other areas of the audit. In addition, we involved valuation professionals with specialized skills and knowledge, who assisted in:</span></div><div style="margin-bottom:7pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)  evaluating the discount rates used by the Company for certain IPR&amp;D and developed technology rights by comparing them against discount rate ranges that were independently developed using publicly available market data for comparable entities</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) testing the source information underlying the determination of the discount rates.</span></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span><img src="./PFIZER_files/pfe-20241231_g9.jpg" alt="kpmgsignatureq42019a01-keep.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:137px"></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We have not been able to determine the specific year that we or our predecessor firms began serving as the Companys auditor, however, we are aware that we or our predecessor firms have served as the Companys auditor since at least 1942.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">New York, New York</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">February 27, 2025</span></td></tr></tbody></table></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">50</span></div></td></tr></tbody></table></div></div></div><div id="i8531e747ebb543f3bf818166f157d26a_160"></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><span><br></span></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations</span></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div><span><br></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tbody><tr><td style="width:1.0%"></td><td style="width:65.973%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.113%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.113%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.115%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS, EXCEPT PER SHARE DATA)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revenues:</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Product revenues</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-6" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-54">53,816</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-7" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-55">50,914</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-8" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-56">91,793</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Alliance revenues</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="f-57">8,388</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="f-58">7,582</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="f-59">8,537</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Royalty revenues</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-11" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-60">1,423</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-12" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-61">1,058</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-13" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-62">845</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total revenues</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-63">63,627</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-64">59,553</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-65">101,175</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Costs and expenses:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b), (c)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-66">17,851</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-67">24,954</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-68">34,344</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-69">14,730</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-70">14,771</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-71">13,677</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="f-72">10,822</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="f-73">10,679</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="f-74">11,428</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquired in-process research and development expenses</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="f-75">108</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="f-76">194</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="f-77">953</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" format="ixt:num-dot-decimal" scale="6" id="f-78">5,286</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" format="ixt:num-dot-decimal" scale="6" id="f-79">4,733</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" format="ixt:num-dot-decimal" scale="6" id="f-80">3,609</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="f-81">2,419</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="f-82">2,943</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="f-83">1,375</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income)/deductionsnet</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="f-84">4,388</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-85">222</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="f-86">1,062</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Income from continuing operations before provision/(benefit) for taxes on income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-87">8,023</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-88">1,058</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-89">34,729</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Provision/(benefit) for taxes on income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-90">28</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-91">1,115</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-92">3,328</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Income from continuing operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-93">8,051</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-94">2,172</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-95">31,401</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Discontinued operationsnet of tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="f-96">11</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="f-97">15</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="f-98">6</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net income before allocation to noncontrolling interests</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-99">8,062</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-100">2,158</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-101">31,407</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Less: Net income attributable to noncontrolling interests</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="f-102">31</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="f-103">39</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="f-104">35</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-105">8,031</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-106">2,119</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-107">31,372</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Earnings per common sharebasic</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usdPerShare" contextref="c-1" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-108">1.42</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usdPerShare" contextref="c-9" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-109">0.38</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usdPerShare" contextref="c-10" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-110">5.59</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Discontinued operationsnet of tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usdPerShare" contextref="c-1" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="f-111"></ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usdPerShare" contextref="c-9" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="f-112"></ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usdPerShare" contextref="c-10" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="f-113"></ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usdPerShare" contextref="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-114">1.42</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usdPerShare" contextref="c-9" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-115">0.38</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usdPerShare" contextref="c-10" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-116">5.59</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Earnings per common sharediluted</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usdPerShare" contextref="c-1" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-117">1.41</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usdPerShare" contextref="c-9" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-118">0.37</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usdPerShare" contextref="c-10" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-119">5.47</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Discontinued operationsnet of tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usdPerShare" contextref="c-1" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="f-120"></ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usdPerShare" contextref="c-9" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="f-121"></ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usdPerShare" contextref="c-10" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="f-122"></ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usdPerShare" contextref="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-123">1.41</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usdPerShare" contextref="c-9" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-124">0.37</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usdPerShare" contextref="c-10" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-125">5.47</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Weighted-average sharesbasic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="shares" contextref="c-1" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="f-126">5,664</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="shares" contextref="c-9" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="f-127">5,643</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="shares" contextref="c-10" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="f-128">5,608</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Weighted-average sharesdiluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="shares" contextref="c-1" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="f-129">5,700</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="shares" contextref="c-9" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="f-130">5,709</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="shares" contextref="c-10" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="f-131">5,733</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="fn-1" footnoterole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">See </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_178">Note 1A</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><ix:footnote id="fn-2" footnoterole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Exclusive of amortization of intangible assets.</span></ix:footnote></div><div style="margin-bottom:220pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><ix:footnote id="fn-3" footnoterole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">See </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_271">Note</a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_271"> </a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_271">17A</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></ix:footnote></div><div style="padding-right:-13.5pt;text-align:center;text-indent:9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">See Accompanying Notes.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">51</span></div></td></tr></tbody></table></div></div></div><div id="i8531e747ebb543f3bf818166f157d26a_163"></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><span><br></span></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Comprehensive Income</span></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div><span><br></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tbody><tr><td style="width:1.0%"></td><td style="width:72.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.096%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.798%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.248%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net income before allocation to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-132">8,062</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-133">2,158</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-134">31,407</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign currency translation adjustments, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="f-135">32</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="f-136">452</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="f-137">2,328</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unrealized holding gains/(losses) on derivative financial instruments, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="f-138">499</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="f-139">626</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="f-140">1,444</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Reclassification adjustments for (gains)/losses included in net income</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-141">159</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-142">413</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-143">2,062</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="f-144">341</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="f-145">213</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="f-146">618</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unrealized holding gains/(losses) on available-for-sale securities, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" scale="6" id="f-147">152</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" scale="6" id="f-148">121</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-149">1,306</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Reclassification adjustments for (gains)/losses included in net income</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" scale="6" id="f-150">42</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" scale="6" id="f-151">141</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-152">1,809</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" scale="6" id="f-153">111</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" scale="6" id="f-154">261</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" scale="6" id="f-155">502</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Benefit plans: prior service (costs)/credits and other, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" scale="6" id="f-156">193</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" scale="6" id="f-157">25</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" scale="6" id="f-158">24</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Reclassification adjustments related to amortization of prior service costs and other, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="f-159">109</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="f-160">117</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="f-161">129</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Reclassification adjustments related to curtailments of prior service costs and other, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax" format="ixt:fixed-zero" scale="6" id="f-162"></ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" sign="-" name="pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax" scale="6" id="f-163">15</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" sign="-" name="pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax" scale="6" id="f-164">12</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="f-165">84</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="f-166">157</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="f-167">166</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other comprehensive income/(loss), before tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" scale="6" id="f-168">347</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" scale="6" id="f-169">246</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-170">2,609</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tax provision/(benefit) on other comprehensive income/(loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="f-171">231</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="f-172">85</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="f-173">187</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other comprehensive income/(loss) before allocation to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-174">116</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-175">331</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-176">2,422</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Comprehensive income/(loss) before allocation to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-177">8,178</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-178">2,488</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-179">28,985</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Less: Comprehensive income/(loss) attributable to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="f-180">28</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="f-181">26</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="f-182">20</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Comprehensive income/(loss) attributable to Pfizer Inc.</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-183">8,149</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-184">2,462</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-185">28,965</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="fn-4" footnoterole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Reclassified into </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductionsnet </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">. See </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_229">Note 7E</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></ix:footnote></div><div style="margin-bottom:355pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><ix:footnote id="fn-5" footnoterole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Reclassified into </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductionsnet</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></ix:footnote></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">See Accompanying Notes.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">52</span></div></td></tr></tbody></table></div></div></div><div id="i8531e747ebb543f3bf818166f157d26a_166"></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><span><br></span></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div><span><br></span></div></div><div style="margin-bottom:97pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tbody><tr><td style="width:1.0%"></td><td style="width:73.266%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.971%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.973%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS, EXCEPT PER SHARE DATA)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-14" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-186">1,043</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-15" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-187">2,853</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-14" decimals="-6" name="us-gaap:OtherShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-188">19,434</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-15" decimals="-6" name="us-gaap:OtherShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-189">9,837</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Trade accounts receivable, net of allowance for doubtful accounts: 2024$<ix:nonfraction unitref="usd" contextref="c-14" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="f-190">438</ix:nonfraction>; 2023$<ix:nonfraction unitref="usd" contextref="c-15" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="f-191">470</ix:nonfraction></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-14" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-192">11,463</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-15" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-193">11,566</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Inventories</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-14" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="f-194">10,851</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-15" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="f-195">10,189</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Current tax assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-14" decimals="-6" name="pfe:OtherTaxAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-196">3,314</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-15" decimals="-6" name="pfe:OtherTaxAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-197">3,978</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-14" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-198">4,253</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-15" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-199">4,911</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-14" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-200">50,358</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-15" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-201">43,333</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Equity-method investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-14" decimals="-6" name="us-gaap:EquityMethodInvestments" scale="6" id="f-202">217</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-15" decimals="-6" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-203">11,637</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-14" decimals="-6" name="us-gaap:OtherLongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-204">2,010</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-15" decimals="-6" name="us-gaap:OtherLongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-205">3,731</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Property, plant and equipment, net</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-14" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-206">18,393</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-15" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-207">18,940</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Identifiable intangible assets, net</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-14" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-208">55,411</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-15" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-209">64,900</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Goodwill</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-14" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-210">68,527</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-15" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-211">67,783</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Noncurrent deferred tax assets and other noncurrent tax assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-14" decimals="-6" name="pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-212">8,662</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-15" decimals="-6" name="pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-213">3,706</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-14" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-214">9,817</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-15" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-215">12,471</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-14" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-216">213,396</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-15" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-217">226,501</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Liabilities and Equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Short-term borrowings, including current portion of long-term debt: 2024$<ix:nonfraction unitref="usd" contextref="c-14" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="6" id="f-218">3,747</ix:nonfraction>; 2023$<ix:nonfraction unitref="usd" contextref="c-15" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="6" id="f-219">2,254</ix:nonfraction></span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-14" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="f-220">6,946</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-15" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="f-221">10,350</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Trade accounts payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-14" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="f-222">5,633</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-15" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="f-223">6,710</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Dividends payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-14" decimals="-6" name="us-gaap:DividendsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="f-224">2,437</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-15" decimals="-6" name="us-gaap:DividendsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="f-225">2,372</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Income taxes payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-14" decimals="-6" name="us-gaap:TaxesPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="f-226">2,910</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-15" decimals="-6" name="us-gaap:TaxesPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="f-227">2,349</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accrued compensation and related items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-14" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-228">3,838</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-15" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-229">2,776</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Deferred revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-14" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-230">1,511</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-15" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-231">2,700</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-14" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-232">19,720</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-15" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-233">20,537</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-14" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-234">42,995</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-15" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-235">47,794</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Long-term debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-14" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-236">57,405</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-15" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-237">61,538</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pension and postretirement benefit obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-14" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-238">2,115</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-15" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-239">2,167</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Noncurrent deferred tax liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-14" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="f-240">2,122</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-15" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="f-241">640</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other taxes payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-14" decimals="-6" name="us-gaap:LiabilityForUncertainTaxPositionsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-242">6,112</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-15" decimals="-6" name="us-gaap:LiabilityForUncertainTaxPositionsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-243">8,534</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-14" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-244">14,150</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-15" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-245">16,539</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-14" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="f-246">124,899</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-15" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="f-247">137,213</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commitments and Contingencies</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonfraction unitref="usd" contextref="c-14" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-248"></ix:nonfraction></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><ix:nonfraction unitref="usd" contextref="c-15" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-249"></ix:nonfraction></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Common stock, $<ix:nonfraction unitref="usdPerShare" contextref="c-14" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-250"><ix:nonfraction unitref="usdPerShare" contextref="c-15" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-251">0.05</ix:nonfraction></ix:nonfraction> par value; <ix:nonfraction unitref="shares" contextref="c-14" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-252"><ix:nonfraction unitref="shares" contextref="c-15" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-253">12,000</ix:nonfraction></ix:nonfraction> shares authorized; issued: 2024<ix:nonfraction unitref="shares" contextref="c-14" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="f-254">9,593</ix:nonfraction>; 2023<ix:nonfraction unitref="shares" contextref="c-15" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="f-255">9,562</ix:nonfraction></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-14" decimals="-6" name="us-gaap:CommonStockValue" scale="6" id="f-256">480</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-15" decimals="-6" name="us-gaap:CommonStockValue" scale="6" id="f-257">478</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Additional paid-in capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-14" decimals="-6" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="f-258">93,603</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-15" decimals="-6" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="f-259">92,631</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Treasury stock, shares at cost: 2024<ix:nonfraction unitref="shares" contextref="c-14" decimals="-6" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="6" id="f-260">3,926</ix:nonfraction>; 2023<ix:nonfraction unitref="shares" contextref="c-15" decimals="-6" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="6" id="f-261">3,916</ix:nonfraction></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-14" decimals="-6" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="6" id="f-262">114,763</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-15" decimals="-6" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="6" id="f-263">114,487</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Retained earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-14" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-264">116,725</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-15" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-265">118,353</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-14" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-266">7,842</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-15" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-267">7,961</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total Pfizer Inc. shareholders equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-14" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-268">88,203</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-15" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-269">89,014</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Equity attributable to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-14" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="f-270">294</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-15" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="f-271">274</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-14" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-272">88,497</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-15" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-273">89,288</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total liabilities and equity</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-14" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-274">213,396</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-15" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-275">226,501</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">See Accompanying Notes.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">53</span></div></td></tr></tbody></table></div></div></div><div id="i8531e747ebb543f3bf818166f157d26a_169"></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><span><br></span></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Equity</span></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="margin-bottom:10pt"><span><br></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.680%"><tbody><tr><td style="width:1.0%"></td><td style="width:30.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:4.843%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.843%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.843%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.843%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.289%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.992%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.289%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.437%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.858%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">&nbsp;</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="45" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">PFIZER INC. SHAREHOLDERS</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">&nbsp;</span></td></tr><tr style="height:11pt"><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">Common Stock</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">&nbsp;</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">Treasury Stock</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">&nbsp;</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">&nbsp;</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS,&nbsp;EXCEPT PER SHARE DATA)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">Par Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">Addl<br>Paid-In<br>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">Retained Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">Accum.<br>Other<br>Comp. Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">Share -<br>holders<br>Equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">Non-controlling Interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">Total<br>Equity</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">Balance, January&nbsp;1, 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="shares" contextref="c-16" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="f-276">9,471</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-16" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-277">473</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-17" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-278">90,591</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="shares" contextref="c-18" decimals="-6" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="6" id="f-279">3,851</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-18" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-280">111,361</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-19" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-281">103,394</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-20" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-282">5,897</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-21" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-283">77,201</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-22" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-284">262</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-23" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-285">77,462</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">Net income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-24" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-286">31,372</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-25" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-287">31,372</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-26" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="f-288">35</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-289">31,407</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">Other&nbsp;comprehensive income/(loss), net of tax</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-27" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-290">2,407</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-25" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-291">2,407</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-26" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-292">15</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-293">2,422</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">Cash dividends declared, per share: $<ix:nonfraction unitref="usdPerShare" contextref="c-10" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="f-294">1.61</ix:nonfraction></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">Common stock </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-24" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="f-295">9,037</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-25" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="f-296">9,037</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="f-297">9,037</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">Noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-26" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="f-298">13</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="f-299">13</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">Share-based payment transactions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="shares" contextref="c-28" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="f-300">48</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-28" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-301">2</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-29" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="f-302">1,192</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="shares" contextref="c-30" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="f-303">13</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-30" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-304">608</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-24" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-305">73</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-25" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-306">513</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-307">513</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">Purchases of common stock</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="shares" contextref="c-30" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="f-308">39</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-30" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="f-309">2,000</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-25" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="f-310">2,000</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="f-311">2,000</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-29" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="f-312">19</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-30" decimals="-6" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="6" id="f-313"></ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-24" decimals="-6" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="6" id="f-314"></ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-25" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="f-315">19</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-26" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="f-316">13</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="f-317">6</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">Balance, December 31, 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="shares" contextref="c-31" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="f-318">9,519</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-31" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-319">476</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-32" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-320">91,802</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="shares" contextref="c-33" decimals="-6" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="6" id="f-321">3,903</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-33" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-322">113,969</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-34" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-323">125,656</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-35" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-324">8,304</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-36" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-325">95,661</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-37" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-326">256</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-38" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-327">95,916</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">Net income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-39" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-328">2,119</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-40" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-329">2,119</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-41" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="f-330">39</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-331">2,158</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">Other&nbsp;comprehensive income/(loss), net of tax</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-42" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-332">343</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-40" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-333">343</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-41" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-334">12</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-335">331</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">Cash dividends declared, per share: $<ix:nonfraction unitref="usdPerShare" contextref="c-9" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="f-336">1.65</ix:nonfraction></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">Common stock </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-39" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="f-337">9,316</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-40" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="f-338">9,316</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="f-339">9,316</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">Noncontrolling interests</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-41" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="f-340">8</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="f-341">8</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">Share-based payment transactions</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="shares" contextref="c-43" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="f-342">43</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-43" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-343">2</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-44" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-344">829</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="shares" contextref="c-45" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="f-345">12</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-45" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-346">518</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-39" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-347">106</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-40" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-348">208</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-349">208</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-44" decimals="-6" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="6" id="f-350"></ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-39" decimals="-6" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="6" id="f-351"></ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-40" decimals="-6" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="6" id="f-352"></ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-41" decimals="-6" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="6" id="f-353"></ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="6" id="f-354"></ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">Balance, December 31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="shares" contextref="c-46" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="f-355">9,562</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-46" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-356">478</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-47" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-357">92,631</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="shares" contextref="c-48" decimals="-6" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="6" id="f-358">3,916</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-48" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-359">114,487</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-49" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-360">118,353</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-50" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-361">7,961</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-51" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-362">89,014</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-52" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-363">274</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-15" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-364">89,288</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%">Net income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-53" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-365">8,031</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-54" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-366">8,031</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-55" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="f-367">31</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-368">8,062</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%">Other&nbsp;comprehensive income/(loss), net of tax</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-56" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-369">118</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-54" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-370">118</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-55" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-371">3</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-372">116</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%">Cash dividends declared, per share: $<ix:nonfraction unitref="usdPerShare" contextref="c-1" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="f-373">1.69</ix:nonfraction></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%">Common stock </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-53" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="f-374">9,577</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-54" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="f-375">9,577</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="f-376">9,577</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%">Noncontrolling interests</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#cceeff;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%"></span><span style="color:#cceeff;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-55" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="f-377">7</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="f-378">7</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%">Share-based payment transactions</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="shares" contextref="c-57" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="f-379">31</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-57" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-380">2</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-58" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-381">972</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%">(<ix:nonfraction unitref="shares" contextref="c-59" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="f-382">10</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-59" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-383">276</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-53" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-384">107</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-54" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-385">591</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-386">591</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#cceeff;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-58" decimals="-6" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="6" id="f-387"></ix:nonfraction></span><span style="color:#cceeff;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-53" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="f-388">25</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-54" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="f-389">25</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-55" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="f-390">1</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="f-391">23</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%">Balance, December 31, 2024</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="shares" contextref="c-60" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="f-392">9,593</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-60" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-393">480</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-61" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-394">93,603</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%">(<ix:nonfraction unitref="shares" contextref="c-62" decimals="-6" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="6" id="f-395">3,926</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-62" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-396">114,763</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-63" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-397">116,725</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-64" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-398">7,842</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-65" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-399">88,203</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-66" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-400">294</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-14" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-401">88,497</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="text-indent:9pt"><span><br></span></div><div style="margin-top:285pt;text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">See Accompanying Notes.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">54</span></div></td></tr></tbody></table></div></div></div><div id="i8531e747ebb543f3bf818166f157d26a_172"></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><span><br></span></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows</span></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div><span><br></span></div></div><div style="margin-top:5pt"><span><br></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:72.145%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;text-decoration:underline">Operating Activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Net income before allocation to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-402">8,062</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-403">2,158</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-404">31,407</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Discontinued operationsnet of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="f-405">11</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="f-406">15</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="f-407">6</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Net income from continuing operations before allocation to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-408">8,051</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-409">2,172</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-410">31,401</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Adjustments to reconcile net income from continuing operations before allocation to noncontrolling interests to net cash provided by/(used in) operating activities:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-411">7,013</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-412">6,290</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-413">5,064</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Asset write-offs and impairments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="pfe:AssetWriteOffsAndAssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="f-414">4,242</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="pfe:AssetWriteOffsAndAssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="f-415">3,408</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="pfe:AssetWriteOffsAndAssetImpairmentCharges" scale="6" id="f-416">550</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Deferred taxes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-417">2,102</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-418">3,442</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-419">3,764</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Share-based compensation expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="f-420">877</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="f-421">525</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="f-422">872</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Benefit plan contributions in excess of expense/income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" scale="6" id="f-423">12</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" scale="6" id="f-424">787</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" format="ixt:num-dot-decimal" scale="6" id="f-425">1,158</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Inventory write-offs and related charges associated with COVID-19 products</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:InventoryWriteDown" format="ixt:fixed-zero" scale="6" id="f-426"></ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="f-427">6,199</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="f-428">1,183</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Other adjustments, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="f-429">2,260</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="f-430">3,492</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="f-431">758</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Other changes in assets and liabilities, net of acquisitions and divestitures:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Trade accounts receivable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="f-432">109</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="f-433">347</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="f-434">261</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Inventories</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="f-435">854</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="6" id="f-436">1,169</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="f-437">591</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Other assets</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="6" id="f-438">3,380</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="6" id="f-439">663</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="6" id="f-440">4,506</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Trade accounts payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" format="ixt:num-dot-decimal" scale="6" id="f-441">1,023</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="6" id="f-442">300</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" format="ixt:num-dot-decimal" scale="6" id="f-443">1,191</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Other liabilities</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-444">3,115</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="f-445">595</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-446">1,449</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Other tax accounts, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedTaxesPayable" format="ixt:num-dot-decimal" scale="6" id="f-447">1,345</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedTaxesPayable" scale="6" id="f-448">982</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedTaxesPayable" scale="6" id="f-449">545</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Net cash provided by/(used in) operating activities</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-450">12,744</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-451">8,700</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-452">29,267</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;text-decoration:underline">Investing Activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Purchases of property, plant and equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-453">2,909</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-454">3,907</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-455">3,236</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Purchases of short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-456">10,133</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-457">30,974</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-458">36,384</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Proceeds from redemptions/sales of short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-459">4,128</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-460">39,264</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-461">44,821</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" sign="-" name="pfe:PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess" format="ixt:num-dot-decimal" scale="6" id="f-462">3,136</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" sign="-" name="pfe:PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess" format="ixt:num-dot-decimal" scale="6" id="f-463">5,174</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="pfe:PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess" scale="6" id="f-464">483</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Purchases of long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="f-465">180</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="f-466">204</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="f-467">1,913</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Proceeds from redemptions/sales of long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-468">1,570</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-469">1,979</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" scale="6" id="f-470">641</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Proceeds from partial sales of investment in Haleon</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-471">7,040</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="f-472"></ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="f-473"></ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Acquisitions of businesses, net of cash acquired</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="f-474"></ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="f-475">43,430</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="f-476">22,997</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Dividend received from the Consumer Healthcare JV</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:fixed-zero" scale="6" id="f-477"></ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:fixed-zero" scale="6" id="f-478"></ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:num-dot-decimal" scale="6" id="f-479">3,960</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Other investing activities, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="f-480">2</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="f-481">179</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="f-482">192</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Net cash provided by/(used in) investing activities</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-483">2,652</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-484">32,278</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-485">15,783</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;text-decoration:underline">Financing Activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Proceeds from short-term borrowings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-486">8,907</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-487">4,525</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-488">3,891</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Payments on short-term borrowings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-489">11,226</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" scale="6" id="f-490">3</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-491">3,887</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" sign="-" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" format="ixt:num-dot-decimal" scale="6" id="f-492">2,590</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" format="ixt:num-dot-decimal" scale="6" id="f-493">3,161</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" sign="-" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" scale="6" id="f-494">222</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Proceeds from issuance of long-term debt</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="6" id="f-495"></ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-496">30,831</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="6" id="f-497"></ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Payments on long-term debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-498">2,250</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-499">2,569</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-500">3,298</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Purchases of common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="6" id="f-501"></ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="6" id="f-502"></ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-503">2,000</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Cash dividends paid</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:PaymentsOfOrdinaryDividends" format="ixt:num-dot-decimal" scale="6" id="f-504">9,512</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:PaymentsOfOrdinaryDividends" format="ixt:num-dot-decimal" scale="6" id="f-505">9,247</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:PaymentsOfOrdinaryDividends" format="ixt:num-dot-decimal" scale="6" id="f-506">8,983</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Other financing activities, net</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="f-507">469</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="f-508">631</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="f-509">335</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Net cash provided by/(used in) financing activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-510">17,140</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-511">26,066</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-512">14,834</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-513">66</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-514">40</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-515">165</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="f-516">1,810</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="f-517">2,448</ix:nonfraction>&nbsp;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="f-518">1,515</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-15" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-519">2,917</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-38" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-520">468</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-23" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-521">1,983</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Cash and cash equivalents and restricted cash and cash equivalents, at end of period</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-14" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-522">1,107</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-15" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-523">2,917</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-38" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-524">468</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="21" style="padding:0 1pt"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">- Continued -</span></td></tr></tbody></table></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">55</span></div></td></tr></tbody></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><span><br></span></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows</span></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div><span><br></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:72.145%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.091%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="21" style="border-bottom:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;text-decoration:underline">Supplemental Cash Flow Information</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Cash paid/(received) during the period for:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Income taxes</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="6" id="f-525">3,605</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="6" id="f-526">3,147</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="6" id="f-527">7,867</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Interest paid</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="6" id="f-528">3,227</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="6" id="f-529">2,215</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="6" id="f-530">1,442</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Interest rate hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="pfe:InterestPaidReceivedInterestRateHedges" scale="6" id="f-531">178</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="pfe:InterestPaidReceivedInterestRateHedges" scale="6" id="f-532">134</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="pfe:InterestPaidReceivedInterestRateHedges" scale="6" id="f-533">54</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Non-cash transaction:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Right-of-use assets obtained in exchange for lease liabilities</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-1" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="f-534">283</ix:nonfraction></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-9" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="f-535">614</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="c-10" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="f-536">752</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="fn-6" footnoterole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">See </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_271">Note</a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_271"> </a></span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_271">17A</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><ix:footnote id="fn-7" footnoterole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">See </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_280">Note 17C</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></ix:footnote></div><div style="margin-bottom:495pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><ix:footnote id="fn-8" footnoterole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">See </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_187">Note 2C</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></ix:footnote></div><div style="text-align:center"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">See Accompanying Notes.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">56</span></div></td></tr></tbody></table></div></div></div><div id="i8531e747ebb543f3bf818166f157d26a_175"></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:justify"><span><br></span></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></tbody></table></div></div><div><span><br></span></div><div id="i8531e747ebb543f3bf818166f157d26a_178"></div><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Note 1. <ix:nonnumeric contextref="c-1" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="f-537" continuedat="f-537-1" escape="true">Basis of Presentation and Significant Accounting Policies</ix:nonnumeric></span></div><ix:continuation id="f-537-1" continuedat="f-537-2"><div style="margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Basis of Presentation</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-538" escape="true">The consolidated financial statements include the accounts of our parent company and all subsidiaries and are prepared in accordance with U.S. GAAP.</ix:nonnumeric> <ix:nonnumeric contextref="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-539" escape="true">The decision of whether or not to consolidate an entity for financial reporting purposes requires consideration of majority voting interests, as well as effective economic or other control over the entity. Typically, we do not seek control by means other than voting interests. For subsidiaries operating outside the U.S., the financial information is included as of and for the year ended November 30 for each year presented. Pfizer's fiscal year-end for U.S. subsidiaries is as of and for the year ended December 31 for each year presented. All significant transactions among our subsidiaries have been eliminated.</ix:nonnumeric></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="c-1" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-540" escape="true">We manage our commercial operations through <ix:nonfraction unitref="segment" contextref="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-541">three</ix:nonfraction> operating segments, each led by a single manager: Biopharma, PC1 and Pfizer Ignite. Biopharma is the only reportable segment.</ix:nonnumeric> See </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_271">Note 17A</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">On December 14, 2023, we completed the acquisition of Seagen. In addition, other acquisitions and business development activities completed in 2024, 2023 and 2022 impacted financial results in the periods presented. See </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_181">Note 2</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><ix:nonnumeric contextref="c-1" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="f-542" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We have made certain reclassification adjustments to conform prior-period amounts to the current presentation for:</span></div><div style="margin-top:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">in the first quarter of 2024, we reclassified royalty income (substantially all of which is related to Biopharma) from </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductionsnet</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and began presenting </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Royalty revenues</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> as a separate line item within </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Total revenues</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in our consolidated statements of operations, and reclassified the associated royalty receivables from </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Trade accounts receivable, less allowance for doubtful accounts</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in our consolidated balance sheet; and</span></div><div style="margin-top:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">segment reporting and geographic information in connection with the commercial reorganization that went into effect on January 1, 2024 (see </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Notes </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_238">9</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_271">1</a><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_271">7</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain amounts in the consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts.</span></div></ix:nonnumeric><div style="margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">. </span><ix:nonnumeric contextref="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-543" continuedat="f-543-1" escape="true"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">New Accounting Standards Adopted in 2024</span></ix:nonnumeric></div><ix:continuation id="f-543-1"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">On January 1, 2024, we adopted a new accounting standard which clarifies that contractual sale restrictions are not considered in measuring equity securities at fair value. The new guidance is consistent with our existing policy; therefore, it had no impact on our consolidated financial statements.</span></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:112%">In the fourth quarter of 2024, we adopted a new accounting standard which requires the disclosure of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss, other segment items by reportable segment and a description of its composition. See </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_271">Note 17A</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:112%">.</span></div></ix:continuation><div style="margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. <ix:nonnumeric contextref="c-1" name="us-gaap:UseOfEstimates" id="f-544" continuedat="f-544-1" escape="true">Estimates and Assumptions</ix:nonnumeric></span></div><ix:continuation id="f-544-1"><div style="margin-top:8pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">In preparing these financial statements, we use certain estimates and assumptions that affect reported amounts and disclosures. These estimates and assumptions can impact all elements of our financial statements. For example, in the consolidated statements of operations, estimates are used when accounting for deductions from revenues, determining the cost of inventory that is sold, allocating cost in the form of depreciation and amortization, and estimating restructuring charges and the impact of contingencies, as well as determining provisions for taxes on income. On the consolidated balance sheets, estimates are used in determining the valuation and recoverability of assets, and in determining the reported amounts of liabilities, all of which also impact the consolidated statements of operations. Certain estimates of fair value and amounts recorded in connection with acquisitions, revenue deductions, impairment reviews, restructuring-associated charges, investments and financial instruments, valuation allowances, pension and postretirement benefit plans, contingencies, share-based compensation, and other calculations can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our estimates are often based on complex judgments and assumptions that we believe to be reasonable, but that can be inherently uncertain and unpredictable. If our estimates and assumptions are not representative of actual outcomes, our results could be materially impacted. As future events and their effects cannot be determined with precision, our estimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. We are subject to risks and uncertainties that may cause actual results to differ from estimated amounts, such as changes in the healthcare environment, competition, litigation, legislation, development of competing assets by us or others, regulatory actions, or product recalls or withdrawals. We regularly evaluate our estimates and assumptions using historical experience and expectations about the future. We adjust our estimates and assumptions when facts and circumstances indicate the need for change.</span></div></ix:continuation><div style="margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">D. <ix:nonnumeric contextref="c-1" name="us-gaap:BusinessCombinationsPolicy" id="f-545" continuedat="f-545-1" escape="true">Acquisitions</ix:nonnumeric></span></div><ix:continuation id="f-545-1" continuedat="f-545-2"><div style="margin-top:8pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our consolidated financial statements include the operations of acquired businesses after the completion of the acquisitions. We account for acquired businesses using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired IPR&amp;D be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired is recorded as goodwill. When we acquire net assets that do not constitute a business, as defined in U.S. GAAP, no goodwill is recognized and acquired IPR&amp;D is expensed in </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Acquired in-process research and development expenses</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Contingent consideration in a business combination is included as part of the acquisition cost and is recognized at fair value as of the acquisition date. Fair value is generally estimated by using a probability-weighted discounted cash flow approach. See </span><span style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm#i8531e747ebb543f3bf818166f157d26a_268">Note 16D</a></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Any liability </span></div></ix:continuation></ix:continuation><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 Form 10-K</span></div></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:9pt;font-weight:700;line-height:120%">57</span></div></td></tr></tbody></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:justify"><span><br></span></div><div><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></tbody></table></div></div><ix:continuation id="f-537-2" continuedat="f-537-3"><ix:continuation id="f-545-2"><div style="margin-top:8pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">resulting from contingent consideration is remeasured to fair value at each reporting date until the contingency is resolved. These changes in fair value are recognized in earnings in </span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductionsnet</span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div style="margin-top:8pt"><span style="color:#00497f;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">E. <ix:nonnumeric contextref="c-1" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="f-546" continuedat="f-546-1" escape="true">Fair Value</ix:nonnumeric></span></div><ix:continuation id="f-546-1"><div style="margin-top:8pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">We measure certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting. We estimate fair value using an exit price approach, which requires, among other things, that we determine the price that would be received to sell an asset or paid to transfer a liability in an orderly market. The determination of an exit price is considered from the perspective of market participants, considering the highest and best use of non-financial assets and, for liabilities, assuming that the risk of non-performance will be the same before and after the transfer. </span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">When estimating fair value, depending on the nature and complexity of the asset or liability, we may use one or all of the following techniques:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Income approach, which is based on the present value of a future stream of net cash flows. </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Cost approach, which is based on the cost to acquire or construct comparable assets, less an allowance for functional and/or economic obsolescence.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our fair value methodologies depend on the following types of inputs:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs).</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following inputs and valuation techniques are used to estimate the fair value of our financial assets and liabilities:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:&#39;Arial&#39;,sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Available-for-sale debt securitiesthird-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data and credit-adjusted yield curves. </span></div></ix:continuation></ix:continuation></body></html>